

# Dissertation

## **Phospholipid Biogenesis in the Apicomplexan Parasites *Eimeria falciformis* and *Toxoplasma gondii***

zur Erlangung des akademischen Grades

**Doctor of Philosophy**

(Ph.D.)

im Fach Biologie

eingereicht an der

Lebenswissenschaftlichen Fakultät  
der Humboldt-Universität zu Berlin

von

M. Sc. Pengfei Kong

Präsidentin der Humboldt-Universität zu Berlin

Prof. Dr. Sabine Kunst

Dekan der Lebenswissenschaftlichen Fakultät

Prof. Dr. Bernhard Grimm

Gutachter: 1. Dr. Nishith Gupta  
2. Prof. Dr. Richard Lucius  
3. Prof. Dr. Jos F. Brouwers

eingereicht am: 23.11.2016

Tag der mündlichen Prüfung: 28.04.2017

## Abstract

The survival and proliferation of apicomplexan parasites oblige efficient synthesis of phospholipids throughout their life cycles. Here, we first deployed *Eimeria falciformis* to investigate the process of lipid biogenesis in sporozoites. Lipidomics analyses demonstrate the occurrence of two exclusive lipids phosphatidylthreonine (PtdThr) and inositol phosphorylceramide along with other prototypical lipids. The parasite expresses nearly the entire lipid biogenesis network, which is an evolutionary mosaic of eukaryotic- and prokaryotic-type enzymes. Using *Toxoplasma gondii* as a gene-tractable surrogate to examine the *Eimeria* enzymes, we show a highly compartmentalized network of lipid synthesis distributed primarily in the apicoplast, ER, Golgi and mitochondrion. Likewise, trans-species complementation of a *T. gondii* mutant with a PtdThr synthase from *E. falciformis* suggests a convergent function of PtdThr in promoting the lytic cycle in coccidian parasites.

We also employed the well-established model parasite *T. gondii* to explore *de novo* synthesis and metabolic roles of one major lipid precursor CDP-diacylglycerol (CDP-DAG). We report the occurrence of two phylogenetically divergent CDP-DAG synthase (CDS) enzymes in *T. gondii*. Eukaryotic-type *TgCDS1* and prokaryotic-type *TgCDS2* reside in the ER and apicoplast, respectively. Conditional knockdown of *TgCDS1* severely attenuates parasite growth, which translates into a nearly complete loss of virulence in a mouse model. Residual growth of the *TgCDS1* mutant is abolished by subsequent deletion of *TgCDS2*. Lipidomics analyses reveal significant and specific decline in phosphatidylinositol (PtdIns) and phosphatidylglycerol (PtdGro) upon loss of *TgCDS1* and *TgCDS2*, respectively. Taken together, our work establishes a phospholipid biogenesis model involving significant inter-organelle cooperation and lipid trafficking in apicomplexan parasites.

**Keywords:** apicomplexan parasite, *Toxoplasma*, *Eimeria*, phospholipid biogenesis

## **Zusammenfassung**

Das Überleben und die Vermehrung der parasitär lebenden Apicomplexa setzen eine effiziente Synthese von Phospholipiden während ihres gesamten Lebenszyklus voraus. In dieser Arbeit nutzten wir zunächst *Eimeria falciformis* um den Prozess der Lipid-Biogenese in Sporozoiten zu untersuchen. Durch Lipidomics-Analysen wurde das Auftreten von zwei exklusiven Lipiden, Phosphatidylthreonin (PtdThr) und Inositolphosphorylceramid. Der Parasit exprimiert fast das gesamte Lipid-Biogenese-Netzwerk aus eukaryotischen und prokaryotischen Enzymen. *Toxoplasma gondii* diente als genmanipulierbarer Ersatz für die Untersuchung der *Eimeria*-Enzyme, mit dem wir ein stark räumlich segmentiertes Netzwerk der Lipidsynthese im Apicoplast, ER, Golgi und Mitochondrium zeigen konnten. Ebenso legte die Komplementierung einer *T. gondii*-Mutante mit einer PtdThr-Synthase von *E. falciformis* eine konvergente Funktion von PtdThr für den lytischen Zyklus von Kokzidien-Parasiten nahe.

Außerdem setzten wir *T. gondii* als etablierten Modelorganismus ein, um die *De-novo*-Synthese und die metabolische Rolle eines bedeutenden Lipidvorläufers, CDP-Diacylglycerin (CDP-DAG), zu untersuchen. Wir konnten zwei phylogenetisch divergente CDP-DAG-Synthase (CDS) Enzyme in *T. gondii* nachweisen. Das eukaryotisch-typische *TgCDS1* und das prokaryotisch-typische *TgCDS2* lokalisieren im ER bzw. im Apicoplast. Der konditionierte Knockdown von *TgCDS1* bremst das Parasitenwachstum stark ab, was den fast vollständigen Verlust der Virulenz im Mausmodell hervorruft. Das restliche marginale Wachstum der *TgCDS1* Mutante wird durch zusätzliche Deletion der *TgCDS2* verhindert. Lipidomics-Analysen zeigten eine signifikante und spezifische Abnahme der Phosphatidylinositol (PtdIns)- und Phosphatidylglycerol (PtdGro)-Level bei Verlust der *TgCDS1*- bzw. *TgCDS2*-Gene. Zusammengenommen zeigt unsere Arbeit ein Phospholipid-Biogenese-Modell mit erstaunlicher Kooperation verschiedener Organellen und einem extensiven Lipidtransport im Parasiten.

**Schlüsselwörter:** Apikomplexan-Parasit, *Toxoplasma*, *Eimeria*, Phospholipid-Biogenese

## Table of contents

<b>Abstract</b> .....	1
<b>Zusammenfassung</b> .....	2
<b>Table of contents</b> .....	3
<b>List of abbreviations</b> .....	7
<b>1. Introduction</b> .....	8
<b>1.1. Apicomplexan parasites</b> .....	8
1.1.1. <i>Eimeria</i> .....	8
1.1.2. <i>Toxoplasma</i> .....	10
<b>1.2. Lipid biology in apicomplexan parasites</b> .....	11
1.2.1. Phospholipid biogenesis in prokaryotes and eukaryotes .....	11
1.2.2. Phospholipid biogenesis in <i>T. gondii</i> .....	13
<b>1.3. Objective of this study</b> .....	14
<b>2. Materials and methods</b> .....	15
<b>2.1. Materials</b> .....	15
2.1.1. Biological resources .....	15
2.1.2. Vectors .....	15
2.1.3. Antibodies .....	15
2.1.4. Oligonucleotides .....	16
2.1.5. Chemical reagents .....	19
2.1.6. Buffers and media .....	20
2.1.7. Enzymes .....	22
2.1.8. Commercial kits .....	22
2.1.9. Instruments .....	22
2.1.10. Plasticware and other disposables .....	24
<b>2.2. Bioinformatics and phylogeny studies</b> .....	24
<b>2.3. Parasite and host cell cultivation</b> .....	25
2.3.1. Propagation of <i>E. falciformis</i> in mice and isolation of sporozoites .....	25
2.3.2. Propagation of HFF cells .....	25
2.3.3. <i>In vitro</i> culture of <i>T. gondii</i> and purification of tachyzoites .....	25
<b>2.4. Molecular cloning and construction of vectors</b> .....	26
2.4.1. Preparation of parasite RNA and DNA .....	26
2.4.2. PCR reactions .....	26
2.4.3. DNA digestion and ligation .....	26
2.4.4. Preparation of competent <i>E. coli</i> cells .....	27
2.4.5. Transformation of <i>E. coli</i> .....	27
2.4.6. Isolation of plasmid DNA .....	27

---

## TABLE OF CONTENTS

<b>2.5. Generation of transgenic <i>T. gondii</i> tachyzoites .....</b>	27
2.5.1. Transfection of tachyzoites and making of clonal transgenic lines .....	28
2.5.2. Generation of tachyzoites expressing <i>E. falciformis</i> enzymes .....	28
2.5.3. Generation of the $\Delta tgpts/EfPTS$ strain .....	28
2.5.4. Generation of transgenic tachyzoites for localization study of selected <i>T. gondii</i> enzymes.....	29
2.5.5. Generation of the $\Delta tgcds1_r$ and $\Delta tgcds1/\Delta tgcds2$ mutants .....	29
<b>2.6. RNA and protein detection .....</b>	30
2.6.1. Real-time PCR .....	30
2.6.2. Indirect immunofluorescence assay .....	30
2.6.3. Immunoblot assay .....	31
<b>2.7. Lytic cycle assays .....</b>	31
2.7.1. Plaque assay .....	31
2.7.2. Yield assay .....	32
2.7.3. Invasion assay.....	32
2.7.4. Replication and egress assays.....	32
2.7.5. Motility assay .....	32
<b>2.8. Lipid analysis .....</b>	33
<b>2.9. Virulence assay in mice .....</b>	33
<b>2.10. Statistics .....</b>	34
<b>3. Results</b>	35
<b>3.1. Exclusive phospholipid expression and autonomous membrane biogenesis in <i>E. falciformis</i> indicate a host-independent lifestyle of apicomplexan sporozoites .....</b>	35
3.1.1. Lipid profile of <i>Eimeria</i> sporozoites differs markedly from <i>Toxoplasma</i> tachyzoites .....	35
3.1.2. <i>Eimeria</i> sporozoites encode entire network for <i>de novo</i> phospholipid biogenesis .....	37
3.1.3. Lipid synthesis in <i>E. falciformis</i> is a phylogenetic mosaic of divergent pathways .....	40
3.1.4. Enzymes of <i>Eimeria</i> lipid synthesis show compartmentalized distribution in <i>T. gondii</i> .....	42
3.1.5. Trans-species expression of <i>EfPTS</i> rescues the lytic cycle of the $\Delta tgpts$ mutant.....	45
3.1.6. <i>EfPTS</i> can restore the loss of tachyzoite-specific PtdThr species in the $\Delta tgpts$ mutant .....	47
<b>3.2. Two phylogenetically and compartmentally distinct CDP-diacylglycerol synthases cooperate for lipid biogenesis in <i>T. gondii</i> .....</b>	49
3.2.1. <i>T. gondii</i> harbors two phylogenetically distinct CDS proteins .....	49
3.2.2. <i>TgCDS1</i> is expressed in the ER, whereas <i>TgCDS2</i> in the apicoplast .....	51
3.2.3. CDS enzymes are indispensable for the lytic cycle of tachyzoites .....	53
3.2.4. Conditional knockdown of <i>TgCDS1</i> impairs biogenesis of PtdIns and PtdSer .....	55
3.2.5. Loss of <i>TgCDS2</i> results in selective impairment of PtdGro synthesis .....	57
3.2.6. The CDS mutants show a defective growth due to impaired replication .....	58
3.2.7. A deficiency of CDP-DAG synthesis attenuates the parasite virulence .....	60
3.2.8. PtdGro-P and PtdIns are made in the mitochondrion and Golgi bodies, respectively .....	60
<b>4. Discussion</b>	62
<b>4.1. Phospholipid synthesis in <i>E. falciformis</i> sporozoites .....</b>	62
4.1.1. Phospholipid profile of sporozoites.....	62

---

## TABLE OF CONTENTS

---

4.1.2. Phylogenetically divergent pathways of lipid synthesis .....	64
4.1.3. Inter-organelle cooperation for lipid biogenesis .....	65
<b>4.2. Biogenesis and metabolic roles of CDP-DAG in <i>T. gondii</i> tachyzoites</b> .....	68
4.2.1. Origins and subcellular localizations of CDS enzymes .....	68
4.2.2. Functions of CDP-DAG in parasite biology .....	69
4.2.3. A “division of labor” model of lipid biogenesis .....	70
<b>5. Conclusions and perspectives</b>	72
<b>Appendices</b> .....	73
<b>References</b> .....	109
<b>List of conferences and courses</b> .....	118
<b>List of publications</b> .....	119
<b>Acknowledgements</b> .....	120
<b>Selbständigkeitserklärung</b> .....	121

---

## TABLE OF CONTENTS

---

<b>Figure 1.</b> Life cycles of coccidian parasites <i>Eimeria falciformis</i> and <i>Toxoplasma gondii</i> .....	9
<b>Figure 2.</b> Lytic cycle of <i>T. gondii</i> tachyzoites.....	10
<b>Figure 3.</b> Synthesis of major phospholipids in prokaryotes and eukaryotes. ....	12
<b>Figure 4.</b> Summary of the lipid biogenesis enzymes identified in <i>T. gondii</i> . ....	13
<b>Figure 5.</b> Lipidomics identifies differences and similarities of the phospholipid compositions between <i>E. falciformis</i> sporozoites and <i>T. gondii</i> tachyzoites.....	36
<b>Figure 6.</b> Schematic illustration showing the primary structures of putative enzymes in the phospholipid synthesis pathways of <i>E. falciformis</i> . ....	39
<b>Figure 7.</b> The phospholipid biogenesis in <i>E. falciformis</i> involves enzymes of various origins.....	41
<b>Figure 8.</b> Syntheses of phospholipids and their precursors are highly compartmentalized in <i>E. falciformis</i> . ....	44
<b>Figure 9.</b> EfPTS can complement the defects of invasion, egress and motility in a PTS-knockout mutant of <i>T. gondii</i> .....	46
<b>Figure 10.</b> EfPTS rescues the loss of tachyzoite-specific PtdThr species in the $\Delta tgpts$ mutant. ....	48
<b>Figure 11.</b> <i>T. gondii</i> expresses two distinct CDS enzymes located in the ER and apicoplast.....	50
<b>Figure 12.</b> The N-terminal of <i>TgCDS2</i> but not of <i>TgCDS1</i> is required for correct localization. ....	52
<b>Figure 13.</b> Conditional mutagenesis of <i>TgCDS1</i> and deletion of <i>TgCDS2</i> in <i>T. gondii</i> . ....	54
<b>Figure 14.</b> Conditional knockdown of <i>TgCDS1</i> results in a reduction of PtdIns and PtdSer, whereas deletion of <i>TgCDS2</i> impairs PtdGro biogenesis. ....	56
<b>Figure 15.</b> The $\Delta tgcds1$ , and $\Delta tgcds1/\Delta tgcds2$ mutants show an attenuated growth.....	59
<b>Figure 16.</b> CDP-DAG-dependent biogenesis of PtdGro-P and PtdIns in the mitochondrion and Golgi bodies of <i>T. gondii</i> tachyzoites. ....	61
<b>Figure 17.</b> Model of highly compartmentalized network of phospholipid biogenesis in <i>E. falciformis</i> sporozoites. ....	67
<b>Figure 18.</b> A “division of labor” model of CDP-DAG-dependent biogenesis of PtdIns, PtdSer and PtdGro involving the inter-organelle cooperation of specified organelles. ....	71
 <b>Table 1.</b> Oligonucleotides used in this study. ....	16
<b>Table 2.</b> EuPathDB accession numbers of the enzymes involved in phospholipid biogenesis of selected protozoan parasites. ....	38
 <b>Appendix 1.</b> List of sequences from <i>E. falciformis</i> and <i>T. gondii</i> deposited to GenBank in this study. ....	73
<b>Appendix 2.</b> Schematic illustration showing the primary structures of putative enzymes involved in phospholipid synthesis of <i>T. gondii</i> . ....	74
<b>Appendix 3.</b> Multiple alignments of the conserved functional motifs of chosen lipid synthesis enzymes from selected organisms. ....	75
<b>Appendix 4.</b> Phylogeny of selected lipid synthesis enzymes. ....	84
<b>Appendix 5.</b> Sequences used for phylogenetic analysis.....	85
<b>Appendix 6.</b> <i>TgCDS2</i> harbors bipartite signal and transit peptides. ....	93
<b>Appendix 7.</b> Phospholipid profiles of the $\Delta tgcds1$ , and $\Delta tgcds1/\Delta tgcds2$ mutants. ....	94
<b>Appendix 8.</b> Vector sequences. ....	95

---

## List of abbreviations

### Lipids and their precursors

**CDP-DAG** cytidine diphosphate-diacylglycerol  
**DAG** diacylglycerol  
**EPC** ethanolamine phosphorylceramide  
**Glycerol-3P** glycerol 3-phosphate  
**GPI** glycosylphosphatidylinositol  
**IPC** inositol phosphorylceramide  
**Lyso-PtdOH** lysophosphatidic acid  
**MUFA** monounsaturated fatty acid  
**PIP** phosphatidylinositol phosphate  
**PtdCho** phosphatidylcholine  
**PtdEtn** phosphatidylethanolamine  
**PtdGro** phosphatidylglycerol;  
**PtdGro-P** phosphatidylglycerol phosphate  
**PtdIns** phosphatidylinositol  
**PtdOH** phosphatidic acid  
**PtdSer** phosphatidylserine  
**PtdThr** phosphatidylthreonine  
**PUFA** polyunsaturated fatty acid  
**SM** sphingomyelin

### Enzymes of lipid synthesis

**CDS** cytidine diphosphate-diacylglycerol synthase  
**CEPT** choline/ethanolamine phosphotransferase  
**CLS** cardiolipin synthase  
**DGK** diacylglycerol kinase  
**EPT** ethanolamine phosphotransferase  
**FAE** fatty acid elongase  
**FASII** type II fatty acid synthase  
**G3PAT** glycerol 3-phosphate acyltransferase  
**LPAAT** lysophosphatidic acid acyltransferase  
**PAP** phosphatidic acid phosphatase  
**PEMT** phosphatidylethanolamine N-methyltransferase  
**PGPP** phosphatidylglycerol phosphate phosphatase  
**PGPS** phosphatidylglycerol phosphate synthase  
**PIS** phosphatidylinositol synthase  
**PSD** phosphatidylserine decarboxylase  
**PSS** phosphatidylserine synthase  
**PTS** phosphatidylthreonine synthase

### Subcellular locations and markers

**DER1** degradation in the endoplasmic reticulum protein 1  
**DG** dense granule  
**ER** endoplasmic reticulum  
**ERD2** endoplasmic reticulum deficient mutant 2  
**F1B** ATPase subunit F1-B  
**Fd** ferredoxin  
**GAP45** glideosome-associated protein 45  
**GRA1** dense granule protein 1  
**PV** parasitophorous vacuole  
**SAG1** surface antigen 1

### Selection markers and drugs

**CAT** chloramphenicol acetyltransferase  
**DHFR-TS** dihydrofolate reductase-thymidylate synthase  
**FUDR** 5-Fluoro-2'-deoxyuridine  
**HGPRT** hypoxanthine-xanthine-guanine phosphoribosyltransferase  
**MPA** mycophenolic acid  
**UPRT** uracil phosphoribosyltransferase

### Chemicals and media

**ATc** anhydrotetracycline  
**BSA** bovine serum albumin fraction V  
**DMEM** Dulbecco's modified eagle media  
**DMSO** dimethyl sulfoxide  
**DTT** 1,4-Dithiothreitol  
**FBS** fetal bovine serum  
**HBSS** Hank's balanced salt solution  
**PBS** phosphate buffered saline

### Real-time PCR references

**EFA** elongation factor A  
**GT1** glucose transporter 1  
**TubA** tubulin A

### Others

**HFF** human foreskin fibroblast  
**HPLC** high-performance liquid chromatography  
**MS** mass spectrometry

## 1. Introduction

### 1.1. Apicomplexan parasites

The protozoan phylum Apicomplexa comprises >6000 extant species of obligate intracellular parasites, most of which are well known for the possession of an apical complex structure required for host cell invasion<sup>1-4</sup>, as well as a unique plastid-like organelle apicoplast acquired by secondary endosymbiosis of red algae<sup>5-8</sup>. These parasites infect a wide range of organisms including livestock and humans. Some of the most prevalent and representative apicomplexan parasites infecting mammals include *Plasmodium*, *Toxoplasma*, *Eimeria* and *Cryptosporidium*. These parasites together impose a significant healthcare burden and socioeconomic impact globally.


Most apicomplexans have complex lifecycles occurring in either one (e.g. *Eimeria* and *Cryptosporidium*) or more (e.g. *Plasmodium* and *Toxoplasma*) host organisms. The natural lifecycle comprises asexual and sexual reproduction gyrating often between the primary (i.e. definitive or sexual) and secondary (i.e. intermediate or asexual) hosts. Infective stages of the apicomplexans are termed zoites, which are formed after sexual (sporozoite) or asexual (merozoite, tachyzoite, etc.) developments (Figure 1). Infection of a host typically starts with ingestion of the sporulated oocysts following the sporogony process, which leads to sporozoite release and invasion of host cells. After proliferation, parasites break out of the host cell and infect neighboring cells as merozoites. This schizogony/merogony proliferation usually occurs several times until gametogony takes place, which eventually leads to the formation of new oocysts. Beside sporozoites and merozoites, another infectious form of parasites has been described as tachyzoites during the asexual development of *Toxoplasma gondii*<sup>9</sup> (Figure 1B).

#### 1.1.1. *Eimeria*

The genus *Eimeria* consists of >1800 species of diverse vertebrate hosts and represents the largest clade in the phylum Apicomplexa<sup>10</sup>. *Eimeria* species are best known for their monoxenous (single host) lifecycle and high host specificity (Figure 1A). Upon ingestion of sporulated oocysts present in the environment, sporozoites are released and infect host intestinal epithelial cells. Then parasites develop into

## 1. INTRODUCTION


merozoites and undergo several rounds of proliferation by schizogony. Eventually, merozoites differentiate into male and female gametes, which fertilize to yield oocysts. Oocysts are shed into environment, where each oocyst is sporulated to produce 8 sporozoites for subsequent transmission to the next host. The egress of merozoites and oocysts causes the lytic collapse of intestinal epithelia, leading to severe coccidiosis, which is potentially fatal to young animals. This causes substantial economic losses in husbandry worldwide<sup>11,12</sup>. *Eimeria tenella* is the most studied species because it infects the poultry<sup>13-17</sup>. Some other species of *Eimeria* parasitizing mouse (including *E. falciformis*) are particularly attractive to examine *in vivo* parasite-host interactions and mucosal infection immunology due to well-established utility of the host as a model organism<sup>18-29</sup>. However, *in vitro* culture of *Eimeria* species and genetic manipulation have not been established yet.



**Figure 1. Life cycles of coccidian parasites *Eimeria falciformis* and *Toxoplasma gondii*.** (A) *E. falciformis* completes its entire monoxenous life cycle in the mouse. After ingestion by the host, 8 sporozoites are released from each sporulated oocyst and invade the epithelial cells of the mouse caecum. Asexual schizogony takes place when the parasites transform into trophozoites and schizonts, which leads to merozoite production. Merozoites then burst out of the host cell and invade neighboring cells to start the next round of schizogony. Following 3-4 rounds of schizogony, parasites start sexual development into male and female gametes through gametogony process, leading to the formation of zygote and eventually unsporulated oocysts. The oocysts are shed into the environment where sporulation takes place. Mature oocysts are formed after sporogony and start the next life cycle in a new host. (B) The heteroxenous life cycle of *T. gondii* occurs between intermediate hosts (mostly mammals and birds) and definitive hosts (felids). The asexual development of parasites begins when sporozoites differentiate into rapid-proliferating tachyzoites and lead to a short acute infection in the intermediate hosts. Tachyzoites then transform into slow-growing bradyzoites, which persist as cysts mainly in brain, liver and muscle tissue. Bradyzoites could differentiate back to tachyzoites when host immunity is suppressed. After cats ingest the infected tissues of intermediate hosts, parasites undergo schizogony process, followed by sexual proliferation to complete the life cycle.

### 1.1.2. *Toxoplasma*

The genus *Toxoplasma* contains only one species *T. gondii*, and yet remains among the most cosmopolitan parasites in the phylum Apicomplexa. *T. gondii* is able to infect and reproduce in most nucleated cells of virtually all warm-blood organisms. Infection, pathogenesis and transmission of *T. gondii* depend on reversible switching of two asexual stages, tachyzoites and bradyzoites, causing acute and chronic infection, respectively (Figure 1B) <sup>9</sup>. Although usually asymptomatic in healthy human adults, the latent infection has recently been reported to be associated with altered behavioral changes and neurological disorders <sup>30,31</sup>. The parasite infection of developing fetus and individuals with deteriorated immunity can be potentially fatal due to severe tissue necrosis (acute infection), which is caused by successive rounds of lytic cycles of the tachyzoites that duplicate rapidly through endodyogeny process (Figure 2). Thanks to the well-annotated genome <sup>32,33</sup> and advanced methods for genetic manipulation <sup>34-40</sup>, *T. gondii* has become an excellent model to study the biology of parasites and free-living protozoans.




**Figure 2. Lytic cycle of *T. gondii* tachyzoites.** The lytic cycle starts when tachyzoites attach and invade a host cell, followed by rapid replication in a parasitophorous vacuole (PV) to generate new tachyzoites. PV and host cell are eventually lysed when tachyzoites egress, glide to neighbor cells and initiate the next cycle.

## **1.2. Lipid biology of apicomplexan parasites**

Lipids are essential components of all cell types in every organism, and are particularly important for intracellular pathogens to survive and proliferate in their host cells. In apicomplexan parasites, phospholipids are the main structural components of both plasma membrane and intracellular membranes of compartmentalized organelles<sup>41-47</sup>. Phospholipids and their downstream products also serve as crucial pathogenesis factors by facilitating lytic cycles and escaping host immune responses<sup>48-50</sup>. Thus, parasites impose a substantial demand for phospholipids throughout their life cycles. Although apicomplexans have been shown to salvage lipids from host cells<sup>51-54</sup>, recent genetic and biochemical studies have proven that *de novo* phospholipid synthesis is often essential for parasite viability and virulence at different life stages<sup>50,55-59</sup>.

### **1.2.1. Phospholipid biogenesis in prokaryotes and eukaryotes**

*De novo* synthesis of main phospholipids commences with the assembly of lysophosphatidic acid (Lyo-PtdOH) and phosphatidic acid (PtdOH) using glycerol 3-phosphate (Glycerol-3P) and fatty acids (Figure 3). In prokaryotes, PtdOH is converted into CDP-diacylglycerol (CDP-DAG) that serves as a substrate to synthesize all lipids (Figure 3). In eukaryotes, PtdOH functions as a precursor for both CDP-DAG and diacylglycerol (DAG) that subsequently enable the synthesis of distinct phospholipid classes. CDP-DAG is utilized to make phosphatidylinositol (PtdIns) and phosphatidylglycerol (PtdGro), whereas DAG drives the synthesis of phosphatidylcholine (PtdCho) and phosphatidylethanolamine (PtdEtn) via the CDP-choline and CDP-ethanolamine pathway, respectively. PtdEtn can also be generated by decarboxylation of phosphatidylserine (PtdSer), which itself is either derived by a base-exchange reaction from PtdEtn or PtdCho (mammals) or produced by fusion of CDP-DAG and serine (yeast). In some eukaryotic cells, such as yeast and mammalian hepatocytes, PtdEtn can also be methylated to yield PtdCho (Figure 3).




**Figure 3. Synthesis of major phospholipids in prokaryotes and eukaryotes.** The depicted pathways with black arrows in red box are present in mammalian cells (human/mouse), whereas bacteria harbor only the part of the network in blue box (including PSS<sub>c</sub> shown with blue arrow). PTS is recently identified in apicomplexan parasite *T. gondii*, and is shown in red arrow. Major phospholipids, intermediates of their synthesis and underlying enzymes are in grey, white and black background, respectively. The structures of major phospholipids are shown on the right side to the network. Abbreviations: CDP-DAG, cytidine diphosphate-diacylglycerol; CDS, cytidine diphosphate-diacylglycerol synthase; CEPT, choline/ethanolamine phosphotransferase; CLS, cardiolipin synthase; DAG, diacylglycerol; DGK, diacylglycerol kinase; EPT, ethanolamine phosphotransferase; G3PAT, glycerol 3-phosphate acyltransferase; Glycerol-3P, glycerol 3-phosphate; LPAAT, lysophosphatidic acid acyltransferase; Lyso-PtdOH, lysophosphatidic acid; PAP, phosphatidic acid phosphatase; PEMT, phosphatidylethanolamine N-methyltransferase; PGPP, phosphatidylglycerol phosphate phosphatase; PGPS, phosphatidylglycerol phosphate synthase; PIS, phosphatidylinositol synthase; PSD, phosphatidylserine decarboxylase; PSS<sub>b</sub>, phosphatidylserine synthase (base-exchange type); PSS<sub>c</sub>, phosphatidylserine synthase (CDP-DAG-dependent type); PtdCho, phosphatidylcholine; PtdEtn, phosphatidylethanolamine; PtdGro, phosphatidylglycerol; PtdGro-P, phosphatidylglycerol phosphate; PtdIns, phosphatidylinositol; PtdOH, phosphatidic acid; PtdSer, phosphatidylserine; PtdThr, phosphatidylthreonine; PTS, phosphatidylthreonine synthase.

### 1.2.2. Phospholipid biogenesis in *T. gondii*

The lipid biogenesis in *T. gondii* initiates with the production of short acyl chains through a prokaryotic-like type II fatty acid synthase (FASII) pathway located in the apicoplast<sup>60,61</sup>. These acyl chains could be exported to the endoplasmic reticulum (ER), where they are modified through the fatty acid elongase (FAE) pathway to generate longer-chained and unsaturated fatty acids<sup>62</sup>. Glycerol-3P and fatty acids are utilized to synthesize Lyso-PtdOH and PtdOH, presumably in the apicoplast and/or ER<sup>63</sup>, which subsequently facilitate the synthesis of major phospholipids.

The *T. gondii* membranes consist of polar lipids and neutral lipids<sup>45,55</sup>. We have shown that phospholipids account for a major fraction of total membrane lipids isolated from *T. gondii* tachyzoites. PtdCho is the most abundant phospholipid present in tachyzoites, followed by PtdEtn, phosphatidylthreonine (PtdThr), PtdIns, PtdSer, PtdGro and PtdOH<sup>50,55</sup>. Additionally, our previous work identified the endogenous routes of PtdCho, PtdEtn, PtdThr and PtdSer synthesis in the parasite (Figure 4)<sup>50,64-66</sup>. Synthesis of PtdCho, PtdThr and PtdSer occurs in the ER, whereas PtdEtn can be made in ER, mitochondrion, dense granule (DG) and parasitophorous vacuole (PV).



**Figure 4. Summary of the lipid biogenesis enzymes identified in *T. gondii*.** Several enzymes responsible for the synthesis of major lipids (PtdEtn, PtdSer and PtdThr)<sup>50,65-66</sup> and their precursors (Lyso-PtdOH, PtdOH and DAG)<sup>63,118</sup> are identified in various subcellular compartments in *T. gondii* tachyzoites as indicated in the figure. The sketch of *T. gondii* subcellular structure is modified from reference 126. Abbreviations: DAG, diacylglycerol; DGK, diacylglycerol kinase; G3PAT/ATS, glycerol 3-phosphate acyltransferase; Glycerol-3P, glycerol 3-phosphate; Lyso-PtdOH, lysophosphatidic acid; PAP, phosphatidic acid phosphatase; PSD, phosphatidylserine decarboxylase; PSS, phosphatidylserine synthase; PtdEtn, phosphatidylethanolamine; PtdOH, phosphatidic acid; PtdSer, phosphatidylserine; PtdThr, phosphatidylthreonine; PTS, phosphatidylthreonine synthase.

### **1.3. Objective of this study**

The formation of apicomplexan “zoites” during infectious stages obliges considerable lipid biogenesis when parasites replicate inside a host cell. Previous studies on *Toxoplasma* tachyzoite and *Plasmodium* merozoite have demonstrated that these parasites not only deploy host-derived precursors to synthesize the required phospholipids<sup>50,55-59</sup>, but also competent in salvaging selected lipids from the sheltering host cells<sup>51-53</sup>. Unlike all other infectious stages of the natural lifecycle that parasitize corresponding host cells to ensure survival and reproduction, the sporozoite development occurs extracellularly and does not involve intimate interactions with host cells. Being outside the host milieu, it is not known however, how freely developing sporozoites satisfy their phospholipid demands. Moreover, from a conceptual viewpoint, the sporozoite stage imparts an excellent model to evaluate the “actual” metabolic potential of otherwise host-dependent organism. Despite the outlined importance, the sporozoite metabolism remains literally a black box from any representative apicomplexan parasite, principally because it is somewhat challenging to obtain sufficient amounts of pure sporozoites from non-model primary hosts. One aim of this study is to employ the common rodent parasite *E. falciformis* to discern the network design principles of phospholipid biogenesis in sporozoites.

In addition to an archetypal lipid network, apicomplexan pathogens have evolved many novel and often physiologically essential pathways. Some of them have originated by the endosymbiosis processes of their common ancestor with red alga, as confirmed by the existence of a chloroplast relict (termed as apicoplast) in most extant apicomplexan parasites<sup>61,63,67-69</sup>. Such divergent lipid synthesis pathways offer therapeutic targets to selectively inhibit the parasite reproduction. The enzyme CDP-DAG synthase (CDS) is one of the most central enzymes of lipid synthesis in both prokaryotes and eukaryotes. Given the functional integration of apicoplast with other organelles harboring lipid synthesis, understanding the mechanisms and importance of CDP-DAG synthesis is particularly interesting in apicomplexans. The other aim of this study is to explore the phylogenetic and metabolic roles of two divergent CDS enzymes identified in the well-established model organism *T. gondii*.

## **2. MATERIALS AND METHODS**

---

## **2. Materials and methods**

### **2.1. Materials**

#### **2.1.1. Biological resources**

<i>E. falciformis</i> oocysts	Bayer (Leverkusen, Germany)
<i>T. gondii</i> tachyzoites	
- RHΔku80-Δhxgprt strain <sup>40</sup>	Vern Carruthers (University of Michigan)
- RHΔku80-TaTi strain <sup>70</sup>	Boris Striepen (University of Georgia)
- Δtgpts starin <sup>50</sup>	Ruben D. Arroyo-Olarte (Humboldt University Berlin)
Human foreskin fibroblast (HFF) cells	Cell Lines Service (Eppelheim, Germany)
NMRI mouse	Charles River Laboratories (Wilmington, MA)
<i>E. coli</i> XL-1Blue strain	Stratagene (Heidelberg, Germany)

#### **2.1.2. Vectors**

<i>pNTP3</i>	Isabelle Coppens (John Hopkins University)
<i>pG152</i>	Markus Meissner (University of Glasgow)
<i>pTKO-HXGPRT</i>	John Boothroyd (Stanford University School of Medicine)
<i>pTUB8-CAT</i>	Dominique Soldati-Favre (University of Geneva)
<i>pTUB8-TgDER1-GFP</i>	Boris Striepen (University of Georgia)
<i>pTETO7SAG1-UPKO</i>	modified from <i>pNTP3</i>
<i>pGRA1-UPKO</i>	modified from <i>pTKO-HXGPRT</i>
<i>pTKO-CAT</i>	modified from <i>pTKO-HXGPRT</i>
<i>pTKO-DHFR-TS</i>	modified from <i>pTKO-HXGPRT</i>

#### **2.1.3. Antibodies**

α-TgF1B (mouse) <sup>71</sup>	1:1000	Peter Bradley (University of California)
α-TgFd (rabbit) <sup>72</sup>	1:500	Frank Seeber (Robert-Koch Institute Berlin)
α-TgGAP45 (rabbit) <sup>73</sup>	1:10000	Dominique Soldati-Favre (University of Geneva)
α-TgGRA1 (mouse) <sup>74</sup>	1:500	Marie-France Cesbron-Delauw (CNRS- Grenoble)
α-TgHSP90 (rabbit) <sup>75</sup>	1:10000	Sergio Angel (IIB-INTECH Argentina)
α-TgSAG1 (mouse) <sup>76</sup>	1:1000	Jean-Francois Dubremetz (University of Montpellier)
α-HA (mouse)	1:3000	Sigma-Aldrich (St. Louis, MO)

## 2. MATERIALS AND METHODS

α-HA (rabbit) 1:1000	Sigma-Aldrich (St. Louis, MO)
α-Myc (mouse) 1:5000	Sigma-Aldrich (St. Louis, MO)
α-Myc (rabbit) 1:1000	Sigma-Aldrich (St. Louis, MO)
α-Ty1 (Mouse) 1:50	Sigma-Aldrich (St. Louis, MO)
α-mouse IgG Alexa Fluor 488 (goat) 1:3000	Life Technologies (Waltham, MA)
α-mouse IgG Alexa Fluor 594 (goat) 1:3000	Life Technologies (Waltham, MA)
α-rabbit IgG Alexa Fluor 488 (goat) 1:3000	Life Technologies (Waltham, MA)
α-rabbit IgG Alexa Fluor 594 (goat) 1:3000	Life Technologies (Waltham, MA)
α-mouse IgG IRDye 800CW (goat) 1:20000	LI-COR Biosciences (Lincoln, NE)
α-rabbit IgG IRDye 680RD (goat) 1:20000	LI-COR Biosciences (Lincoln, NE)

### 2.1.4. Oligonucleotides

All oligonucleotides used in this study were supplied from Life Technologies (Waltham, MA) and are listed in Table 1.

**Table 1. Oligonucleotides used in this study.**

Primer name (Restriction site)	Primer sequence (Restriction site underlined)	Vector (Objective)
Ectopic expression of selected <i>E. falciformis</i> enzymes in <i>T. gondii</i> tachyzoites ( $\Delta$ ku80- $\Delta$ hxgprt strain)		
<i>Ef</i> G3PAT1-F ( <i>Nsi</i> I) <i>Ef</i> G3PAT1-HA-R ( <i>Pac</i> I)	CTCATCAT <u>GCATTATTCCTGGTTAAGTGGCTCTG</u> CTCAT <u>CTTAATTAAC</u> TAAGCGTAATCTGGAACATCGTATGGG TAAATGACTTCCGTAGAACCGC	<i>pGRA1-UPKO</i> (Ectopic expression)
<i>Ef</i> G3PAT2-F ( <i>Sbf</i> I) <i>Ef</i> G3PAT2-HA-R ( <i>Pac</i> I)	CTCAT <u>CCCTGCAGGGGGCCC</u> TATTCGCTT CTCAT <u>CTTAATTAAGCGTAAT</u> CTGGAACATCGTATGGTAGC GCGAAGAGACAACGC	
<i>Ef</i> LPAAT1-F ( <i>Nsi</i> I) <i>Ef</i> LPAAT1-HA-R ( <i>Pac</i> I)	CTCATCAT <u>GCATGCC</u> CATAAAATTTATGTTTCTC CTCAT <u>CTTAATTAAGCGTAAT</u> CTGGAACATCGTATGGTAGA GCCATGACCGCG	
<i>Ef</i> LPAAT2-F ( <i>Nsi</i> I) <i>Ef</i> LPAAT2-HA-R ( <i>Pac</i> I)	CTCATCAT <u>GCATCCC</u> CTGCTGCCGAG CTCAT <u>CTTAATTAAC</u> TAAGCGTAATCTGGAACATCGTATGGG TACTGCAGTGCTGCCCTGCTCT	
<i>Ef</i> CDS1-F ( <i>Sbf</i> I) <i>Ef</i> CDS1-HA-R ( <i>Pac</i> I)	CTCAT <u>CCCTGCAGGCGGAGGGGT</u> GAAAATGC CTCAT <u>CTTAATTAAGCGTAAT</u> CTGGAACATCGTATGGTAAT CCCCAGCGGCCG	
<i>Ef</i> CDS2-F ( <i>Nsi</i> I) <i>Ef</i> CDS2-HA-R ( <i>Pac</i> I)	CTCATCAT <u>GCATCCC</u> GTGGCACCCAC CTCAT <u>CTTAATTAAC</u> TAAGCGTAATCTGGAACATCGTATGGG TACCGCCTCATTCCCTTGTCT	
<i>Ef</i> PAP-F	CTCATCAT <u>GCATAAGCCGACAGATCAAGATTG</u>	

## 2. MATERIALS AND METHODS

<i>EfPAP</i> -HA-R ( <i>Pacl</i> )	CTCAT <u>CTTAATTA</u> ACTAAGCGTAATCTGGAACATCGTATGGG TAAGCCCTGAGATCCACAACAA	
<i>EfDGK1</i> -F ( <i>Nsil</i> ) <i>EfDGK1</i> -HA-R ( <i>Pacl</i> )	CTCAT <u>CATGCATCTGT</u> CCGTAAAGGAGAGCAACT CTCAT <u>CTTAATTA</u> ACTAAGCGTAATCTGGAACATCGTATGGG TATGGATCAGCTGCACAGC	
<i>EfDGK2</i> -F ( <i>PstI</i> ) <i>EfDGK2</i> -HA-R ( <i>Pacl</i> )	CTCAT <u>CCTGCAGG</u> ACTCCTGCTCCGATATGG CTCAT <u>CTTAATTA</u> ACTAAGCGTAATCTGGAACATCGTATGGG TACTTCGATCTCGGTATCTTAGCAT	
<i>EfPGPS</i> -F ( <i>Nsil</i> ) <i>EfPGPS</i> -HA-R ( <i>Pacl</i> )	CTCAT <u>CATGCATGC</u> AGCGTCGAC CTCAT <u>CTTAATTA</u> AGCGTAATCTGGAACATCGTATGGTAGA GCAAAGATCCGAGGCC	
<i>EfCLS</i> -F ( <i>EcoRV</i> ) <i>EfCLS</i> -HA-R ( <i>Pacl</i> )	CTCAT <u>CGATATCATGGT</u> GCTGCAGTCC CTCAT <u>CTTAATTA</u> ATCAAGCGTAATCTGGAACATCGTATGGG TAGCATCCGCAGAAGATGGG	
<i>EfPIS</i> -F ( <i>Nsil</i> ) <i>EfPIS</i> -HA-R ( <i>Pacl</i> )	CTCAT <u>CATGCATTCT</u> TATGGACAAGGGTTGAGG CTCAT <u>CTTAATTA</u> ACTAAGCGTAATCTGGAACATCGTATGGG TAGTCCTCGGCCTTCCTCG	
<i>EfCEPT1</i> -F ( <i>Nsil</i> ) <i>EfCEPT1</i> -HA-R ( <i>Pacl</i> )	CTCAT <u>CATGCATATGGT</u> GGCTGGGCCT CTCAT <u>CTTAATTA</u> AGCGTAATCTGGAACATCGTATGGTAGT CGTCTTGACCTGCGC	
<i>EfCEPT2</i> -F ( <i>Nsil</i> ) <i>EfCEPT2</i> -HA-R ( <i>Pacl</i> )	CTCAT <u>CATGCATGGGG</u> GAGCCTCGGG CTCAT <u>CTTAATTA</u> AGCGTAATCTGGAACATCGTATGGTATT TGCCTTCTGTCCCTTCG	
<i>EfPSD1</i> -F ( <i>Nsil</i> ) <i>EfPSD1</i> -HA-R ( <i>Pacl</i> )	CTCAT <u>CATGCATGGCT</u> GTCGAATTCCGTTG CTCAT <u>CTTAATTA</u> ACTAAGCGTAATCTGGAACATCGTATGGG TAGTAATGCACGAATCTGCGTTC	
<i>EfPSD2</i> -F ( <i>SbfI</i> ) <i>EfPSD2</i> -HA-R ( <i>Pacl</i> )	CTCAT <u>CCCTGCAGG</u> GAGCTTTGCTCCATTCTGTT CTCAT <u>CTTAATTA</u> AGCGTAATCTGGAACATCGTATGGTATT GCGGTTTTCTAAGTCAAAG	
<i>EfPSS</i> -F ( <i>Nsil</i> ) <i>EfPSS</i> -HA-R ( <i>Pacl</i> )	CTCAT <u>CATGCATGACGT</u> GCGGGCGTCG CTCAT <u>CTTAATTA</u> ACTAAGCGTAATCTGGAACATCGTATGGG TAGCTGCTGCAACAACTGAAG	
<i>EfPTS</i> -F ( <i>Nsil</i> ) <i>EfPTS</i> -HA-R ( <i>Pacl</i> )	CTCAT <u>CATGCATAGGG</u> AACCAAAGAACAAAGC CTCAT <u>CTTAATTA</u> AGCGTAATCTGGAACATCGTATGGTAGG ATCCGTAGTAGTACTGCTTG	
3' HA tagging of selected genes ( $\Delta$ ku80- $\Delta$ hxgprt strain)		
<i>TgCDS1</i> -COS-F <i>TgCDS1</i> -COS-R	TACTTCCAATCCA <u>ATTTA</u> ATGCTCTGCGAAGGGAAAGC TCCTCCACTCCA <u>ATTTAG</u> CCGAATT CGGTTGTCC	<i>pG152</i> (Ligation independent cloning)
<i>TgCDS2</i> -COS-F <i>TgCDS2</i> -COS-R	TACTTCCAATCCA <u>ATTTA</u> ATGCTCTCCGGTGTCTGCGTCT TCCTCCACTCCA <u>ATTTAG</u> CGGGCCTGCATCTGCGGGAC	
<i>TgPGPS</i> -COS-F	TACTTCCAATCCA <u>ATTTA</u> ATGCAGAAGGCGGAGAAGAG	

## 2. MATERIALS AND METHODS

<i>TgPGPS-COS-R</i>	TCCTCCACTCCAATTTAGCAAACAACCAGATTCCCTT	
Ectopic expression of <i>TgCDS1</i> and <i>TgCDS2</i> without N-terminal extensions and with C-terminal Myc tag ( <i>TgCDS1</i> or <i>TgCDS2</i> 3' tagging strains)		
<i>TgCDS1</i> <sup>398-1068</sup> -F ( <i>Nsil</i> )	CTCAT <u>CTGCATCGCGTCGGTCGCT</u>	<i>pTKO-CAT</i> (Ectopic expression)
<i>TgCDS1-Myc-R</i> ( <i>Pacl</i> )	CTCAT <u>CTTAATTAATCAGAGGTCTTCGGAAATCAACTTCT</u> GTTCCCAGAAATTGGTTGTCCT	
<i>TgCDS2</i> <sup>527-1044</sup> -F ( <i>SbfI</i> )	CTCAT <u>CCCTGCAGGAGCATTGCGAGTGAGCACTG</u>	<i>pTKO-DHFR-TS</i> (Ectopic expression)
<i>TgCDS2-Myc-R</i> ( <i>Pacl</i> )	CTCAT <u>CTTAATTAATCAGAGGTCTTCGGAAATCAACTTCT</u> GTTCGGCCTGCATCTGCGG	
Ectopic expression of <i>TgCDS1</i> and <i>TgCDS2</i> with N-terminal Myc and C-terminal HA tags as well as <i>TgPIS</i> with C-terminal HA tag ( $\Delta$ <i>ku80</i> -TaTi strain)		
<i>TgCDS1-Myc-F</i> ( <i>BspHI</i> )	CTCAT <u>CTCATGAGTGAACAGAACAGTTGATTCCGAAGAACACC</u>	<i>pTETO7SAG1-UPKO</i> (Ectopic expression)
<i>TgCDS1-HA-R</i> ( <i>Pacl</i> )	TCGAACCCCCGTCGTCGC CTCAT <u>CTTAATTAATCAAGCGTAATCTGGAACATCGTATGGG</u> TACCGAAATTGGTTGTCCTGCAC	
<i>TgCDS2-Myc-F</i> ( <i>BspHI</i> )	CTCAT <u>CTCATGAGTGAACAGAACAGTTGATTCCGAAGAACACC</u>	
<i>TgCDS2-HA-R</i> ( <i>Pacl</i> )	TCGAGGAAACGCGAGACTTCAGAGAAC CTCAT <u>CTTAATTAATCAAGCGTAATCTGGAACATCGTATGGG</u> TAGGCCTGCATCTGCGGGAC	
<i>TgPIS-F</i> ( <i>Ncol</i> )	CTCAT <u>CCCATGGCGGGACTTCTGCAAGCCG</u>	
<i>TgPIS-HA-R</i> ( <i>Pacl</i> )	CTCAT <u>CTTAATTAATCAAGCGTAATCTGGAACATCGTATGGG</u> TACGACGAGGGCGCACAAA	
Making the $\Delta$ <i>tgcds1</i> , mutant ( $\Delta$ <i>ku80</i> -TaTi strain)		
<i>TgCDS1-F</i> ( <i>BspHI</i> )	CTCAT <u>CTCATGAAACCCCCGTCGTCGCCGATA</u>	<i>pTETO7SAG1-UPKO</i> (Ectopic expression)
<i>TgCDS1-HA-R</i> ( <i>Pacl</i> )	CTCAT <u>CTTAATTAATCAAGCGTAATCTGGAACATCGTATGGG</u> TACCGAAATTGGTTGTCCTGCAC	
<i>TgCDS1-5'UTR-F</i> ( <i>XcmI</i> )	CTCAT <u>CCCACCGGTACCTGGCGAATCGTGTGTTGTTCCCTCT</u>	<i>pTKO-DHFR-TS</i> (Homologous recombination)
<i>TgCDS1-5'UTR-R</i> ( <i>SpeI</i> )	T CTCAT <u>CACTAGTCCGGGTTTGACCTTA</u>	
<i>TgCDS1-3'UTR-F</i> ( <i>HindIII</i> )	CTCAT <u>CAAGCTTCATTGTAAGAGTATGCACACGTG</u>	
<i>TgCDS1-3'UTR-R</i> ( <i>Apal</i> )	CTCAT <u>CGGCCCGGGAGCCTGGTAGAGGTC</u>	
<i>TgCDS1-5'Scr-F</i>	TGTCTTCCTGCCTGTCTG	<i>pDrive</i> (Verification)
<i>TgCDS1-5'Scr-R</i>	ACAGTCTCACCTCGCCTTGT	
<i>TgCDS1-3'Scr-F</i>	CTCGCTGGTAGTCCAACTG	
<i>TgCDS1-3'Scr-R</i>	CAAAGCGAGACAGCATAACCA	
Making the $\Delta$ <i>tgcds1</i> / $\Delta$ <i>tgcds2</i> mutant ( $\Delta$ <i>tgcds1</i> , mutant)		
<i>TgCDS2-5'UTR-F</i> ( <i>Apal</i> )	CTCAT <u>CGGGCCCAGTCCTGCGATTTCCTCCCTG</u>	<i>pTUB8-CAT</i> (Homologous recombination)
<i>TgCDS2-5'UTR-R</i> ( <i>Apal</i> )	CTCAT <u>CGGCCCTTCGTCGCCTGCAAGTTT</u>	
<i>TgCDS2-3'UTR-F</i> ( <i>XbaI</i> )	CTCAT <u>CTCGAGACGCAGGAGGGGAGG</u>	
<i>TgCDS2-3'UTR-R</i> ( <i>XbaI</i> )	CTCAT <u>CTAGAAGACGCTTCTGCTCGCG</u>	
<i>TgCDS2-5'Scr-F</i>	AAGGCGACGAAACTCAAC	<i>pDrive</i>

## 2. MATERIALS AND METHODS

<i>TgCDS2-5'Scr-R</i>	GCTTATCGATAACCGTCGAGG	(Verification)
<i>TgCDS2-3'Scr-F</i> <i>TgCDS2-3'Scr-R</i>	CTATCAGTTGTTTAGTCGAACCG CGAATCTGAATCTGAAGAACCC	
Real-time PCR ( $\Delta tgcds1$ , and $\Delta tgcds1/\Delta tgcds2$ mutants)		
<i>TgCDS1-qPCR-F</i>	GTCTCGTCACGTACACTGCG	Real-time PCR
<i>TgCDS1-qPCR-R</i>	GATCACGAGCGAGGTTGG	
<i>TgCDS2-qPCR-F</i>	GCATCTTCAATCCTCTCTCAA	
<i>TgCDS2-qPCR-R</i>	CCAAATCAGGGAGAAAGATGG	
<i>TgEFA-qPCR-F</i>	AGTCGACCACTACCGGACAC	
<i>TgEFA-qPCR-R</i>	CTCGGCCTTCAGTTATCCA	
<i>TgTubA-qPCR-F</i>	AGGATGCTGCGAACAACTTC	
<i>TgTubA-qPCR-R</i>	TCAAGAAACCTGGAGACCA	
<i>TgGT1-qPCR-F</i>	GGCTATTGCGACCTTCA	
<i>TgGT1-qPCR-R</i>	AACGGGAAGACAAACCACAG	

### 2.1.5. Chemical reagents

1,4-Dithiothreitol (DTT)	Carl Roth (Karlsruhe, Germany)
5-Fluoro-2'-deoxyuridine (FUDR)	Sigma-Aldrich (St. Louis, MO)
ATP	Sigma-Aldrich (St. Louis, MO)
Agarose	Biozym (Hessisch Oldendorf, Germany)
Ampicillin	Applichem (Darmstadt, Germany)
Anhydrotetracycline (ATc)	IBA Lifesciences (Goettingen, Germany)
Bovine serum albumin fraction V (BSA)	Applichem (Darmstadt, Germany)
Bromophenol blue	Merck (Darmstadt, Germany)
Chloramphenicol	Carl Roth (Karlsruhe, Germany)
Chloroform	Carl Roth (Karlsruhe, Germany)
Crystal violet	Sigma-Aldrich (St. Louis, MO)
Dimethyl sulfoxide (DMSO)	Sigma-Aldrich (St. Louis, MO)
DNA ladder (1 kb)	Fermentas (Waltham, MA)
Distilled water (HPLC-purified)	Carl Roth (Karlsruhe, Germany)
dNTP-Mix (100 mM)	Fermentas (Waltham, MA)
Dulbecco's modified eagle media (DMEM)	Biowest (Riverside, MO)
Ethanol	Carl Roth (Karlsruhe, Germany)
Fetal bovine serum (FBS)	PAN-Biotech (Aidenbach, Germany)
Fluoromount-G/DAPI	SouthernBiotech (Birmingham, AL)
Glycerol	Applichem (Darmstadt, Germany)
Hank's balanced salt solution (HBSS)	PAA (Linz, Austria)
Isopropanol	Applichem (Darmstadt, Germany)

## **2. MATERIALS AND METHODS**

---

L-glutamine (100x stock)	Biowest (Riverside, MO)
MEM non-essential amino acids (100x stock)	Biowest (Riverside, MO)
Methanol	Carl Roth (Karlsruhe, Germany)
Mycophenolic acid (MPA)	AppliChem (Darmstadt, Germany)
Natural and synthetic lipids	Avanti Polar Lipids (Alabaster, AL)
Paraformaldehyde	Merck (Darmstadt, Germany)
Penicillin/Streptomycin (100x stock)	Biowest (Riverside, MO)
Phosphat buffered saline (PBS)	Biowest (Riverside, MO)
Protein marker (prestained)	Fermentas (Waltham, MA)
Pyrimethamine	AK Scientific (Union City, CA)
Rotiphorese gel 30 (Acrylamide)	Carl Roth (Karlsruhe, Germany)
Sodium pyruvate (100x stock)	Biowest (Riverside, MO)
Tris-HCl	Promega (Fitchburg, WI)
Trizol	Life Technologies (Waltham, MA)
Trypsin/EDTA	Biowest (Riverside, MO)

Other standard chemicals used in preparations for media and buffers were purchased from AppliChem, Carl Roth or Sigma-Aldrich.

### **2.1.6. Buffers and media**

#### *T. gondii* culture - Cytomix

120 mM KCl; 25 mM HEPES (pH 7.6); 5 mM MgCl<sub>2</sub>; 2 mM EDTA; 0.15 mM CaCl<sub>2</sub>; 10 mM K<sub>2</sub>HPO<sub>4</sub>/KH<sub>2</sub>PO<sub>4</sub> (pH 7.6); in deionized H<sub>2</sub>O; adjusted to pH 7.6; filter-sterilized with 0.22 µm filter; stored at 4 °C.

#### *T. gondii* culture - D10 medium

500 ml DMEM (high glucose, no L-glutamine); 50 ml iFBS (heat-inactivated); 5.5 ml L-glutamine (200 mM); 5.5 ml non-essential amino acids (100x); 5.5 ml penicillin/streptomycin (100x); 5.5 ml sodium pyruvate (100 mM); stored at 4 °C.

#### *T. gondii* culture - Freezing stock medium

10% DMSO in heat-inactivated iFBS, stored at -20 °C.

#### *E. coli* culture - LB medium

## **2. MATERIALS AND METHODS**

---

10 g tryptone; 5 g yeast extract; 10 g NaCl; optional 15 g agar for plates; in 1 L deionized H<sub>2</sub>O; autoclaved.

*E. coli* culture - SOB/SOC medium

20 g tryptone; 5 g yeast extract; 0.5 g NaCl; 0.186 g KCl; in 1 L deionized H<sub>2</sub>O; autoclaved; 0.952 g MgCl<sub>2</sub>; optional 3.603 g glucose for SOC medium; filter-sterilized with 0.22 µm filter.

Preparation of competent *E. coli* - TFB-I buffer

30 mM KOAc; 50 mM MnCl<sub>2</sub>; 100 mM RbCl; 10 mM CaCl<sub>2</sub>; 15% Glycerol; adjusted to pH 5.8; filter-sterilized with 0.22 µm filter; stored at 4 °C.

Preparation of competent *E. coli* - TFB-II buffer

10 mM NaMOPS; 10 mM RbCl; 75 mM CaCl<sub>2</sub>; 15% Glycerol; adjusted to pH 7.0; filter-sterilized with 0.22 µm filter; stored at 4 °C.

Agarose electrophoresis - TAE buffer

40 mM Tris-HCl (pH8); 1 mM EDTA; 0.11% acetic acid; in deionized H<sub>2</sub>O.

Western blotting - 5% stacking gel

1.4 ml deionized H<sub>2</sub>O; 0.33 ml 30% acrylamide; 0.25 ml 1 M Tris-HCl (pH 6.8); 20 µl 10% SDS; 20 µl 10% APS; 10 µl TEMED.

Western blotting - 10% resolving gel

1.93 ml deionized H<sub>2</sub>O; 1.67 ml 30% acrylamide; 1.3 ml 1.5 M Tris-HCl (pH 8.8); 50 µl 10% SDS; 50 µl 10% APS; 3 µl TEMED.

Western blotting - SDS loading buffer (2x)

0.1% bromophenol blue; 100 mM DTT; 20% glycerol; 5% mercaptoethanol; 4% SDS; 100 mM Tris-HCl (pH 6.8); in deionized H<sub>2</sub>O.

Western blotting - SDS running buffer (5x)

1.25 M glycine; 0.5% SDS; 125 mM Tris-HCl (pH 8.3); in deionized H<sub>2</sub>O.

Western blotting - Semi-dry blot transfer buffer

38 mM glycine; 20% methanol; 0.0037% SDS; 48 mM Tris-HCl (pH 8.3); in deionized H<sub>2</sub>O.

## **2. MATERIALS AND METHODS**

---

Western blotting - TBS buffer (10x)  
0.5 M Tris-HCl (pH 7.6); 1.5 M NaCl; in deionized H<sub>2</sub>O.

Western blotting - TBS-T buffer  
10% 10x TBS buffer; 0.2% Tween 20; in deionized H<sub>2</sub>O.

Western blotting - Blocking buffer  
5% skimmed milk powder; in TBS-T buffer.

### **2.1.7. Enzymes**

Antarctic phosphatase	New England Biolabs (Ipswich, MA)
Dream Taq polymerase	Fermentas (Waltham, MA)
Klenow enzyme	New England Biolabs (Ipswich, MA)
Pfu Ultra II Fusion HS DNA polymerase	Stratagene (Heidelberg, Germany)
Proteinase K	Sigma-Aldrich (St. Louis, MO)
Q5 polymerase	New England Biolabs (Ipswich, MA)
Restriction endonucleases	New England Biolabs (Ipswich, MA)
T4 ligase	Life Technologies (Waltham, MA)

### **2.1.8. Commercial kits**

CloneEZ PCR cloning kit	GenScript (Piscataway, NJ)
First-strand cDNA synthesis kit	Life Technologies (Waltham, MA)
Genomic DNA preparation kit	Analytik Jena (Jena, Germany)
InnuPREP DOUBLEpure kit	Analytik Jena (Jena, Germany)
InnuPREP plasmid mini kit	Analytik Jena (Jena, Germany)
pDrive PCR cloning kit	Qiagen (Hilden, Germany)
Platinum SYBR green qPCR superscript-UDG kit	Invitrogen (Waltham, MA)
PureLink RNA mini kit	Life Technologies (Waltham, MA)
PureLink HiPure plasmid midiprep kit	Life Technologies (Waltham, MA)

### **2.1.9. Instruments**

Camera system (E.A.S.Y. RH)	Herolab (Wiesloch, Germany)
Centrifuge (5415C, 5417R and 5810R)	Eppendorf (Hamburg, Germany)
Centrifuge (Ultra, Avanti J-26S XP)	Beckmann Coulter (Brea, CA)

## **2. MATERIALS AND METHODS**

---

Counting chamber (Neubauer improved)	Fuchs Rosenthal (Freiburg, Germany)
Cryo container (Nalgene Mr. Frosty)	Thermo Fisher Scientific (Waltham, MA)
Electric pipetting aid (Accu-jet Pro)	Brand (Wertheim, Germany)
Electrophoresis power supply (EPS 300)	Pharmacia Biotech (Uppsala, Sweden)
Electroporator (Amaxa Nucleofector)	Lonza (Basel, Switzerland)
Electroporator (BTX Square Porator ECM 830)	BTX (Holliston, MA)
Gel electrophoresis system (Easy Phor)	Biozym (Hessisch Oldendorf, Germany)
Ice machine (ZBE 110-35)	Ziegra (Isernhagen, Germany)
Incubator (Modell 500)	Memmert (Schwabach, Germany)
Incubator-CO <sub>2</sub> (APT.line C 150)	Binder (Tuttlingen, Germany)
Incubator-CO <sub>2</sub> (FUNCTIONLine)	Heraeus Instruments (Hanau, Germany)
Incubator-CO <sub>2</sub> (HERACELL 150i)	Thermo Fisher Scientific (Waltham, MA)
Incubator-shaking (New Brunswick Innova 4000)	Eppendorf (Hamburg, Germany)
Infrared imaging system (Odyssey Fc)	LI-COR Biosciences (Lincoln, NE)
Microscope-fluorescence (Axio Image.Z2)	Zeiss (Oberkochen, Germany)
Microscope-inverted (LABOVERT)	Leica (Wetzlar, Germany)
Microscope-light optical (DM750)	Leica (Wetzlar, Germany)
Microwave (M805 Typ KOR-6115)	Alaska (Düsseldorf, Germany)
PCR cycler (Flex Cycler)	Analytik Jena (Jena, Germany)
Photometer (BioPhotometer)	Eppendorf (Hamburg, Germany)
Photometer (NanoDrop spectral, ND-1000)	Peqlab (Darmstadt, Germany)
Pipette	Eppendorf (Hamburg, Germany)
Pipette-multichannel (Transferpipette-8/-12)	Brand (Wertheim, Germany)
Real-time RT-PCR cycler (Mastercycler realplex <sup>2</sup> )	Eppendorf (Hamburg, Germany)
Safety work bench (HeraSafe)	Heraeus Instruments (Hanau, Germany)
Scale (BP 110 S)	Sartorius (Göttingen, Germany)
Scale (FA-30100-2)	Faust (Schaffhausen, Switzerland)
Scale (PCB400-2)	Kern & Sohn (Balingen, Germany)
SDS-PAGE system (SE 250 Mighty Small II)	Hoefer (Holliston, MA)
Shaker-thermo (Thermomixer comfort)	Eppendorf (Hamburg, Germany)
Steam-sterilizer (VARIOKLAV)	Thermo Fisher Scientific (Waltham, MA)
UV-transilluminator (UVT-20M/W)	Herolab (Wiesloch, Germany)
Waterbath (U3)	Julabo (Seelbach, Germany)
Waterbath (WB-4MS)	Biosan (Riga, Latvia)

## 2. MATERIALS AND METHODS

---

Western Blotting System (SEDEC M)

Peqlab (Darmstadt, Germany)

### 2.1.10. Plasticware and other disposables

Cell culture plate (6-, 24- and 96-well)	Sarstedt (Nümbrecht, Germany)
Cell culture dish (60x15 mm)	Sarstedt (Nümbrecht, Germany)
Cell scraper (30 cm)	TPP (Trasadingen, Switzerland)
Cuvette-electroporation	Eppendorf (Hamburg, Germany)
Cuvette-UV	Carl Roth (Karlsruhe, Germany)
DuraSeal laboratory sealing film	Diversified Biotech (Dedham, MA)
Filter (5 µm)	Merck Millipore (Billerica, MA)
Filter (0.22 µm)	Schleicher Schuell (München, Germany)
Glass cover slip and microscopic slide	Carl Roth (Karlsruhe, Germany)
Glove	Sempermed (Vienna, Austria)
Hypodermic needle	BD Bioscience (Franklin Lakes, NJ)
Nitrocellulose transfer membrane	Applichem (Darmstadt, Germany)
Parafilm	Bemis Company (Neenah, WI)
Petri dish (94x16 mm)	Greiner Bio One (Kremsmünster, Austria)
Pipette-pasteur	A. Hartenstein (Würzburg, Germany)
Pipette-serological (10 ml and 25 ml)	Greiner Bio One (Kremsmünster, Austria)
Syringe	BD Bioscience (Franklin Lakes, NJ)
Syringe-hamilton	Hamilton (Reno, NV)
Tip-pipette (10 - 1000 µl)	Greiner Bio One (Kremsmünster, Austria)
Tip-RNAase free barrier (10 - 1000 µl)	Biozym (Hessisch Oldendorf, Germany)
Tube-borosilicate glass (16 ml)	Sigma-Aldrich (St. Louis, MO)
Tube-cryo preservation (1.8 ml)	Sarstedt (Nümbrecht, Germany)
Tube-falcon (15 ml and 50 ml)	Greiner Bio One (Kremsmünster, Austria)
Tube-PCR (0.2 ml) )	Sarstedt (Nümbrecht, Germany)
Tube-PCR stripe (0.2 ml)	Biozym (Hessisch Oldendorf, Germany)
Tube-polypropylene culture (12 ml)	Greiner Bio One (Kremsmünster, Austria)
Tube-reaction (1.5 ml and 2 ml)	Sarstedt (Nümbrecht, Germany)
Whatman paper (3 MM)	A. Hartenstein (Würzburg, Germany)

### 2.2. Bioinformatics and phylogeny studies

## **2. MATERIALS AND METHODS**

---

Initial identification of the enzymes in phospholipid biogenesis pathways of protozoan parasites was performed using EuPathDB ([www.eupathdb.org](http://www.eupathdb.org)) and ToxoDB ([www.toxodb.org](http://www.toxodb.org))<sup>33,77</sup>. The functional domains and transmembrane regions of the enzymes were predicted by Simple Modular Architecture Research Tool (SMART) (<http://smart.embl-heidelberg.de>) and Transmembrane Hidden Markov Model (TMHMM) (<http://www.cbs.dtu.dk/services/TMHMM/>). The signal and transit peptides were predicted by SignalP 4.1 (<http://www.cbs.dtu.dk/services/SignalP/>), ChloroP 1.1 (<http://www.cbs.dtu.dk/services/ChloroP/>) and PlasmoAP algorithm (<http://v4-4.plasmodb.org/restricted/PlasmoAPcgi.shtml>). The peptides for mitochondrial targeting were predicted by Mitoprot (<https://ihg.gsf.de/ihg/mitoprot.html>). The phylogenetic trees were constructed with CLC Sequence Viewer 7.7 (<http://www.clcbio.com/products/clc-sequence-viewer/>) and visualized with FigTree v1.4.2 (<http://tree.bio.ed.ac.uk/software/figtree/>).

### **2.3. Parasite and host cell cultivation**

#### **2.3.1. Propagation of *E. falciformis* in mice and isolation of sporozoites**

The life cycle of *E. falciformis* was maintained by continuous passage of parasite oocysts in NMRI mice<sup>25</sup>. Oocysts in the animal feces were washed in water, sterilized, floated with NaOCl, and stored in potassium dichromate at 4 °C up to 3 months<sup>18</sup>. Purified oocysts were digested with 0.4% pepsin (pH 3, 37 °C, 1 h) before wash with PBS. Sporocysts were released by mixing oocyst pellet with glass beads (0.5 mm) and vortexing, and incubated in DMEM medium supplemented with 0.25% trypsin, 0.75% sodium tauroglycocholate, 20 mM glutamine, 100 units/ml penicillin and 100 ug/ml streptomycin at 37 °C for 2 h. Free sporozoites were column-purified by DE-52 anion exchange chromatography<sup>78</sup> and stored at -80 °C for lipid analysis.

#### **2.3.2. Propagation of HFF cells**

HFFs were cultured in D10 medium at 37 °C with 5% CO<sub>2</sub> in a humidified incubator. The cells were harvested by trypsinization and grown to confluence in cell culture flasks, dishes or plates, as required.

#### **2.3.3. *In vitro* culture of *T. gondii* and purification of tachyzoites**

## **2. MATERIALS AND METHODS**

---

Tachyzoites of *T. gondii* were propagated by serial passage in HFF monolayers at a MOI of 3. For all assays, parasites were mechanically released from late-stage cultures and used immediately. Parasitized cells (40-42 h post infection) were scraped in fresh culture medium and squirted through 23G and 27G syringes (2x each) to obtain extracellular tachyzoites for direct use in transfection and lytic cycle assays. For lipidomics study, syringe-released parasites were additionally filtered by 5 µm filters and stored in -80 °C. For quantification, parasites were diluted appropriately and counted using the Neubauer improved counting chamber.

### **2.4. Molecular cloning and construction of vectors**

#### **2.4.1. Preparation of parasite RNA and DNA**

Parasite RNA was isolated from freshly purified *E. falciformis* sporozoites or syringe-released *T. gondii* tachyzoites using TRIzol-based extraction method with PureLink RNA mini kit and subsequently reverse-transcribed using First-strand cDNA synthesis kit with oligo-dT primer. Parasite gDNA was isolated using the genomic DNA preparation kit. RNA, cDNA and gDNA samples were stored at -80 °C, -20 °C and 4 °C, respectively.

#### **2.4.2. PCR reactions**

All DNA amplicons for molecular cloning were amplified using Pfu Ultra II Fusion polymerase or Q5 polymerase. 10-200 ng of cDNA or gDNA was used as template in standard PCR reactions in a Flex PCR according to the manufacturer's protocol. For colony PCR, *E. coli* cells were suspended in 20 µl of distilled H<sub>2</sub>O, and 3 µl was used as PCR template with Dream Taq polymerase. The PCR outcome was mixed with DNA-loading dye before DNA was separated on 0.8 % agarose gels stained with RedSafe DNA staining solution at 90-120 V in TAE buffer and visualized by a UV-transilluminator. PCR products were purified from column or agarose gel using the innuPREP DOUBLEpure kit. NanoDrop Spectrophotometer ND-1000 was used to determine the DNA concentration.

#### **2.4.3. DNA digestion and ligation**

## **2. MATERIALS AND METHODS**

---

DNA fragments were cloned into the respective vectors either by ligation-independent or restriction endonuclease-mediated cloning. CloneEZ PCR cloning kit was used for ligation-independent cloning. For restriction cloning, DNA fragments and vectors were digested with 3 units per  $\mu$ g DNA of indicated restriction endonucleases following manufacturing instruction. Digested insert and vector DNA was purified and ligated in a molar ratio of 3:1 or 5:1 (fmol of insert : fmol of vector) for sticky or blunt end ligation, respectively, using T4 ligase at room temperature for 1 h or at 4 °C overnight before transformation in *E. coli*.

### **2.4.4. Preparation of competent *E. coli* cells**

5 ml SOB culture (with 12.5  $\mu$ g/ml tetracycline) of XL-1Blue cells was inoculated over night, then diluted in 200 ml of the same medium for further inoculation at 37 °C until OD<sub>600</sub> reaches 0.4 - 0.6. Cells were harvested (1300 g, 10 min, 4°C). The pellet was washed once in 50 ml of ice-cold TFB-I buffer and resuspended in 6.4 ml of TFB-II buffer before stocking at -80 °C.

### **2.4.5. Transformation of *E. coli***

The ligation reaction was mixed with competent *E. coli* XL-1Blue cells (90-100  $\mu$ l) before incubation for 30 min on ice. The cells were then heat-shocked for 45 sec at 42 °C and immediately chilled on ice for 2 min before addition of 700  $\mu$ l SOC medium and incubation at 37 °C for 1 h. Cells were pelleted and suspended in 100  $\mu$ l of fresh SOC medium for plating on selective LB-agar containing 0.1 mg/ml ampicillin. Plates were incubated at 37 °C overnight and colonies were screened for plasmid expression by colony PCR. Positive clones were selected for plasmid isolation and stocking by cryo-preserving overnight culture in 25% glycerol at -80 °C.

### **2.4.6. Isolation of plasmid DNA**

For plasmid DNA preparation, 5 ml of *E. coli* overnight culture was used with the innuPREP plasmid mini kit. For preparation of large-scale plasmid, 200 ml of *E. coli* overnight culture was used with the PureLink HiPure plasmid midiprep kit. Plasmid samples were stored at -20 °C.

## **2.5. Generation of transgenic *T. gondii* tachyzoites**

---

## **2. MATERIALS AND METHODS**

---

### **2.5.1. Transfection of tachyzoites and making of clonal transgenic lines**

The respective plasmid constructs were transfected into freshly released tachyzoites of specified strains suspended in cytomix using a BTX 830 electroporator (50 µg plasmid DNA, ~10<sup>7</sup> parasites, 700 µl cytomix, 30 µl 100 mM ATP, 12 µl 250 mM GSH, 2 kV, 50 Ω, 25 µF, 250 µs) or an Amaxa Nucleofector (10 µg plasmid DNA, ~2x10<sup>6</sup> parasites, 100 µl cytomix, 2 µl 100 mM ATP, 2 µl 250 mM GSH, program T-16). Transformed tachyzoites were used to infect HFF cells immediately and selected for resistance to a drug corresponding to the selection marker encoded by transfected plasmid. The drug-resistant transgenic parasites were cloned by limiting dilution in 96-well plates and individual clones were screened by PCR and/or immunofluorescence assays. Positive stable transgenic lines were selected for further experiments.

### **2.5.2. Generation of tachyzoites expressing *E. falciformis* enzymes**

For ectopic expression of selected *E. falciformis* enzymes in *T. gondii*, all enzyme ORFs were cloned into the *pGRA1-UPKO* vector at *Nsi*I/*Pac*I restriction sites (Appendix 8A). Gene-specific primers used for PCRs are listed in Table 1. Constructs were transfected into freshly released tachyzoites of the RHΔku80-Δhxgprt strain. Parasites expressing ER-localized enzymes (*EfG3PAT1*, *EfLPAAT2*, *EfCDS1* and *EfPTS*) and Golgi-localized enzymes (*EfLPAAT1*, *EfPSS*, *EfCEPT1*, *EfCEPT2* and *EfPIS*) were co-transfected with the constructs encoding *TgPTS-Myc* and *TgERD2-Ty1* for co-localization studies. The transfected parasites were used to infect HFFs for immunofluorescence assays and screened for positive transient expressions of *E. falciformis* enzymes.

### **2.5.3. Generation of the Δtgpts/EfPTS strain**

The *pGRA1-UPKO-EfPTS* construct (generated as described above, Appendix 8A) was transfected into the Δtgpts strain. Transfected tachyzoites were selected for the disruption of the uracil phosphoribosyltransferase (*UPRT*) locus using 5 µM FUDR <sup>36</sup>. The drug-resistant transgenic parasites were cloned and positive clones were used for the lytic cycle assays and lipidomics studies.

## **2. MATERIALS AND METHODS**

---

### **2.5.4. Generation of transgenic tachyzoites for localization study of selected *T. gondii* enzymes**

For tagging of the *TgCDS1*, *TgCDS2* and *TgPGPS* genes with a C-terminal HA tag, 1.0 to 1.3 kb of the 3'-end of these genes excluding stop codon (crossover sequence, COS) were amplified using tachyzoite gDNA and gene-specific primers (Table 1). Amplicons were inserted into the *pG152* vector by ligation independent cloning (Appendix 8B-D). Constructs were linearized using an appropriate enzyme (*Nael*, *Xhol* or *SacI* as specified in figures) present in the COS and transfected into the RH $\Delta$ ku80- $\Delta$ hxgp $r$  strain. Parasites were selected for hypoxanthine-xanthine-guanine phosphoribosyltransferase (HXGPRT) expression using 25 µg/ml MPA and 50 µg/ml xanthine <sup>37</sup>. The resulting transgenic strains expressed *TgCDS1*-HA, *TgCDS2*-HA or *TgPGPS*-HA under the control of corresponding endogenous promoters and 3'UTR of *TgSAG1*. Parasites expressing *TgCDS1*-HA were subsequently transfected with the construct *pTUB8-TgDER1-GFP* for co-localization studies.

For ectopic expression of *TgCDS1*<sup>398-1068</sup>-Myc (lacking N-terminal extension and tagged with a C-terminal Myc epitope), the partial ORF was cloned into the *pTKO-CAT* plasmid at *Nsil/Pacl* sites (Appendix 8E). The deletion variants of *TgCDS2*, including *TgCDS2*<sup>527-1044</sup>-Myc and those lacking the signal peptide (*TgCDS2*<sub>ΔSP</sub>-Myc), transit peptide (*TgCDS2*<sub>ΔTP</sub>-Myc) or the entire bipartite sequence (*TgCDS2*<sub>ΔBS</sub>-Myc), were engineered in the *pTKO-DHFR-TS* vector using appropriate primers at *Nsil/Pacl* sites (Appendix 8F). The plasmid constructs were linearized with *NotI* and transfected into strains expressing full-length *TgCDS1*-HA or *TgCDS2*-HA. For ectopic expression of *TgCDS1* and *TgCDS2* with dual epitopes (N-terminal Myc tag and C-terminal HA tag), as well as *TgPIS* with a C-terminal HA tag, their cDNAs were ligated into the *pTETO7SAG1-UPKO* plasmid at *Ncol/Pacl* sites (Appendix 8G-I). Constructs were linearized by *NotI* and then transfected into the RH $\Delta$ ku80-TaTi strain. Parasites expressing *TgPIS*-HA were subsequently transfected with a construct encoding for *TgERD2*-Ty1 (regulated by *pGRA1* promoter) for co-localization studies.

### **2.5.5. Generation of the $\Delta$ *tgcds1*<sub>r</sub> and $\Delta$ *tgcds1*/ $\Delta$ *tgcds2* mutants**

## **2. MATERIALS AND METHODS**

---

The conditional mutant of *TgCDS1* ( $\Delta tgcds1_r$ ) was generated in two steps. First, *TgCDS1*-HA regulated by ATc-repressible promoter (pTETO7SAG1) was targeted at the *TgUPRT* locus. The ORF of *TgCDS1* containing a C-terminal HA tag was inserted into the pTETO7SAG1-UPKO vector at *Ncol/Pacl* restriction sites (Appendix 8J). The eventual construct was linearized by *NotI* and transfected into the RH $\Delta$ ku80-TaTi strain, followed by negative selection for the disruption of the *TgUPRT* locus using 5  $\mu$ M FUDR <sup>36</sup>. In the second step, the *TgCDS1* locus was deleted by double homologous recombination in the merodiploid strain expressing an ATc-regulatable copy of *TgCDS1*. To achieve this, the 5' and 3'UTRs of *TgCDS1* were amplified from tachyzoite gDNA and cloned into the pTKO-DHFR-TS vector using *XcmI/Spel* and *HindIII/Apal* enzyme pairs, respectively (Appendix 8K). The construct was linearized using *Apal*, and transfected into the merodiploid strain generated in the first step. The conditional mutant was selected for the expression of dihydrofolate reductase-thymidylate synthase (DHFR-TS) using 1  $\mu$ M pyrimethamine <sup>34</sup>. To make a knockout of the *TgCDS2* gene, the 5' and 3'UTRs amplified from tachyzoite gDNA were cloned into the pTUB8-CAT plasmid at *Apal* and *Xhol/XbaI* restriction sites, respectively (Appendix 8L). The plasmid was linearized (*XbaI*) and transfected into  $\Delta tgcds1_r$  strain, followed by selection for the expression of chloramphenicol acetyltransferase (CAT) using 20  $\mu$ M chloramphenicol <sup>35</sup>. The resulting strain ( $\Delta tgcds1_r/\Delta tgcds2$ ) lacked the expression of *TgCDS2* entirely and allowed conditional knockdown of *TgCDS1* by ATc treatment.

### **2.6. RNA and protein detection**

#### **2.6.1. Real-time PCR**

Total RNA was first reverse-transcribed using oligo-dT primer and analyzed by SYBR green-based assays in a Mastercycler. The relative expression of transcripts (fold-induction) was calculated with respect to the parental strain using the  $\Delta\Delta CT$  method. Transcripts of elongation factor A (EFA), tubulin A (TubA) and glucose transporter 1 (GT1) were used as housekeeping genes to normalize the expression of *TgCDS1* and *TgCDS2* across samples.

#### **2.6.2. Indirect immunofluorescence assay**

## **2. MATERIALS AND METHODS**

---

Parasitized HFFs cultured on glass coverslips were washed with PBS 24 h post-infection, fixed with 4% paraformaldehyde for 10 min, and neutralized with 0.1 M glycine in PBS for 5 min. Cells were permeabilized with 0.2% triton X-100 in PBS for 20 min and treated with 2% BSA in 0.2% triton X-100 in PBS for 30 min. Samples were stained with a combination of primary antibodies for 1 h, as shown in respective figures. Cells were washed three times with 0.2% triton X-100 in PBS and then stained with Alexa488/594-conjugated antibodies for 45 min. Following three additional washings with PBS, samples were mounted in fluoromount-G/DAPI and stored at 4 °C. Imaging was done using a fluorescence microscope. For co-localization studies, the organelle markers used in this study include *TgPTS*-Myc and *TgDER1*-GFP for ER, *TgFd* for apicoplast, *TgERD2*-Ty1 for Golgi body, *TgF1B* for mitochondrion, *TgGAP45* for parasite periphery, as well as *TgGRA1* for DG and PV.

### **2.6.3. Immunoblot assay**

Fresh extracellular parasites ( $1.5 \times 10^7$ ) were washed twice with PBS, pelleted (400 g, 10 min, 4°C), resuspended in loading buffer and subjected to gel electrophoresis. Proteins were resolved by 10% SDS-PAGE and then transferred to a nitrocellulose membrane (85 mA, 90 min). The membrane was treated with 5% skimmed milk suspended in TBS-T buffer (overnight, 4 °C), incubated with anti-HA and anti-*TgHSP90* antibodies (2 h at room temperature), washed 3 times for 5 min each, and incubated with IRDye-conjugated secondary antibodies 680RD and 800CW. Proteins were visualized using LI-COR imaging system.

## **2.7. Lytic cycle assays**

For assays with the  $\Delta tgcds1_r$  and  $\Delta tgcds1_r/\Delta tgcds2$  mutants, tachyzoites were pretreated with or without ATc (1 µM) for 2 passages (4 d) before assays, as well as during the assays.

### **2.7.1. Plaque assay**

Plaque assays were performed by infecting HFF monolayers in 6-well plates (250 tachyzoites per well). In assays with  $\Delta tgcds1_r$  and  $\Delta tgcds1_r/\Delta tgcds2$  mutants, CDP-DAG, PtdIns, PtdGro and cardiolipin, were dissolved in serum and added to plaque cultures (0.05-0.1 µM). Cultures were incubated unperturbedly for 7 days and

## **2. MATERIALS AND METHODS**

---

samples were fixed with ice-cold methanol for 2 min and stained with crystal violet dye for 15 min. Plaques were imaged and scored for sizes and numbers using the ImageJ software.

### **2.7.2. Yield assay**

$3 \times 10^6$  tachyzoites of each strain were used to infect confluent HFFs (MOI, 3). Parasites were syringe-released from host cells after 40 h and numerated.

### **2.7.3. Invasion assay**

$1 \times 10^7$  tachyzoites of each strain were used to infect confluent HFFs (MOI, 10) for 1 h and fixed. Noninvasive parasites were stained with anti-*TgSAG1* antibody prior to detergent permeabilization. Cells were then washed 3 times with PBS, permeabilized with 0.2% triton 100/PBS for 20 min, and stained with anti-*TgGAP45* antibody to visualize intracellular parasites. Samples were then treated with anti-mouse IgG Alexa Fluor 488 and anti-rabbit IgG Alexa Fluor 594 antibodies before washing and mounting in fluoromount-G/DAPI. Intracellular and extracellular parasites were distinguished by differential staining with *TgGAP45* signal only or with both *TgSAG1* and *TgGAP45* signals, respectively. The percentages of invaded parasites were used to compare the invasion efficiencies of the strains.

### **2.7.4. Replication and egress assays**

Confluent HFFs cultured on coverslips in 24-well plates were infected with tachyzoites of each strain (MOI, 1), fixed at indicated time points (40 h for replication assays; 48 and 72 h for egress assays), and then subjected to immunostaining using anti-*TgGAP45* antibody. For replication assays, the mean percentages of vacuoles containing variable numbers of intracellular parasites were scored to examine the replication phenotype. For egress assays, the rate of egressed vacuoles was calculated by comparing the vacuole numbers between 48 h and 72 h.

### **2.7.5. Motility assay**

For motility assays, freshly syringe-released parasites were incubated on BSA (0.01%)-coated coverslips in HBSS buffer (15 min, 37°C), fixed with 4% paraformaldehyde and 0.05% glutaraldehyde (10 min), and then stained with anti-

## **2. MATERIALS AND METHODS**

---

*TgSAG1* and Alexa488 antibodies. Motile fractions and trail lengths were quantified using the ImageJ software.

### **2.8. Lipid analysis**

Pellets of *E. falciformis* sporozoites and *T. gondii* tachyzoites ( $3 \times 10^7$  parasites per sample) were suspended in 0.8 ml PBS and lipids were extracted according to Bligh-Dyer method<sup>79</sup>. Briefly, 1 ml chloroform and 2 ml methanol were added before vortexing and incubating for 20 min. Then samples were centrifuged (2000 g, 5 min), transferred to a new glass tube (only supernatant) and mixed with 2 ml water and 2 ml chloroform. After vortexing and centrifuging (2000 g, 5 min), the upper chloroform phase was transferred to a conical glass tube. The lower phase was mixed with 2 ml chloroform, vortexed and centrifuged (2000 g, 5 min) before the upper phase was transferred to the previous conical tube. Lipids were dried under nitrogen and suspended in 1 ml of chloroform and methanol 1:1 mixture, from which 10 µl aliquot was introduced onto a Kinetex HILIC column (dimensions 50x4.6 mm, 2.6 µm, Phenomenex, Torrance CA). Phospholipids were resolved at a flow rate of 1 ml/min, as described elsewhere<sup>80</sup>. The column effluent was introduced into a mass spectrometer instrument (LTQ-XL, Thermo Scientific, Waltham, MA) and analyzed by electrospray ionization in positive and negative ion modes. Calibration curves of authentic standards were used to quantify lipids. Fatty acid composition of individual lipid was determined by MS/MS. Data were processed using the package "XCMS" in R (<https://www.R-project.org/>)<sup>81</sup>.

### **2.9. Virulence assay in mice**

Tachyzoites of the parental (RHΔku80-TaTi) and Δtgcds1<sub>r</sub> strains were pretreated with or without ATc (1 µM) for 3 passages (6 d) in cultures. ATc treatment of C57BL/6J mice (female, 6-8 weeks old) was initiated 2 days before inoculation by supplying the drug in drinking water (0.2 mg/ml) and continued for 2 weeks during infection. Animals were inoculated with fresh extracellular tachyzoites ( $10^3$ ) via intraperitoneal route and monitored for mortality and morbidity over a period of 4 weeks. For re-infection, animals immunized with the Δtgcds1<sub>r</sub> strains (ATc-treated) were challenged with tachyzoites of the parental strains ( $10^3$ ) and monitored for additional 28 days.

---

## **2. MATERIALS AND METHODS**

### **2.10. Statistics**

All data are shown as mean with standard error of mean (SEM) from three or six independent assays as indicated in figure legends. Statistical analyses were performed using the GraphPad Prism program (Version 5). Significance was tested by unpaired two-tailed Student's *t* test with equal variances or ANOVA (\**p* < 0.05, \*\**p* < 0.01, \*\*\**p* < 0.001).

### **3. Results**

#### **3.1. Exclusive phospholipid expression and autonomous membrane biogenesis in *E. falciformis* indicate a host-independent lifestyle of apicomplexan sporozoites**


##### **3.1.1. Lipid profile of *Eimeria* sporozoites differs markedly from *Toxoplasma* tachyzoites**

To examine the phospholipid composition of *E. falciformis* sporozoites, we isolated total lipids from purified parasites and performed high-performance liquid chromatography (HPLC). The total lipids extracted from tachyzoites of *T. gondii*, which served as a comparative reference, were also analyzed alongside. The most abundant phospholipid detected in sporozoites was PtdCho (79.32%), followed by PtdEtn (13.12%), PtdThr (5.75%), PtdIns (1.26%), PtdSer (0.51%) and PtdGro (0.04%), whereas the sole dominant sphingolipid is inositol phosphorylceramide (IPC) (Figure 5A). *T. gondii* tachyzoites shared similar phospholipid classes with *E. falciformis* sporozoites (PtdCho 79.04%, PtdEtn 9.09%, PtdThr 5.89%, PtdIns 4.35%, PtdSer 1.55% and PtdGro 0.09%), but possessed ethanolamine phosphorylceramide (EPC) and sphingomyelin (SM) instead of IPC as the major sphingolipids, as also reported previously<sup>45,50</sup> (Figure 5A). The PtdThr peaks of *E. falciformis* and *T. gondii* appeared at different retention time, which indicated the presence of divergent lipid species. Quantification of lipids based on external calibration standard showed that *E. falciformis* sporozoites harbor more PtdCho, PtdEtn and PtdThr, however less PtdIns, PtdSer and PtdGro than *T. gondii* tachyzoites (Figure 5B).

Mass spectrometry (MS) analysis of HPLC-fractionated phospholipids revealed that the acyl-chain compositions of different species were much more uniform in sporozoites compared to tachyzoites. The most abundant species in each phospholipid class of tachyzoites included PtdCho 36:2 (22%), PtdEtn 36:3 and 34:2 (both 23%), PtdThr 40:5 (62%), PtdIns 34:1 (46%), PtdSer 36:3 (17%) and PtdGro 30:0 (45%) (Figure 5C). On the other hand, C36:2 (18:1/18:1) was the dominant species of most lipids in sporozoites, followed by shorter chains between C30 and C34 (Figure 5C). PtdThr was the only exception with C36:1 (41%) and C36:2 (26%) as its first and second most abundant species (Figure 5C). Moreover, when

### 3. RESULTS

compared to other sporozoite phospholipids, PtdThr and PtdSer contained a higher proportion of long acyl chains C38-C42 (26% of PtdThr and 20% of PtdSer) and less of shorter acyl chains C28-C34 (7% of PtdThr and 3% of PtdSer). Collectively, these results show the presence of notably distinct lipid species in otherwise closely related coccidian parasites, *E. falciformis* and *T. gondii*.



**Figure 5. Lipidomics identifies differences and similarities of the phospholipid compositions between *E. falciformis* sporozoites and *T. gondii* tachyzoites.** (A) Retention times and relative intensities of lipids isolated from *E. falciformis* sporozoites (red) and *T. gondii* tachyzoites (black). (B) Amounts of major phospholipids in *E. falciformis* (red) and *T. gondii* (black). (C) Colored columns comparing the compositions of major phospholipid species between the two parasites. Percentages of the three most abundant species in each lipid are shown on the corresponding columns. Abbreviations: EPC, ethanolamine phosphorylceramide; IPC, inositol phosphorylceramide; PtdCho, phosphatidylcholine; PtdEtn, phosphatidylethanolamine; PtdGro, phosphatidylglycerol; PtdIns, phosphatidylinositol; PtdSer, phosphatidylserine; PtdThr, phosphatidylthreonine; SM, sphingomyelin.

### 3. RESULTS

---

#### 3.1.2. *Eimeria* sporozoites encode entire network for *de novo* phospholipid biogenesis

Having identified major lipid classes expressed in sporozoites, we next performed a thorough bioinformatic search for the presence of corresponding enzymes in the *E. falciformis* genome ([www.eupathdb.org](http://www.eupathdb.org)). The query sequences included enzymes that have been characterized from various eukaryotic and prokaryotic organisms. We could identify a total of 20 enzymes potentially involved in lipid synthesis of *E. falciformis* (Table 2 and Appendix 1). Some enzymes, PtdGro-phosphate phosphatase (PGPP), ethanolamine phosphotransferase (EPT), PtdEtn methyltransferase (PEMT) and IPC synthase could not be found in *E. falciformis* despite their prediction by aforementioned lipidomics analyses. We also compared the repertoire of lipid synthesis genes present in *E. falciformis* with other parasitic protists. Our results showed that three coccidian parasites *E. falciformis*, *T. gondii* and *Neospora caninum* shared similar inventory, which was more intricate than other apicomplexans (*Plasmodium* and *Cryptosporidium* sp.), as well as kinetoplastid parasites (*Trypanosome* and *Leishmania* sp.). For example, *Eimeria*, *Toxoplasma* and *Neospora* all possessed a PtdThr synthase (PTS), absent in other parasites (Table 2). Likewise, many enzymes occur as two or even three distinct isoforms in coccidians, e.g., we detected 3 paralogs for DAG kinase (DGK) and choline/ethanolamine phosphotransferase (CEPT), as well as 2 isoforms of PtdSer decarboxylase (PSD) and each of three enzymes synthesizing PtdOH and CDP-DAG, glycerol-3P acyltransferase (G3PAT), Lys-PtdOH acyltransferase (LPAAT) and CDS.

We were able to clone and experimentally annotate the full-length sequence of 18 enzymes using the RNA isolated from *Eimeria* sporozoites, which confirmed the transcription of nearly all lipid synthesis genes. Two open reading frames encoding for *EfDGK3* and *EfCEPT3* could not be amplified from the parasite RNA. Primary structures of the cloned enzymes revealed that all of them harbor an intact catalytic domain with conserved residues required for substrate/cofactor binding (Figure 6, Appendix 2-3). Most proteins except for LPAAT2, DGK1/2, PtdGro-phosphate synthase (PGPS), cardiolipin synthase (CLS), PSD1/2 and *EfCEPT3* harbor one or more defined transmembrane regions, signifying their membrane-binding nature. Notably, G3PAT1, DGK2 and PSD2 contain a predicted (secretory) signal peptide at


### 3. RESULTS

their N-terminal. Likewise, the N-termini of PGPS, CLS and PSD1 comprise a mitochondrial targeting peptide (Figure 6). Taken together, the results suggest expression of an almost complete network for *de novo* synthesis of major phospholipids with distinct subcellular distribution in sporozoites.

**Table 2. EuPathDB accession numbers of the enzymes involved in phospholipid biogenesis of selected protozoan parasites.**

	<i>Elmeria falciiformis</i> (Bayre Haberkorn 1970)	<i>Toxoplasma gondii</i> (GT1)	<i>Neospora caninum</i> (Liverpool)	<i>Plasmodium berghei</i> (ANKA)	<i>Plasmodium falciparum</i> (3D7)	<i>Cryptosporidium parvum</i> (Iowa II)	<i>Trypanosoma brucei</i> (TREU927)	<i>Trypanosoma cruzi</i> (CL Brener Non-Esmeraldo-like)	<i>Leishmania major</i> (Fiedlin)
Glycerol 3-Phosphate Acyltransferase (G3PAT)	Efab_PLUS_45924_g2877 Efab_MINUS_3469_g362	TGGT1_256980 TGGT1_270910	NCLIV_029980 NCLIV_035870	PBANKA_1428500 PBANKA_1416700	PF3D7_1212500 PF3D7_1318200	cgd6_1270	Tb927.10.3100	TcCLB_510943.150	LmjF.03.0080
Lysophosphatidic Acid Acyltransferase (LPAT)	Efab_MINUS_17400_g1567 Efab_MINUS_12065_g1058	TGGT1_240860 TGGT1_297640	NCLIV_017010 NCLIV_066550	PBANKA_1308200 PBANKA_1032600	PF3D7_1444300 PF3D7_1409900	cgd8_1400 cgd7_450	Tb927.11.15150 Tb927.7.220	TcCLB_510723.29 TcCLB_508707.140	LmjF.32.1960
CDP-Diacylglycerol Synthase (CDS)	Efab_PLUS_1048_g115 Efab_PLUS_36188_g2485	TGGT1_281980 TGGT1_263785	NCLIV_023660 NCLIV_024160	PBANKA_1032600	-	PFD7_0805600	cgd8_5200 Tb927.8.480 Tb927.10.13930	TcCLB_511237.40 TcCLB_503809.110 TcCLB_51277.370	LmjF.26.1620
Phosphatidic Acid Phosphatase (PAP)	Efab_MINUS_22960_g1971	TGGT1_247360	NCLIV_063870	-	PFD7_1409900	-	Tb927.7.220 Tb927.10.13400	TcCLB_503809.110 TcCLB_51277.359	LmjF.32.2870
Diacylglycerol Kinase (DGK)	Efab_MINUS_36188_g2575 Efab_MINUS_11882_g1052	TGGT1_202460 TGGT1_259830	NCLIV_0222470 NCLIV_027060	PBANKA_1334600 PBANKA_0831200	PF3D7_1471400 PF3D7_9505000	cgd4_4340 cgd8_2390 cgd3_2630	Tb927.8.5140	TcCLB_506575.60 TcCLB_510329.290	LmjF.16.1290 LmjF.35.5370
Phosphatidylglycerophosphate Synthase (PGPS)	Efab_MINUS_17907_g1626	TGGT1_246530	NCLIV_063320	PBANKA_0710600	PF3D7_0820200	-	Tb927.8.1720	TcCLB_505071.100	LmjF.07.0200
Cardiolipin Synthase (CLS)	Efab_PLUS_56725_g2797	TGGT1_309940	NCLIV_054060	PBANKA_0108000	PF3D7_0609400	cgd3_2940	Tb927.4.2560	TcCLB_506559.40	LmjF.34.2110
Phosphatidylinositol Synthase (PI-S)	Efab_PLUS_6039572	TGGT1_207710	NCLIV_002660	PBANKA_1414100	PF3D7_1315600	cgd8_560	Tb927.9.1610	TcCLB_503925.80	LmjF.26.2480
Choline/Ethanolamine Phosphotransferase (CEPT)	Efab_MINUS_56725_g2919 Efab_MINUS_15745_g1427 Efab_MINUS_25455_g2174	TGGT1_257510 TGGT1_261760 TGGT1_276190	NCLIV_029590 NCLIV_025720 NCLIV_009660	PBANKA_1127000	PF3D7_0628300	cgd4_2790 cgd4_390	Tb927.10.8900	TcCLB_509791.150	LmjF.36.5900
Ethanolamine Phosphotransferase (EPT)	-	-	-	-	-	-	Tb927.10.13290	TcCLB_503681.20	LmjF.18.0810
Phosphatidylethanolamine N-Methyltransferase (PEMT)	-	-	-	-	-	-	-	-	LmjF.31.3120 LmjF.31.2280
Phosphatidylserine Decarboxylase (PSD)	Efab_MINUS_22450_g1948 Efab_MINUS_1072_g165	TGGT1_225550 TGGT1_269920	NCLIV_047160 NCLIV_036570	PBANKA_0828700	PF3D7_0927900	cgd3_2100	Tb927.9.10080	TcCLB_407335.9	LmjF.35.4590
Phosphatidylserine Synthase (PSS)	Efab_PLUS_1794_g212	TGGT1_261480	NCLIV_026010	PBANKA_1142700	PF3D7_1366800	cgd1_1110	Tb927.7.3760	TcCLB_509937.30	LmjF.14.1200
Phosphatidylthreonine Synthase (PTS)	Efab_MINUS_800_g81	TGGT1_273540	NCLIV_034110	-	-	-	-	-	-


**Figure 6. Schematic illustration showing the primary structures of putative enzymes in the phospholipid synthesis pathways of *E. falciformis*.** Predicted functional domains, transmembrane regions, as well as signal and mitochondrial targeting peptides are shown with boxes in different colors as indicated in the figure. The numbers represent the positions of the functional domains and the lengths of the proteins. The length of domains and enzymes are all shown to a proper scale. Structure drawing for the enzymes in *T. gondii* can be found in Appendix 2. For phospholipid synthesis pathways and related enzymes in protozoan parasites, see Figure 3 and Table 2. Abbreviations: CDS, cytidine diphosphate-diacylglycerol synthase; CEPT, choline/ethanolamine phosphotransferase; CLS, cardiolipin synthase; DGK, diacylglycerol kinase; G3PAT, glycerol 3-phosphate acyltransferase; LPAAT, lysophosphatidic acid acyltransferase; PAP, phosphatidic acid phosphatase; PGPS, phosphatidylglycerol phosphate synthase; PIS, phosphatidylinositol synthase; PSD, phosphatidylserine decarboxylase; PSS, phosphatidylserine synthase; PTS, phosphatidylthreonine synthase.



### 3.1.3. Lipid synthesis in *E. falciformis* is a phylogenetic mosaic of divergent pathways

We performed the phylogenetic clustering of selected enzymes involved in both eukaryotic and prokaryotic lipid biogenesis pathways to determine their evolutionary origins. G3PAT, LPAAT, CDS, PGPS/CLS, PSD and PtdSer synthase (PSS)/PTS were subjected to cladogram analysis with respective orthologs from all major domains of the tree of life (Figure 7, see Appendix 4 for phylogeny trees of other enzymes). *EfG3PAT1* and *EfLPAAT1* segregated with their corresponding homologs from other protozoan parasites, whereas *EfG3PAT2* and *EfLPAAT2* clustered with homologs from red and green algae and plants (Figure 7A-B). Similar phylogenetical pattern also applied to *EfCDS1* and *EfCDS2*, of which the latter grouped with CDSs from not only algae and plants but also cyanobacteria (Figure 7C). In the PtdGro and cardiolipin synthesis pathway, two enzymes (*EfPGPS* and *EfCLS*) were identified in *E. falciformis*, both of which encompassed the classic duplicated phospholipase D-like domains (see Figure 6). They and their protozoan homologs clustered with PGPSs from animals and fungi, as well as prokaryotic CLSs, forming the phospholipase-D-type clade (Figure 7D). The rest of PGPS and CLS sequences belonged to the CDP-alcohol-phosphotransferase-type clade. The two PSDs from *E. falciformis* (*EfPSD1* and *EfPSD2*) grouped in different clades. *EfPSD1* orthologs appear conserved across phyla in the eukaryotic-type-I clade, while *EfPSD2*-type proteins could only be identified in related coccidian parasites (Figure 7E). Phylogenetic analysis of *EfPSS* and *EfPTS* demonstrated that they both belong to the base-exchange-type enzymes unlike CDP-DAG-dependent bacterial and fungal counterparts. Again, *EfPSS* orthologs are present across the domains of life, whereas *EfPTS*-type enzymes were found only in selected coccidians (Figure 7F). These data together indicate a surprising occurrence of fairly divergent enzyme isoforms in *Eimeria*, which have likely been acquired and repurposed to serve the specialized parasitic lifestyle.

### 3. RESULTS



**Figure 7. The phospholipid biogenesis in *E. falciformis* involves enzymes of various origins.**  
 Phylogenetic trees show the evolutionary relationships of G3PAT (A), LPAAT (B), CDS (C), PGPS/CLS (D), PSD (E) and PSS/PTS (F) enzymes in *E. falciformis* and various organisms representing major tree of life. Branch support was estimated by 100 bootstrap replicates. See Appendix 4 for phylogeny trees of other enzymes. Sequence information including accession numbers and full organism names are shown in Appendix 5. Abbreviations: CDS, cytidine diphosphate-diacylglycerol synthase; CLS, cardiolipin synthase; G3PAT, glycerol 3-phosphate acyltransferase; LPAAT, lysophosphatidic acid acyltransferase; PGPS, phosphatidylglycerol phosphate synthase; PSD, phosphatidylserine decarboxylase; PSS, phosphatidylserine synthase; PTS, phosphatidylthreonine synthase.

### 3. RESULTS

---

#### 3.1.4. Enzymes of *Eimeria* lipid synthesis show compartmentalized distribution in *T. gondii*

Next, we determined subcellular distributions of aforementioned enzymes from *E. falciformis*. To this end, we performed ectopic overexpression of epitope-tagged proteins in tachyzoites of *T. gondii* because *in vitro* culture of *E. falciformis* and methods for its genetic manipulation have not been established yet. Transgenic tachyzoites expressing *Eimeria* enzymes tagged with a C-terminal HA epitope were co-localized with pertinent organelle markers by indirect immunofluorescence assay (Figure 8A).

*EfG3PAT1-HA* and *EfCDS1-HA* were targeted to the ER (Figure 8B and 8F), whereas *EfG3PAT2* and *EfCDS2* were found in the apicoplast (Figure 8C and 8G), which resonates with the phylogenetic origin of both enzymes and the evolutionary trace of this organelle. *EfLPAAT1-HA* was expressed primarily in the Golgi bodies with a week staining in the ER (Figure 8D). Surprisingly, *EfLPAAT2* was localized in the ER despite its algal origin (Figure 8E), indicating an incomplete apicoplast pathway and potential transport of Lyso-PtdOH and PtdOH between ER/Golgi and apicoplast. After CDP-DAG is synthesized in the apicoplast and ER, it serves as the precursor for the biogenesis of PtdGro, cardiolipin and PtdIns (Figure 3). The two enzymes in the PtdGro and cardiolipin pathway, *EfPGPS* and *EfCLS*, were expressed in the mitochondrion (Figure 8H-I), whilst the PtdIns synthase (*EfPIS*) was localized in the Golgi bodies (Figure 8J). These data demonstrate that transfer of CDP-DAG from the site of its synthesis to the mitochondrion and Golgi bodies would be required for the downstream lipid synthesis.


In eukaryotes, PtdOH is not only used for CDP-DAG production, but also for the synthesis of DAG, which is regulated by two reactions catalyzed by PtdOH phosphatase (PAP) and DGK (Figure 3). *EfPAP-HA* displayed punctate intracellular distribution (Figure 8K), while *EfDGK1-HA* and *EfDGK2-HA* localized in the parasite periphery and DG/PV, respectively (Figure 8L-M). DAG serves as a co-substrate for CEPT to synthesize PtdCho and PtdEtn via the Kennedy pathways (Figure 3). Unexpectedly, both *EfCEPT1* and *EfCEPT2* were expressed in the Golgi bodies (Figure 8N-O). Alternatively, PtdEtn can be synthesized by decarboxylation of PtdSer under the action of PSD enzymes (Figure 3). *EfPSD1* and *EfPSD2* were targeted to

### **3. RESULTS**

---

the mitochondrion and DG/PV, respectively (Figure 8P-Q). Consistent with localization results, all mitochondrion proteins (*EfPGPS*, *EfCLS* and *EfPSD1*) and DG/PV proteins (*EfDGK2* and *EfPSD2*) harbored corresponding targeting motifs (mitochondrial or secretory; Figure 6). PtdEtn and/or PtdCho are used to produce PtdSer and PtdThr *via* base-exchange reactions catalyzed by PSS and PTS, respectively (Figure 3). Both enzymes were found in the parasite ER with *EfPSS* showing a strong Golgi signal (Figure 8R-S). Taken together, our localization studies revealed an assorted subcellular distribution of *Eimeria* enzymes in tachyzoites of *T. gondii*.

### 3. RESULTS



**Figure 8. Syntheses of phospholipids and their precursors are highly compartmentalized in *E. falciformis*.** (A) Selected *E. falciformis* enzymes were ectopically expressed in *T. gondii* tachyzoites under the control of *TgGRA1* promoter and 3'UTR. Immunofluorescence was performed at 24 h post infection to detect *EfG3PAT1-HA* (B), *EfG3PAT2-HA* (C), *EfLPAAT1-HA* (D), *EfLPAAT2-HA* (E), *EfCDS1-HA* (F), *EfCDS2-HA* (G), *EfPGPS-HA* (H), *EfCLS-HA* (I), *EfPIS-HA* (J), *EfPAP-HA* (K), *EfDGK1-HA* (L), *EfDGK2-HA* (M), *EfCEPT1-HA* (N), *EfCEPT2-HA* (O), *EfPSD1-HA* (P), *EfPSD2-HA* (Q), *EfPSS-HA* (R) and *EfPTS-HA* (S) using anti-HA and Alexa594 antibodies. The subcellular localizations of each enzyme were confirmed by co-localization with corresponding organelle markers including *TgPTS-Myc* for ER, *TgFd* for apicoplast, *TgERD2-Ty1* for Golgi body, *TgF1B* for mitochondrion, *TgGAP45* for parasite periphery, as well as *TgGRA1* for DG and PV. Scale bars: 2 μm. Abbreviations: CDS, cytidine diphosphate-diacylglycerol synthase; CEPT, choline/ethanolamine phosphotransferase; CLS, cardiolipin synthase; DGK, diacylglycerol kinase; ERD2, endoplasmic reticulum deficient mutant 2; F1B, ATPase subunit F1-B; Fd, ferredoxin; G3PAT, glycerol 3-phosphate acyltransferase; GAP45, glideosome-associated protein 45; GRA1, dense granule protein 1; LPAAT, lysophosphatidic acid acyltransferase; PAP, phosphatidic acid phosphatase; PGS, phosphatidylglycerol phosphate synthase; PIS, phosphatidylinositol synthase; PSD, phosphatidylserine decarboxylase; PSS, phosphatidylserine synthase; PTS, phosphatidylthreonine synthase.


### 3. RESULTS

---

#### 3.1.5. Trans-species expression of *EfPTS* rescues the lytic cycle of the $\Delta tgpts$ mutant

Next, we tested the functionality of *EfPTS*, a novel coccidian-specific enzyme, in a mutant of *T. gondii* lacking PTS expression. Our recent study has shown that the disruption of the PTS in tachyzoites (Figure 9A - Step 1 and Appendix 3F) ablates the synthesis of PtdThr, which in turn compromises the parasite motility, egress and invasion, leading to impairment of the lytic cycle<sup>50</sup>. The  $\Delta tgpts$  mutant therefore offered a tool to test the catalytic function and physiological role of *EfPTS*. The enzyme was expressed under the control of pGRA1 promoter at the *TgUPRT* locus in the  $\Delta tgpts$  mutant (Figure 9A - Step 2). The eventual complemented strain ( $\Delta tgpts/EfPTS$ ) was subjected to phenotypic assays to elucidate the physiological impact of *EfPTS* expression. The  $\Delta tgpts$  mutant formed significantly smaller (-73%) and less (-69%) plaques compared to the parental strain in the plaque assay (Figure 9B-D), confirming the earlier work<sup>50</sup>. Quite notably, *EfPTS* completely restored the lytic cycle of the PTS mutant. In-depth phenotyping of the  $\Delta tgpts$  strain revealed an evident impairment in its invasion, egress and motility, but not in replication (Figure 9E-J), as reported previously<sup>50</sup>. The parasite invasion, egress as well as gliding motility were reinstated in the complemented strain. Remarkably, ectopic expression of *EfPTS* also conferred an increased proliferation to the mutant (Figure 9F). These assays together confirm that *EfPTS* can compensate for the loss of its counterpart enzyme in *T. gondii* tachyzoites.

### 3. RESULTS



**Figure 9.** *EfPTS* can complement the defects of invasion, egress and motility in a PTS-knockout mutant of *T. gondii*. The  $\Delta$ tgpts mutant was created by Ruben D. Arroyo-Olarte *et al* and found defective in invasion, egress and motility, but not in replication<sup>50</sup>. (A) Scheme shows targeted disruption of the catalytic site of the *TgPTS* gene (Step 1) and insertion of *EfPTS* (Step 2). To achieve the  $\Delta$ tgpts/EfPTS strain, *EfPTS* was integrated at the *TgUPRT* locus under the control of pGRA1 promoter in the  $\Delta$ tgpts mutant *via* double homologous recombination. (B-D) Plaque assays recapitulate successive lytic cycles of tachyzoites in host cells and display the *in vitro* growth fitness of the indicated parasite strains. *EfPTS* complements the  $\Delta$ tgpts mutant in both plaque size (C) and number (D) from 3 independent experiments. The  $\Delta$ tgpts/EfPTS strain also shows similar rate with the parental strain in invasion assays (E), egress assays (G) and motility assays (H-J), and even a higher rate in the replication assay (F). For panel C, 90 plaques of each strain from 3 assays were measured for area using the ImageJ software. For panel E, the invasion rates of 1500–2500 parasites of each strain from 3 assays were presented. For panel F and G, a total of 200–350 vacuoles for each strain from 3 assays were analyzed for the percentages of either vacuoles containing different numbers of parasites (F) or natural egress (G). For panel I and J, 30–60 parasites of each strain were scored from 3–6 assays in total for their motile fractions (I) and trail lengths (J). In all assays, values are means with SEM (\*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001).


### 3. RESULTS

---

#### 3.1.6. *EfPTS* can restore the loss of tachyzoite-specific PtdThr species in the $\Delta tgpts$ mutant

As mentioned above, the composition of PtdThr species were notably different between *E. falciformis* sporozoites and *T. gondii* tachyzoites (Figure 5C). The most abundant PtdThr species in *E. falciformis* sporozoites was C36:1 (41%), followed by C36:2 (26%), C38:4 (10%), C34:1 (7%), C40:6 (6%) and C38:2 (6%) (Figure 5C and 10A). In *T. gondii* tachyzoites, however, all detected PtdThr species contained polyunsaturated fatty acid chains, including C40:5 (62%), 38:4 (12%), 36:4 (11%), 40:6 (10%) and 38:5 (4%) (Figure 5C and 10B). The MS/MS analysis identified 18:0/18:1 and 20:1/20:4 as the most prevalent PtdThr species in *E. falciformis* sporozoites and in the parental tachyzoites of *T. gondii*, respectively (Figure 10C-D). As expected, lipidomics of the  $\Delta tgpts$  strain confirmed the lack of all PtdThr species. Very surprisingly, complementation of the PTS mutant with *EfPTS* fully restored PtdThr content; however with the same species as present in the parental tachyzoites (Figure 10E) but not with those present in *Eimeria*. Interestingly, *EfPTS* does not produce 18:0/18:1 PtdThr in tachyzoites even though the fatty acid is readily available, suggesting a specific need of PtdThr containing polyunsaturated acyl chains (mainly 20:1/20:4) for the lytic cycle of *T. gondii*. These data also demonstrate that *EfPTS* encodes a functional enzyme with wide specificity for substrates and it is capable of synthesizing different PtdThr species in a new environment.

### 3. RESULTS



**Figure 10. EPTS rescues the loss of tachyzoite-specific PtdThr species in the  $\Delta tgpts$  mutant.** (A-B) MS analysis identifies the most abundant species of PtdThr in *E. faeciformis* sporozoites is 36:1, followed by 36:2, while the dominant PtdThr species in *T. gondii* tachyzoites is 40:5. Individual PtdThr species was identified by their fragmentation patterns and  $m/z$  ratios in the negative ionization mode. (C-D) MS/MS study shows the spectrum of the dominant PtdThr peaks ( $m/z$  802.6 for *E. faeciformis* and  $m/z$  850.6 for *T. gondii*) from panel A and B. Acyl chains were identified by their masses as C36:1 ( $18:0/18:1$ ) and C40:5 ( $20:1/20:4$ ). (E) MS analysis reveals the dominant PtdThr species (40:5 and minor species (40:6, 38:4, 38:5 and 36:4)) in *T. gondii* parental strain corresponding to panel B, which are all absent in the  $\Delta tgpts$  mutant. The loss of all detectable PtdThr species is restored by expression of EPTS in the  $\Delta tgpts$ /EPTS strain.

### 3.2. Two phylogenetically and compartmentally distinct CDP-diacylglycerol synthases cooperate for lipid biogenesis in *T. gondii*


#### 3.2.1. *T. gondii* harbors two phylogenetically distinct CDS proteins

Next, we used the well-established model organism *T. gondii* to study the phylogenetic and metabolic roles of CDS, the central enzyme in lipid synthesis network, in details. Our bioinformatics searches using *bona fide* CDS protein sequences from yeast and human identified one CDS gene in *Toxoplasma* database ([www.ToxoDB.org](http://www.ToxoDB.org)), termed as *TgCDS1* henceforth (ToxoDB, TGGT1\_281980; GenBank, KU199242). Similar database mining using the prokaryotic CDS sequences indicated the unexpected existence of a second CDS in the parasite, which was designated as *TgCDS2* (ToxoDB, TGGT1\_263785; GenBank KU199243). Subsequently, we also found prokaryotic-type CDSs in selected protozoan parasites *E. falciformis*, *N. caninum*, *Trypanosoma cruzi* and *Leishmania major* (Table 2), albeit not in many others (*Plasmodium berghei*, *Plasmodium falciparum*, *Cryptosporidium parvum* and *Trypanosoma brucei*). Phylogenetic clustering of CDS sequences revealed discrete eukaryotic and prokaryotic clades (Figure 11A and 7C). All eukaryotes possessed at least one CDS, which clustered with *TgCDS1*. In contrast, *TgCDS2* segregated with prokaryotic-type CDS sequences from bacteria, plants, algae, and indicated parasites. Notably, *TgCDS2* grouped with CDSs from cyanobacteria (*PmCDS*, *SsCDS* and *TeCDS*) and red alga (*CcCDS2* and *GsCDS2*), both are considered as ancestors of the apicoplast in apicomplexan parasites (Figure 11A and 7C).

The ORFs of *TgCDS1* and *TgCDS2* encode for 1068 and 1044 amino acids with several transmembrane regions (Figure 11B). Both proteins contain an archetypal cytidylyltransferase domain encompassing a CDS signature motif (G-X<sub>4</sub>-S-X<sub>2</sub>-KR-X<sub>4</sub>-KD-X<sub>5</sub>-PGHGG-X<sub>2</sub>-DR-X-D, Figure 11B-C). These features are also shared by homologs from other indicated organisms irrespective of the phylogenetic origins. Sequence comparisons also revealed many signature residues that were differentially conserved in eukaryotic- and prokaryotic-type CDS sequences (see red and blue-shaded residues, Figure 11C). In particular, prokaryotic-type proteins harbor acidic and basic residues (aspartate-lysine, DL) instead of small and aromatic pair of amino acids (glycine-phenylalanine, GF) occurring in eukaryotic-type

### 3. RESULTS

orthologs. Likewise, eukaryotic CDSs show a strictly conserved nucleophile-amide motif (cysteine-glutamine, CQ) absent in prokaryotic counterparts.



**Figure 11. *T. gondii* expresses two distinct CDS enzymes located in the ER and apicoplast.**

**(A)** Phylogenetic analysis of *TgCDS1*, *TgCDS2* and orthologs from various organisms representing major tree of life. Branch support was estimated by 100 bootstrap replicates. Other relevant information including accession numbers and full organism names for each CDS sequence is shown in Appendix 5. Similar phylogenetic tree is also presented in Figure 7C.

**(B)** Schematic drawing of the primary structures of *TgCDS1* and *TgCDS2*. The numbers indicate positions of cytidyltransferase domains, CDS signature motifs, transmembrane regions, as well as signal and transit peptides.

**(C)** Multiple alignments of the signature motifs present in eukaryotic- and prokaryotic-type CDS sequences. The residues identical across all sequences are shaded with black color, and amino acids that are conserved only in eukaryotes or prokaryotes are highlighted in red or blue colors, respectively.

**(D-E)** Scheme for 3'-insertional tagging of *TgCDS1* and *TgCDS2* genes with a C-terminal HA tag. Plasmids harboring crossover sequence (COS) of respective genes were linearized with the indicated enzymes and transfected into tachyzoites ( $\text{RH}\Delta\text{ku80}-\Delta\text{hxgppt}$ ), followed by drug selection. Immunofluorescence of stable transgenic tachyzoites expressing *TgCDS1-HA* (D) and *TgCDS2-HA* (E) under the control of respective endogenous promoters and *TgSAG1-3'UTR* was performed using anti-HA and Alexa594 antibodies (24 h post-infection). *TgCDS1-HA* and *TgCDS2-HA* proteins were co-localized with *TgDER1-GFP* signal and anti-*TgFd*/Alexa488 antibodies, respectively. Scale bars: 2 μm.


### 3.2.2. *TgCDS1* is expressed in the ER, whereas *TgCDS2* in the apicoplast

The parasite database indicated a constitutive expression of *TgCDS1* and *TgCDS2* transcripts during the lytic cycle ([www.ToxoDB.org](http://www.ToxoDB.org)). To test whether *TgCDS1* and *TgCDS2* proteins are indeed expressed during the asexual development of tachyzoites, we tagged them with a HA epitope by 3'-insertional tagging of the endogenous loci (Figure 11D-E). The same approach also enabled us to determine subcellular distributions in intracellular parasites by immunofluorescence assays. Consistent with transcript abundance, endogenous expression of *TgCDS1* and *TgCDS2* was readily detectable in stable transgenic strains. *TgCDS1*-HA was expressed primarily in the parasite ER, as confirmed by its co-localization with a known organelle marker *TgDER1*-GFP<sup>82</sup> (Figure 11D). In contrast, *TgCDS2*-HA co-localized with a *bona fide* marker of apicoplast *TgFd*<sup>72</sup> (Figure 11E). Distinct subcellular locations of both CDSs in *T. gondii* are consistent with their respective phylogenetic origins.

The alignment of primary structures revealed prolonged N-terminal extensions in *TgCDS1* and *TgCDS2* when compared to homologs (Figure 12A). Additionally, a putative bipartite sequence composed of a signal peptide and a transit peptide was identified in the N-terminal extension of *TgCDS2*, starting from the second methionine instead of the start codon (Figure 11B and Appendix 6). To address the roles of extended N-termini for subcellular targeting, the two mutant isoforms lacking the designated extensions and fused with a C-terminal Myc tag (*TgCDS1*<sup>398-1068</sup>-Myc and *TgCDS2*<sup>527-1044</sup>-Myc) were ectopically expressed and localized with corresponding full-length proteins. *TgCDS1*<sup>398-1068</sup>-Myc was still targeted to the ER, as discerned by co-staining with wild-type *TgCDS1* (Figure 12B). In contrast, *TgCDS2*<sup>527-1044</sup>-Myc was not localized in the apicoplast anymore and appeared to be cytosolic instead (Figure 12B), suggesting a crucial function of N-terminal peptide for its correct location. We then generated additional mutants of *TgCDS2* protein containing internal deletions of either signal (*TgCDS2*<sub>ΔSP</sub>-Myc) or transit peptide (*TgCDS2*<sub>ΔTP</sub>-Myc) or both (*TgCDS2*<sub>ΔBS</sub>-Myc). Localization studies with these mutants revealed a clear role of bipartite sequence for targeting of *TgCDS2* to the apicoplast (Fig. 3B).

### 3. RESULTS

To examine whether the N-termini were processed during maturation and targeting of the two proteins, we expressed dual-tagged isoforms containing a Myc tag at the N-terminus and a HA epitope at the C-terminus (Myc-*TgCDS1*-HA or Myc-*TgCDS2*-HA). In the case of *TgCDS1*, both Myc and HA epitopes were distributed in the ER (Figure 12C). However, the N-terminal region of *TgCDS2* (Myc-tagged) showed an evidently cytosolic signal, while the C-terminal peptide (HA-tagged) was still localized in the apicoplast (Figure 12C), which suggested that the N-terminus of the protein is cleaved off when the rest of the protein is imported and likely integrated into the organelle membrane.



**Figure 12. The N-terminal of *TgCDS2* but not of *TgCDS1* is required for correct localization.**  
**(A)** Comparison of primary structures of CDS orthologs across different organisms. The numbers shown before cytidyltransferase domains indicate the length of the N-termini. The length of full-length proteins and the position of the bipartite sequence in *TgCDS2* are also mentioned.  
**(B)** Immunofluorescence of tachyzoites co-expressing full-length CDS (*TgCDS1*-HA or *TgCDS2*-HA) along with corresponding truncated isoforms lacking the extended N-terminal region (*TgCDS1*<sup>398-1068</sup>-Myc or *TgCDS2*<sup>527-1044</sup>-Myc), signal peptide (*TgCDS2*<sub>ΔSP</sub>-Myc), transit peptide (*TgCDS2*<sub>ΔTP</sub>-Myc) or the entire bipartite sequence (*TgCDS2*<sub>ΔBS</sub>-Myc). Transgenic parasites harboring epitope-tagged wild-type proteins (see Figure 11D-E for details) were transfected with plasmids encoding either of the mutated isoforms (regulated by *TgGRA1* promoter).  
**(C)** Immunofluorescence of intracellular parasites expressing dual-tagged (Myc-*TgCDS1*-HA or Myc-*TgCDS2*-HA) under the control of pTETO7SAG1 promoter. Immunostaining in panel B and C were performed 24 h post-infection using anti-HA/Alexa488 and anti-Myc/Alexa594 antibodies. Scale bars: 2 μm.


### 3.2.3. CDS enzymes are indispensable for the lytic cycle of tachyzoites

To investigate the physiological importance of *TgCDS1* and *TgCDS2* in *T. gondii* tachyzoites, we first attempted to create mutants lacking either of the two genes. Our multiple endeavors to delete the *TgCDS1* and *TgCDS2* loci were futile, indicating essential nature of the two proteins in parasites. We therefore generated a conditional mutant of *TgCDS1* using the tetracycline repressor-based system, as described elsewhere<sup>38</sup>. To achieve the mutant, *TgCDS1-HA* was first expressed under the control of a tetracycline-regulated promoter (*pTETO7SAG1*) at *TgUPRT* locus in the RHΔ*ku80*-TaTi strain (Figure 13A, Step 1 - making of a merodiploid strain). We then replaced the native *TgCDS1* locus by the DHFR-TS selection cassette via double homologous recombination (Figure 13A, Step 2 - making of  $\Delta tgcds1_r$  mutant). Genetic deletion of the *CDS1* gene was confirmed by recombination-specific PCR screening, which showed the occurrence of 5' and 3' homologous recombination events in the mutant but not in the parental strain (Figure 13B). RT-PCR validated a conditional repression of *TgCDS1* transcript by ATc in the  $\Delta tgcds1_r$  strain (Figure 13C). *TgCDS1* mRNA was induced 2x under the control of *pTETO7SAG1* promoter, which could be down-regulated by about 14x in ATc-treated cultures. As shown by immunofluorescence and immunoblot analyses (Figure 13D-E), exposure to ATc also repressed the expression of *TgCDS1-HA* protein, which was undetectable after 4 days of cultures with the drug. Unfortunately, measurements of the CDS activity in intact parasites and cell extract have proven extremely challenging, which prevented us from establishing a correlation between the protein level and the enzymatic activity.

Even though we were unsuccessful in generating a *TgCDS2* knockout mutant using the parental strain, we were able to delete the *TgCDS2* locus in the  $\Delta tgcds1_r$  mutant, which was probably due to overexpression of *TgCDS1* in the latter strain (Figure 13C). To make a double mutant, a plasmid containing the 5' and 3'UTRs of *TgCDS2* flanking the CAT selection marker was transfected in the  $\Delta tgcds1_r$  strain (Figure 13A, Step 3 - making of  $\Delta tgcds1_r/\Delta tgcds2$  mutant). The events of double homologous recombination and integration of the selection marker at the *TgCDS2* locus in the double mutant was verified by crossover-specific PCR (Figure 13B). RT-PCR corroborated the absence of *TgCDS2* mRNA in the  $\Delta tgcds1_r/\Delta tgcds2$  strain (Figure 13C). It was not feasible to test the protein level by immunofluorescence or

### 3. RESULTS

immunoblot assays due to unavailability of antibody recognizing *TgCDS2*. With respect to the transcriptional and translational regulation of *TgCDS1*, the  $\Delta tgcds1/\Delta tgcds2$  mutant behaved akin to the  $\Delta tgcds1_r$  strain (Figure 13C-E). For example, the  $\Delta tgcds1/\Delta tgcds2$  mutant also showed 2-fold elevation of *TgCDS1* transcript in the *on state* (-ATc), which could be repressed by 14-fold in the *off state* (+ATc). Similarly, *TgCDS1* protein was expressed at comparable levels in both mutants (*on state*) and a chemical regulation was achievable within 96 hours.



**Figure 13. Conditional mutagenesis of *TgCDS1* and deletion of *TgCDS2* in *T. gondii*.** (A) Scheme for creating the  $\Delta tgcds1_r$  and  $\Delta tgcds1/\Delta tgcds2$  mutants. Step 1 and 2 depict making of the  $\Delta tgcds1_r$  mutant, which involved integrating a tetracycline-regulatable copy of *TgCDS1* (*TgCDS1*-HA) at the *TgUPRT* locus in the *Tku80-TaTi* strain (Step 1) followed by deletion of the *TgCDS1* gene by the *TgDHFR-TS* selection cassette (S.C.) via double homologous recombination (Step 2). Subsequently, to generate the  $\Delta tgcds1/\Delta tgcds2$  strain (Step 3), the *TgCDS2* gene was deleted in the  $\Delta tgcds1_r$  mutant by the CAT selection marker. Primers used to screen for 5' and 3' recombination at the *TgCDS1* and *TgCDS2* loci are marked as black arrows. (B) Genomic PCR of the  $\Delta tgcds1_r$  and  $\Delta tgcds1/\Delta tgcds2$  strains confirming the events of 5' and 3' crossovers. Genomic DNA of the parental strain was included alongside (negative control). (C) Quantitative PCR of *TgCDS1* and *TgCDS2* transcripts in  $\Delta tgcds1_r$  and  $\Delta tgcds1/\Delta tgcds2$  mutants. Note that *TgCDS1* was induced 2-fold under the control of pTET07SAG1 promoter in the *on state* (-ATc) when compared to the parental strain. It was repressed 14-fold in the *off state* (+ATc). *TgCDS2* transcript was not detectable (N.D.) in the  $\Delta tgcds1/\Delta tgcds2$  strain. The average values with SEM from three independent assays are shown. (D-E) Immunofluorescence and immunoblot analyses of the two mutants showing a conditional regulation of *TgCDS1*-HA by ATc. Staining was performed using anti-HA and anti-*TgHSP90* antibodies (loading control). Scale bars: 2  $\mu$ m.


### 3.2.4. Conditional knockdown of *TgCDS1* impairs biogenesis of PtdIns and PtdSer

To discern the functional importance of *TgCDS1* and *TgCDS2* for phospholipid synthesis, we performed lipidomics analysis. Lipids were isolated from tachyzoites of the parental,  $\Delta tgcds1_r$  and  $\Delta tgcds1_r/\Delta tgcds2$  strains cultured in the absence or presence of ATc and subjected to HPLC and MS analysis. As anticipated, total phospholipids in the parental strain were not perturbed by treatment with ATc, whereas we found a modest increase in the  $\Delta tgcds1_r$  mutant during *on state*, which was further increased in *off state* (Appendix 7A). In-depth analysis of individual lipids revealed a notable elevation of all major phospholipids, which were probably due to ectopic overexpression of *TgCDS1* (Figure 14A and 14C, Appendix 7B-D). More importantly, a knockdown of *TgCDS1* in the  $\Delta tgcds1_r$  strain led to a significant and rather selective reduction in the amounts of PtdIns and PtdSer (Figure 14A and 14C). Other phospholipids were either unaffected (PtdEtn and PtdThr, Appendix 7C-D) or even elevated (PtdCho in Appendix 7B and PtdGro in Figure 14E). Such a modest rise in PtdCho (accounting for 70-80% of phospholipids<sup>41,45</sup>) was sufficient to induce the level of total lipids during the *off state* despite a prominent decline in PtdIns and PtdSer (Appendix 7A), which together accounted for <10% of total phospholipids.

Next, we examined the major species of PtdIns and PtdSer (Figure 14B and 14D). PtdIns species were comprised of primarily short to medium saturated/unsaturated fatty acids (30-36 carbons). In particular, the amount of the most abundant species 34:1 and 34:2 changed dramatically in the  $\Delta tgcds1_r$  mutant in an ATc-regulated manner when compared to the parental strain. Other key species of PtdIns that were declined upon repression of *TgCDS1* included 30:0, 32:1 and 36:2. One particular species 36:4 (C16:0/20:4, confirmed by MS/MS) of PtdIns showed a surprisingly opposite trend in the mutant. Interestingly, the most abundant PtdIns species in HFFs is PtdIns 38:4 (C18:0/20:4, confirmed by MS/MS), which is negligible in the parasite extract, leads to a suspicion that tachyzoites might salvage this species containing C20:4 acyl chain from host cells, and then remodel to its own benefit. The most abundant PtdSer species contained mono and polyunsaturated acyl chains with 34, 36 and 42 carbon atoms. All of them were induced noticeably during *on state* of the  $\Delta tgcds1_r$  strain, and reduced following a down-regulation of *TgCDS1* (*off state*). The

### 3. RESULTS

data together suggest a requirement of *TgCDS1* to produce PtdIns and PtdSer by downstream CDP-DAG-dependent enzymes.



**Figure 14. Conditional knockdown of *TgCDS1* results in a reduction of PtdIns and PtdSer, whereas deletion of *TgCDS2* impairs PtdGro biogenesis.** Total lipids were extracted from tachyzoites of the indicated strains and subjected to HPLC and MS analysis. Amounts of PtdIns (**A**), PtdSer (**C**), PtdGro (**E**) and corresponding major lipid species (**B**, **D**, **F**) in the presence or absence of ATC are depicted in heat-maps. Color-coded gradient in each column is meant to compare the relative abundance of the given lipid species in the mutants with respect to the *on-state* parental strain. Actual amounts of lipid species (pmol/10<sup>6</sup> parasites) are also mentioned for comparing columns. The sums of individual lipid species in panel **B** and **D** are less than the total lipid amount in panel **A** and **C** because only major species are shown. Note that the reduction of PtdSer species in the *off-state* parental strain (+ATC) is relatively negligible even though they appear somewhat blue. Nomenclature (*m:n*) is shown, where *m* and *n* signify the number of carbons and the number of double bonds in both acyl chains, respectively. All values show mean values with SEM from six independent assays (\*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001).

### 3. RESULTS

---

#### 3.2.5. Loss of *TgCDS2* results in selective impairment of PtdGro synthesis

Having evaluated the impact of *TgCDS1* knockdown in the single mutant, we examined a role of *TgCDS2* for phospholipid biogenesis and functional interrelationship of both enzymes using the  $\Delta tgcds1/\Delta tgcds2$  strain. In essence, biochemical phenotypes of the double mutant were similar to the parental and  $\Delta tgcds1_r$  strains with few noteworthy exceptions. One of the most evident effects was >80% reduction in PtdGro biogenesis upon ablation of *TgCDS2* (Figure 14E). All species of PtdGro were significantly decreased irrespective of ATc treatment, which confirmed a need of *TgCDS2* (but not *TgCDS1*) for PtdGro biogenesis (Figure 14F). Consistently, the most common PtdGro species with short saturated fatty acids (30:0) was increased when *TgCDS1* was repressed in the  $\Delta tgcds1_r$  strain (Figure 14F), suggesting utilization of subsequently surplus PtdOH species into PtdGro via *TgCDS2*. Cardiolipin was detectable only occasionally and in minor amounts even in the parental strain; we were therefore unable to reproducibly quantify and compare its levels across the parasite strains.

The deletion of *TgCDS2* in the  $\Delta tgcds1_r$  strain also resulted in an apparent diminution of certain PtdIns (34:2, 30:0) and PtdSer (34:2) species in the  $\Delta tgcds1/\Delta tgcds2$  mutant during *on state*, which were further reduced by deficiency of *TgCDS1* in *off state* (Figure 14B and 14D). In contrast to PtdGro, PtdIns and PtdSer, other major lipids (Appendix 7) were largely unaffected by deletion of *TgCDS2* when compared to the parental strain.


### 3.2.6. The CDS mutants show a defective growth due to impaired replication

We next determined the phenotypic effects of *TgCDS1* knockdown and *TgCDS2* knockout on the lytic cycle of tachyzoites in HFF cells. To measure the growth fitness, we first performed plaque assays, which recapitulate the consecutive lytic cycles of tachyzoites (Figure 15A). The two mutants along with the parental strain were cultured in the absence or presence of ATc. The  $\Delta tgcds1_r$  strain demonstrated a normal growth during *on state*, whereas plaque size was reduced to 25% in *off state* when compared to the parental strain (Figure 15B). Plaque formation of  $\Delta tgcds1_r/\Delta tgcds2$  strain declined by a modest 12% during the *on state* with respect to the parental strain, and was severely reduced by about 90% when the expression of *TgCDS1* was turned off (Figure 15B). As expected, plaque numbers of both  $\Delta tgcds1_r$  and  $\Delta tgcds1_r/\Delta tgcds2$  strains were similar to the parental strain in *on state*, while they dropped down to about 60% and 40% during *off state*, respectively (Figure 15C). The addition of exogenous CDP-DAG, PtdIns, PtdGro and cardiolipin to the plaque cultures were unable to restore the growth of either of the mutants (not shown), indicating that tachyzoites are unable to scavenge these lipids from the surrounding milieu.

Similar phenotype of the mutants was observed in yield assays when parasites were syringe-released and counted 40 hours post-infection (Figure 15D). As expected by aforementioned roles of CDP-DAG in membrane biogenesis, when compared to the parental strain, the parasite yield dropped by 75%, 23% and 96% after the loss of *TgCDS1* (*off-state*  $\Delta tgcds1_r$ ), *TgCDS2* (*on-state*  $\Delta tgcds1_r/\Delta tgcds2$ ) alone or both of them (*off-state*  $\Delta tgcds1_r/\Delta tgcds2$ ), respectively. Based on parasite yields, we also calculated the replication rate of all strains. The doubling time of the parental strain was about 9.4 h, which was prolonged to 16.2 h when *TgCDS1* expression was knocked down in the  $\Delta tgcds1_r$  mutant. Knockout of *TgCDS2* alone caused only a modest delay in cell division (10.2 h). However, a loss of both enzymes severely attenuated the parasite proliferation (doubling time, 56.5 h). In brief, yield assays correlated well with the plaque growth of the mutants. We also assessed the replication by numerating parasites in the parasitophorous vacuoles (Figure 15F). We found an evident downshift in the vacuole sizes of both mutants following treatment with ATc. In other words, mutants in the *off state* showed a higher proportion of

### 3. RESULTS

smaller vacuole and *vice versa*. On contrary, both mutants showed a normal invasion rate despite ATc treatment compared to the parental strain (Fig 15E).



**Figure 15. The  $\Delta tgcds1$ , and  $\Delta tgcds1/\Delta tgcds2$  mutants show an attenuated growth.** (A) Plaque assays using the indicated parasite strains cultured in the presence or absence of ATc. HFF monolayers were infected with 250 tachyzoites (pre-cultured with or without ATc for 4 days) and incubated for 1 week without any perturbation to allow plaque formation. (B) Plaque sizes of the parasite strains from panel A. 90 plaques of each strain were measured for area using the ImageJ software. (C) Plaque numbers of individual strains from panel A. (D) Yield assays in the presence or absence of ATc. Host cells were infected with 3 million tachyzoites pre-treated with ATc for 4 days before the assay (MOI, 3). Parasites were syringe-released 40 h post-infection for counting. (E) Invasion assays in HFFs (MOI, 10). Cells were fixed 1 h post-infection. The invasion rates of 1500–2500 parasites of each strain were presented. (F) Replication assays in HFFs (MOI, 1). Cells were fixed 40 h post-infection and stained with anti-GAP45 antibody to visualize intracellular tachyzoites. A total of 100–150 vacuoles were analyzed for each strain. The percentages of vacuoles containing different numbers of parasites are shown. Values are means with SEM for three (B, C, E, F) or six (D) independent experiments (\* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ ). (G) Virulence assay in a mouse model. Animals (C57BL/6J) were infected intraperitoneally with tachyzoites ( $10^3$ ) of the parental or  $\Delta tgcds1$  strains (pre-cultured with or without ATc for 6 days). Drug treatment during infection (2 weeks) was performed via the drinking water. Infected mice were monitored for 28 days (2 assays, each with 4 mice for the parental strain and 6 mice for the  $\Delta tgcds1_r$  strain). Animals surviving infection with the mutant strain (+ATc) were challenged with the parental strain ( $10^3$ ) and examined for additional 28 days.

### 3.2.7. A deficiency of CDP-DAG synthesis attenuates the parasite virulence


Finally, we tested the physiological relevance of CDP-DAG synthesis within the parasite for virulence in a mouse model (Figure 15G). In this regard, we employed the  $\Delta tgcds1_r$  mutant along with the parental strain. Our rationale for using only the single mutant was based on a robust phenotypic impairment observed *in vitro* (*off state*, Figure 15A-D and 15F), which should ideally translate into a strong weakening of virulence *in vivo*. Hence, a double mutant ( $\Delta tgcds1_r/\Delta tgcds2$ ) with even more inhibited *in vitro* growth would be more attenuated *in vivo*. Indeed, most animals infected with the  $\Delta tgcds1_r$  strain that were treated with ATc in drinking water survived as opposed to the control parental strain that was categorically lethal irrespective of ATc treatment. The mutant in its *on-state* exhibited a lethal phenotype similar to the parental strain. Collectively, these results indicated an essential role of CDS for the parasite lytic cycle and virulence in mice. The data also suggested that the parasites are unable to salvage sufficient amount of CDP-DAG from the host to bypass an ablation of autonomous synthesis. Finally, we explored the vaccination potential of the  $\Delta tgcds1_r$  strain in animals. Notably, all mice surviving the primary infection with the mutant developed sufficient immunity to resist the subsequent lethal challenge by a hypervirulent type I strain, which illustrates the prophylactic utility of a metabolically attenuated mutant to prevent acute toxoplasmosis.

### 3.2.8. PtdGro-P and PtdIns are made in the mitochondrion and Golgi bodies, respectively

The CDS-dependent synthesis of PtdIns and PtdGro resonates with the occurrence of PIS and PGPS in tachyzoites. The second enzyme of PtdGro synthesis PGPP could not be identified in the parasite genome. We examined subcellular distribution of *TgPGPS* (ToxoDB, TGGT1\_246530; GenBank, KX017550) by 3'-insertional tagging (HA) of the endogenous locus in *T. gondii*. *TgPGPS-HA* was expressed in the parasite mitochondrion, as shown by its co-staining with a *bona fide* organelle marker *TgF1B*<sup>66</sup> (Figure 16A). We also performed genomic tagging of the *TgPIS* locus (ToxoDB, TGGT1\_207710; GenBank, KX017549) with a HA tag. However, *TgPIS-HA* was not detectable by immunofluorescence or immunoblot assays. We therefore localized *TgPIS-HA* by ectopic overexpression. It co-localized with a known marker of Golgi body *TgERD2*<sup>83</sup> (Figure 16B). Taken together, these results indicated

### 3. RESULTS

synthesis of PtdGro and PtdIns in the mitochondrion and Golgi, respectively, requiring a transfer of CDP-DAG from apicoplast and ER to the sites of phospholipid biogenesis.



**Figure 16. CDP-DAG-dependent biogenesis of PtdGro-P and PtdIns in the mitochondrion and Golgi bodies of *T. gondii* tachyzoites.** Immunofluorescent images of intracellular tachyzoites expressing either (A) *TgPGPS-HA* (regulated by endogenous promoter), or (B) *TgPIS-HA* (under the control of pTETO7SAG1 promoter) are shown. Indicated proteins were detected 24 h post-infection using anti-HA antibody and corresponding co-localization markers (*TgF1B*, *TgERD2-Ty1*). Scale bars: 2  $\mu$ m.

## 4. Discussion

### 4.1. Phospholipid synthesis in *E. falciformis* sporozoites

#### 4.1.1. Phospholipid profile of sporozoites

Sporozoite is typically the first infective form for most apicomplexan parasites during the initial cell invasion in a new host. The process of sporogony to form sporozoites occurs in isolation from the host cells or environment. Therefore, the essential nutrients during this process, including lipids, are likely sustained solely by *de novo* synthesis, making sporozoite a unique stage to study the parasite metabolic capacity. In this study, we have examined the phospholipid content in the sporozoites of *E. falciformis*, a mouse *Eimeria* species. The detectable glycerophospholipids in sporozoites include PtdCho, PtdEtn, PtdIns, PtdSer and PtdGro. Similar compositions have been described in other protozoan parasites during various life stages, including *T. gondii*<sup>41,45</sup>, *P. falciparum*<sup>43,46,59,84</sup>, *T. brucei*<sup>85-87</sup>, *T. cruzi*<sup>88,89</sup> and *Leishmania donovani*<sup>90,91</sup>, confirming the role of glycerophospholipids as conserved ingredients of the parasite membranes. Additionally, we detected the presence of PtdThr in sporozoites, a rare lipid that has been recently found in *T. gondii* tachyzoites<sup>50</sup>. PTS enzymes could only be identified in 3 coccidian species (*E. falciformis*, *T. gondii* and *N. caninum*, Table 2), suggesting the evolution of PtdThr to facilitate a coccidian-specific role that could not be satisfied otherwise by generic lipids. Correspondingly, we show that *EfPTS* as well as *TgPTS* produce PtdThr to undertake the gliding motility, which in turn drives tachyzoites out of dilapidating host cells and ensuing invasion of fresh host cells. Likewise, *EfPTS* may play a similar role in egression of sporozoites from sporocysts and invasion of epithelial cells. Interestingly, sporozoites and tachyzoites make distinct PtdThr species, which underscores mechanistic differences in the two stages.

Sphingophospholipids are another major group of phospholipids in eukaryotic cells. The main sphingophospholipid in fungi and plants is IPC<sup>92-94</sup>, while SM and EPC are present in mammals<sup>95</sup>. Here we have identified IPC as the prime sphingophospholipid in *E. falciformis* sporozoites. In contrast, *T. gondii* tachyzoites possess EPC and SM, confirming previous study<sup>45</sup>. However, a sphingolipid synthase in *T. gondii* has been recently shown to exhibit the IPC synthase activity<sup>96</sup>,

#### 4. DISCUSSION

---

and *in vitro* replication of tachyzoites is blocked by aureobasidin A, an inhibitor of IPC synthesis<sup>97</sup>. These reports indicate a trace amount of IPC is important for parasitism of *T. gondii* tachyzoites. In addition, previous studies in *T. brucei* have revealed the presence of IPC and SM in the procyclic stage of the parasite, as well as SM and EPC in the bloodstream stage<sup>98</sup>. Taken together, these data suggest that the sphingophospholipid biogenesis is highly stage-specific in parasites. Since IPC synthesis has no equivalent in mammalian cells, several sphingolipid synthases with IPC synthase activity have been reported as potential drug targets to treat protozoan infection<sup>96,99,100</sup>. However, our bioinformatics search failed to identify such enzymes in *E. falciformis* database, which may be due to incomplete annotation of the *Eimeria* genome.

The acyl chain composition determines the physical and chemical properties of lipids, and thus indicates the overall structure and function of membranes. In *Toxoplasma* and *Plasmodium*, short saturated acyl chains (C14:0 and C16:0) are produced through the FASII pathway located in the apicoplast<sup>60,61,101</sup>. These acyl chains are then exported to the ER, where they are modified by the FAE pathway to generate longer saturated and monounsaturated fatty acids (MUFAAs)<sup>62</sup>. The enzymes responsible for the synthesis of polyunsaturated fatty acids (PUFAs) have not yet been identified in apicomplexan parasites. It is proposed that parasites may import PUFAs from host cells. *T. gondii* also encodes a FASI pathway; however, its function and physiological importance have not been established yet. In *E. falciformis* sporozoites, phospholipids are mostly composed of saturated and MUFA chains that are not longer than C18. Among them, the most abundant fatty acid is MUFA C18:1, forming C36:2 (18:1/18:1) as the dominant species for most phospholipids and C36:1 (18:0/18:1) for PtdThr (Figure 5C), similar to the fatty acid content in the oocyst walls of *E. tenella* and *Eimeria maxima* as previously reported<sup>102</sup>. Based on *Toxoplasma* and *Plasmodium* research, these data imply the major contributions of FASII and FAE pathways in the sporozoite stage of *E. falciformis*.

The essential roles of both FASII and FAE pathways have been demonstrated in *Toxoplasma* tachyzoites<sup>62,103,104</sup>. In *Plasmodium*, FASII has been proven to be crucial to merozoite maturation during liver stage but dispensable in blood stage where fatty acids are mainly scavenged from the host erythrocytes<sup>105,106</sup>. Additionally, FASII is essential for the sporozoite development of human *Plasmodium*

## 4. DISCUSSION

---

species *P. falciparum*<sup>68,107</sup>, while in rodent *Plasmodium* species *P. berghei*, FASII is dispensable for the sporozoite formation but crucial to normal sporozoite infectivity in mice<sup>105</sup>. In this study, the expression of *EfPTS* in *T. gondii* Δtgpts mutant causes parasites to produce PtdThr species with tachyzoite-specific fatty acid chains (Figure 10E). Taken together, it indicates that the sources of fatty acids (whether self-biogenesis by FASII and FAE or importing from the host) are highly species- and stage-dependent, which rather than the enzyme specificity cause the different fatty acid contents between *Eimeria* sporozoites and *Toxoplasma* tachyzoites.

### 4.1.2. Phylogenetically divergent pathways of lipid synthesis

After fatty acids are produced in the apicoplast and ER, they are utilized with Glycerol-3P to form Lyso-PtdOH by G3PAT. We identified a fungi-type *EfG3PAT1* in the ER and an algae-type *EfG3PAT2* in the apicoplast of *E. falciformis*. This is cohesive with recent reports of their homologues in *Toxoplasma* and *Plasmodium*<sup>63,67,69,108</sup>. Similar to the FASII pathway, the apico-G3PAT in rodent *Plasmodium* species was found to be essential for merozoite differentiation in the liver stage and normal sporozoite infectivity *in vivo* but dispensable in the blood stage<sup>67,69</sup>. However, the liver stage phenotype of the apico-G3PAT mutant exhibited only partial phenocopy of the FASII mutant<sup>69</sup>, indicating the contribution of limited Lyso-PtdOH from the ER-G3PAT. In addition, the essential algae-type apico-G3PAT in *T. gondii* is found to be responsible for the synthesis of Lyso-PtdOH (C14:0) using the short fatty acids from FASII pathway<sup>63</sup>, while the fungi-type ER-G3PAT in *P. falciparum* displays a major preference for C16:0 and C16:1<sup>108</sup>. Together with our data, it indicates that the Lyso-PtdOH production in apicomplexans is dependent on two G3PATs in the apicoplast and ER with different phylogenetic origins and fatty acid preference (Figure 17).

*E. falciformis* possesses two paralogs of both LPAAT and CDS for downstream PtdOH and CDP-DAG synthesis. The eukaryotic-type LPAATs and CDSs, including *EfLPAAT1* and *EfCDS1*, exist in the ER or ER/Golgi complex in all protozoan parasites according to this study and previous reports<sup>67,109-111</sup>. On the other hand, the homologues of algae-type *EfLPAAT2* and prokaryotic-type *EfCDS2* are only present in selected protozoans (Table 2), indicating these two enzymes are lost during the evolution of other parasites. *EfCDS2* is localized in the apicoplast as

## 4. DISCUSSION

---

expected, while *EfLPAAT2* is found surprisingly in the ER. The results reveal an universal ER-pathway and an incomplete apicoplast pathway cooperate for the biogenesis of lipid precursors PtdOH and CDP-DAG, which requires the transfers of Lyso-PtdOH and PtdOH between apicoplast and ER/Golgi complex (Figure 17).

### 4.1.3. Inter-organelle cooperation for lipid biogenesis

In eukaryotic cells, lipid biosynthesis pathways are highly compartmentalized, and thus define distinct membrane characters of each organelle and their different functions. In this study, we have revealed a similar level of complexity in phospholipid synthesis network of *E. falciformis* sporozoites, however, with notable exceptions (Figure 17). We identify *EfCEPT1* and *EfCEPT2* as the last step of Kennedy pathways to synthesize major lipids PtdCho and PtdEtn, as well as *EfPIS* for PtdIns production, in Golgi bodies. CEPT is previously reported in the ER of *P. berghei*<sup>56</sup> and found essential for the parasite development in *Plasmodium* blood stage<sup>56</sup> and *Trypanosoma* procyclic form<sup>112</sup>. PIS is localized in both ER and Golgi bodies of *T. brucei* and indispensable for glycosylphosphatidylinositol (GPI) synthesis and survival of the bloodstream form<sup>113</sup>. The occurrence of these two pathways in the Golgi bodies of *E. falciformis* endows this organelle with a significant role in lipid biogenesis of this parasite.


Two alternative pathways for PtdEtn synthesis, *EfPSD1* and *EfPSD2*, are found in the mitochondrion and DG/PV of *E. falciformis*. The localizations of these two PSDs are the same as their homologues in *T. gondii*<sup>65,66</sup>, but is different from the ER-residing PSD in *P. falciparum*<sup>114</sup>. Unlike in kinetoplastids where the Kennedy pathways are the main source for PtdEtn<sup>112,115</sup>, PSD activities appear to contribute for the major PtdEtn biogenesis in apicomplexans<sup>55,65,66</sup>. The mitochondrion also harbors *EfPGPS* and *EfCLS* for the synthesis of PtdGro and cardiolipin. Similar results have been reported in *T. brucei*, where PGPS and CLS form a large protein complex on the inner mitochondrial membrane and are both essential for the mitochondrial morphology and parasite survival<sup>116,117</sup>. Additionally, we identify *EfPTS* and *EfPSS* in the ER and ER/Golgi complex, respectively, which resembles *T. gondii*<sup>50</sup>. Last but not least, the enzymes catalyzing the inter-conversion between PtdOH and DAG are found in the parasite periphery (*EfDGK1*) and DG/PV (*EfDGK2*), or with punctate intracellular distribution (*EfPAP*). In *T. gondii*, the balance between PtdOH

#### **4. DISCUSSION**

---

and DAG is achieved by *TgDGK1*, which is critical to the microneme secretion<sup>118</sup>. Such a complex network of glycerophospholipids in *E. falciformis* is expected to require a significant inter-organelle trafficking of lipids and their precursors.

Several lipid trafficking mechanisms have been reported, especially in yeast and mammalian cells, which involve lateral and transbilayer movements within the same organelle, as well as membrane contact sites, vesicular trafficking and protein-mediated transport between organelles<sup>119-122</sup>. In apicomplexan parasites, multiple membrane contact sites have been observed between the ER/Golgi complex, apicoplast and mitochondrion, and predicted to have important metabolic roles<sup>123-126</sup>. In addition, some lipid transporters have been recently identified in *Plasmodium* to transfer lipids between membranes<sup>127,128</sup>. However, whether they serve as privileged mechanisms of inter-organelle lipid exchange merits further investigation.



**Figure 17. Model of highly compartmentalized network of phospholipid biogenesis in *E. falciformis* sporozoites.** The illustration reveals the pathways that have been predicted based on subcellular localizations of the enzymes (italic with black background) in this study. Shown on the upper right corner is a sporulated oocyst enclosing 4 sporozoysts, each with 2 sporozoites. Pathways located in individual organelles are zoomed out on the left. The grey bars between indicated organelles show possible inter-organelle trafficking of phospholipids and precursors. The prokaryotic-type (*Ef*CDS2 and *Ef*CLS), algal-type (*Ef*G3PAT2 and *Ef*LPAAT2) and coccidian-specific (*Ef*PTS and *Ef*PSD2) enzymes are in red, blue and yellow backgrounds, respectively. Note that *Ef*LPAAT1 and *Ef*PSS also reveal weak ER signal in addition to the dominant Golgi localization, as shown in Figure 8. Abbreviations: CDP-DAG, cytidine diphosphate-diacylglycerol; CDS, cytidine diphosphate-diacylglycerol synthase; CEPT, choline/ethanolamine phosphotransferase; CLS, cardiolipin synthase; DAG, diacylglycerol; DGK, diacylglycerol kinase; G3PAT, glycerol 3-phosphate acyltransferase; Glycerol-3P, glycerol 3-phosphate; LPAAT, lysophosphatidic acid acyltransferase; Lyso-PtdOH, lysophosphatidic acid; PAP, phosphatidic acid phosphatase; PGPS, phosphatidylglycerol phosphate synthase; PIS, phosphatidylinositol synthase; PSD, phosphatidylserine decarboxylase; PSS, phosphatidylserine synthase; PtdCho, phosphatidylcholine; PtdEtn, phosphatidylethanolamine; PtdGro, phosphatidylglycerol; PtdGro-P, phosphatidylglycerol phosphate; PtdIns, phosphatidylinositol; PtdOH, phosphatidic acid; PtdSer, phosphatidylserine; PtdThr, phosphatidylthreonine; PTS, phosphatidylthreonine synthase.

## 4.2. Biogenesis and metabolic roles of CDP-DAG in *T. gondii* tachyzoites

### 4.2.1. Origins and subcellular localizations of CDS enzymes

CDP-DAG serves as one of the central lipid precursors in both eukaryotes and prokaryotes. Similar to what has been described in *E. falciformis* in this study, we have identified two phylogenetically distinct enzymes involved in the synthesis of CDP-DAG in *T. gondii*. *TgCDS1* belongs to the eukaryotic-type CDSs that are conserved across the eukaryotic organisms. It is compartmentalized in the ER of tachyzoites, similar to what has been reported for CDSs in yeast<sup>129</sup>, plants<sup>130</sup> and animals<sup>131,132</sup>. In protozoan parasites *P. falciparum* and *T. brucei*, only one eukaryotic-type CDS has been identified, which is required for the biosynthesis of PtdIns and its descendant lipid GPI<sup>109-111</sup>. In mammals and plants, there are two or more eukaryotic-type CDS enzymes with different expression patterns, all of which influence PtdIns and PtdOH levels<sup>130,133</sup>. Interestingly, a mitochondrial maintenance protein lacking the typical cytidyltransferase domain and CDS signature motif (Tam41) was found to catalyze the formation of CDP-DAG from PtdOH in the yeast mitochondria<sup>134</sup>; however, similar proteins have not been identified in any protozoan parasites. Instead, we have discovered a prokaryotic-type *TgCDS2* in *T. gondii* and its orthologs in only selected protozoan parasites (Table 2), suggesting a loss of the prokaryotic-type CDS during the evolution of certain parasites. *TgCDS2* localizes in the apicoplast, a unique plastid-like organelle evolved by two successive endosymbiotic events, first involving cyanobacteria and then red alga<sup>135</sup>. Both events were ensued by horizontal gene transfer from the cyanobacterial genome to the algal genome, and subsequently to the genome of the parasites. As a result, most of the apicoplast proteins, including *TgCDS2*, have prokaryotic and/or algal origin but encoded by the parasite nucleus<sup>135,136</sup>.

Endosymbiotic gene transfer from the apicoplast to the nucleus enables parasites to control the foreign organelle; however it requires post-translational targeting of the proteins back to the apicoplast. For many apicoplast-resident proteins, this process is guided by a N-terminal bipartite sequence comprising a signal peptide and a transit peptide<sup>137</sup>. Most apicoplast proteins are first imported into the ER and then transferred directly from ER to the apicoplast either through the general secretory

## 4. DISCUSSION

---

pathway or *via* vesicular trafficking<sup>138-140</sup>. Recent studies also reveal an involvement of Golgi as a sorting point for soluble proteins destined to the apicoplast<sup>141,142</sup>. A few other proteins, for example the membrane-bound apicoplast phosphate transporter 1 in *T. gondii*, lack a defined bipartite peptide. Instead, a tyrosine and a glycine residue at the position 16 and 17 were found to be necessary for targeting the protein to the apicoplast<sup>143</sup>. Both putative signal and transit peptides were identified in the N-terminal extension of *TgCDS2* starting from the second methionine instead of the start codon (Figure 11B and Appendix 6). Consistently, our mutagenesis studies confirm the importance of prolonged N-terminal extension and bipartite sequence for localization in the apicoplast. The data indicate that the targeting of *TgCDS2* to the apicoplast is mediated by the bipartite signal mechanism (Figure 12).

### 4.2.2. Functions of CDP-DAG in parasite biology

*TgCDS1* and *TgCDS2* mutants showed severely reduced growth and attenuated virulence, which is associated with the loss of PtdIns and PtdGro in parasites. PtdIns serves not only as a structural component of membranes, but also as a precursor for the biogenesis of some central signaling molecules. Earlier studies on the PtdIns phosphates (PIPs) have revealed that phosphatidylinositol 3-monophosphate and phosphatidylinositol (3,5)-bisphosphate are required for the apicoplast biogenesis in tachyzoites<sup>144,145</sup>. Another downstream product of PtdIns, GPI, has been implicated in both host cell attachment and modulation of the immune response, and proven to be crucial for the parasite survival<sup>146-148</sup>. On the other hand, literally nothing is known about the structural and functional relevance of PtdGro in *T. gondii*. PtdGro typically serves as an intermediate for the synthesis of cardiolipin, which is indispensable for mitochondrial homeostasis and viability of kinetoplastid parasites<sup>116,117</sup> but was barely detectable in tachyzoites. It is expected that changes in PtdIns, PtdGro and cardiolipin would result in organelle dysfunction and eventual demise of *T. gondii* unless parasites could salvage CDP-DAG or its descendent lipids from the environment to bypass the ablation of CDS enzymes, which appears to be not the case. A detailed morphological analysis of the CDS mutants shall reveal the underlying basis of the observed growth impairment.

*TgCDS1* and *TgCDS2* mutants did not show a perturbation of other dominant phospholipids except for PtdCho, which can be explained by the nature of underlying

## 4. DISCUSSION

---


pathways present in tachyzoites. We have previously reported the functional existence of PtdCho and PtdEtn syntheses through CDP-choline and CDP-ethanolamine pathways, both of which utilize DAG as the lipid backbone<sup>55,64</sup>. Because synthesis of PtdCho occurs exclusively through the CDP-choline route, a significant increase in the lipid content during *off state* of the two mutants is expected due to potential rerouting of PtdOH to DAG. On the other hand, PtdEtn can also be produced by decarboxylation of PtdSer in the parasite mitochondrion and DG/PV (major routes)<sup>65,66</sup>, which may have balanced its content in the single and double mutants. PtdSer and PtdThr are generated from PtdEtn and/or PtdCho in a base-exchange manner by two distinct routes located in the parasite ER<sup>50</sup>. No change of PtdThr was observed in both mutants. Given its unique acyl chain composition (mostly 20:1, 20:4), it seems that a different source of glycerol backbone or lipid remodeling is required to make PtdThr. In the case of PtdSer, a sizeable increase during *on state* and decline in *off state* of both mutants was surprising and suggests the presence of yet-another PSS (CDP-DAG-dependent) for making PtdSer (Figure 18). Such a global dysregulation of major phospholipids (e.g., accumulation of PtdCho and PtdOH, and/or change in PtdSer) may also underlie the phenotype observed in individual mutants. While the detection of CDP-DAG and DAG in tachyzoite is quite challenging, future studies using isotope labeling of other lipids with precursors (polar head groups or glycerol backbone) should validate aforesaid postulations.

### 4.2.3. A “division of labor” model of lipid biogenesis

*TgCDS1* and *TgCDS2* are utilized for the biogenesis of PtdIns, PtdSer and PtdGro in a rather selective manner. Our data suggest a model, in which ER-derived CDP-DAG fuels the synthesis of PtdIns in the Golgi bodies, whereas CDP-DAG originating in the apicoplast is utilized for PtdGro biogenesis in the mitochondrion (Figure 18). These results are consistent with the presence of two isoforms of each enzyme synthesizing Lyso-PtdOH and PtdOH, as described in *E. falciformis* in this study. One such enzyme, *TgG3PAT2* (termed as ATS1) has recently been reported to localize in the apicoplast<sup>63</sup>, while others remain to be characterized. This highly spatial distribution of lipid syntheses necessitates a coordinated lipid transport among various organelles in *T. gondii*, in particular a ‘retrograde’ transfer of PtdIns from Golgi to ER, and of CDP-DAG from ER/apicoplast to Golgi/mitochondrion. This study

## 4. DISCUSSION

embodying a prototype model of lipid synthesis and trafficking provides a framework for such paradigms in a well-established model eukaryotic pathogen.



**Figure 18. A “division of labor” model of CDP-DAG-dependent biogenesis of PtdIns, PtdSer and PtdGro involving the inter-organelle cooperation of specified organelles.** The illustration depicts abridged inter-organelle trafficking of only selected lipids, especially those relevant to the context. Many other possibilities also exist. Two distinct CDP-DAG pools are utilized to produce PtdIns, PtdSer and PtdGro. The CDP-DAG pool in the ER is generated by *TgCDS1* and used for biogenesis of PtdIns in the Golgi body. PtdIns could subsequently be used to synthesize phosphatidylinositol phosphates (PIP) and glycosylphosphatidylinositol (GPI). *TgCDS2* generates a second pool of CDP-DAG in the apicoplast that contributes to syntheses of PtdGro phosphate (PtdGro-P), PtdGro and cardiolipin in the mitochondrion. Pathways that have been confirmed are marked with solid line arrows, while pathways and transports in postulation are marked with dashed line arrows.

## **5. Conclusions and perspectives**

This work reveals distinct phospholipid profiles of the infective sporozoite and tachyzoite forms of apicomplexan parasites *E. falciformis* and *T. gondii*. We also demonstrate a highly compartmentalized network of parasite lipid biogenesis, involving significant inter-organelle cooperation and lipid trafficking. The enzymes in this network are evolved from various origins including both prokaryotes and eukaryotes. Our work establishes a “division of labor” model of lipid biogenesis in apicomplexan parasites. Natural occurrence of atypical lipids, dependence on *de novo* synthesis and evolutionary divergence of certain pathways together offer unique opportunities to selectively inhibit parasite development and thereby prevent inter-host transmission.

Many questions still remain to be answered in future study, including:


- Synthesis of IPC, PtdIns, GPI and cardiolipin;
- Lipid compositions of individual organelles;
- Mechanism of inter-organelle lipid trafficking;
- Genetic ablation of lipid synthesis in *E. falciformis*;
- Roles of lipids during sexual development of parasites using *E. falciformis* as a model.

## Appendices

**Appendix 1. List of sequences from *E. falciformis* and *T. gondii* deposited to GenBank in this study.**


Gene name	EuPathDB accession number	Genbank accession number
<i>EfG3PAT1</i>	EfaB_PLUS_45924.g2677	KX785365
<i>EfG3PAT2</i>	EfaB_MINUS_3469.g362	KX785366
<i>EfLPAAT1</i>	EfaB_MINUS_17400.g1567	KX785367
<i>EfLPAAT2</i>	EfaB_MINUS_12065.g1058	KX785368
<i>EfCDS1</i>	EfaB_PLUS_1048.g115	KX017547
<i>EfCDS2</i>	EfaB_PLUS_36188.g2485	KX017548
<i>EfPAP</i>	EfaB_MINUS_22960.g1971	KX785369
<i>EfDGK1</i>	EfaB_MINUS_7048.g670	KX785370
<i>EfDGK2</i>	EfaB_MINUS_36188.g2575	KX785371
<i>EfDGK3</i>	EfaB_MINUS_11882.g1052	KX785372
<i>EfPGPS</i>	EfaB_MINUS_17907.g1626	KX785373
<i>EfCLS</i>	EfaB_PLUS_56725.g2797	KX785374
<i>EfPIS</i>	EfaB_PLUS_6035.g572	KX785375
<i>EfCEPT1</i>	EfaB_MINUS_56725.g2919	KX785376
<i>EfCEPT2</i>	EfaB_MINUS_15745.g1427	KX785377
<i>EfCEPT3</i>	EfaB_MINUS_25458.g2174	KX785378
<i>EfPSD1</i>	EfaB_MINUS_22450.g1948	KX785379
<i>EfPSD2</i>	EfaB_MINUS_1072.g165	KX785380
<i>EfPSS</i>	EfaB_PLUS_1974.g212	KX785381
<i>EfPTS</i>	EfaB_MINUS_800.g81	KX785382
<i>TgCDS1</i>	TGGT1_281980	KU199242
<i>TgCDS2</i>	TGGT1_263785	KU199243
<i>TgPGPS</i>	TGGT1_246530	KX017550
<i>TgPIS</i>	TGGT1_207710	KX017549

## Appendix 2. Schematic illustration showing the primary structures of putative enzymes involved in phospholipid synthesis of *T. gondii*.




### Appendix 3. Multiple alignments of the conserved functional motifs of chosen lipid synthesis enzymes from selected organisms.

**(A)** Alignment of conserved motifs of G3PATs in the same clades with *EfG3PAT1* and *EfG3PAT2* in the phylogenetic tree (Figure 7A). The residues identical across all sequences are shaded with black color, while those identical in more than half of the sequences are shaded in grey. The residues only conserved in one clade of sequences were shaded with yellow and green, respectively. The residues contributing to acyl-acceptor binding pockets are marked with stars on top of the alignment. Sequence information including accession numbers and full organism names are shown in Appendix 5.




**(B)** Alignment of conserved motifs of LPAATs from selected organisms (see Figure 7B for phylogenetic tree). The residues identical across all sequences are shaded with black color, while those identical in more than half of the sequences are shaded in grey. The residues contributing to acyl-acceptor binding pockets are marked with stars on top of the alignment. Sequence information including accession numbers and full organism names are shown in Appendix 5.




**(C)** Alignment of conserved motifs of CDSs from selected organisms (see Figure 7C and 11A for phylogenetic tree). The residues identical across all sequences are shaded with black color, while those identical in more than half of the sequences are shaded in grey. The residues only conserved in eukaryotic or prokaryotic sequences were shaded with red and blue, respectively. Sequence information including accession numbers and full organism names are shown in Appendix 5.

	504		539	
<b>EfCDS1</b>	..PFGGGFFASGFKRAVRIKDFGYFIPGHGGVTDRFD <b>CQ</b> ..			
<i>TgCDS1</i>	..PFGGGFFASGFKRAARIKDFGEIIPGHGGVTDRFD <b>CQ</b> ..			
<i>NcCDS1</i>	..PFGGGFFASGFKRAARIKDFGEIIPGHGGVTDRFD <b>CQ</b> ..			
<i>CpCDS</i>	..PFGGGFFASGLKRALRIKDFGSAIPGHGGITDRFD <b>CQ</b> ..			
<i>PbCDS</i>	..PFGGGFFASGFKRALKIKDFGDVIIPGHGGFTDRVDC <b>Q</b> ..			
<i>PfCDS</i>	..PFGGGFFASGFKRALKIKDFGKSIPGHGGVTDRFD <b>CQ</b> ..			
<i>TbCDS</i>	..PFGGGFFASGLKRAFKMKDFGDLIPGHGGITDRMD <b>CQ</b> ..			
<i>TcCDS1</i>	..PFGGGFFASGLKRAFKLKDFGDLIPGHGGITDRMD <b>CQ</b> ..			
<i>LmCDS1</i>	..PFGGGFFASGLKRAFKLKDFGDLIPGHGGMTDRMD <b>CQ</b> ..			
<i>CcCDS1</i>	..PFGGGFFASGAKRAFGVKDFGGLLPGHGGVTDRVDC <b>Q</b> ..			
<i>GsCDS1</i>	..PFGGGFFASGLKRAFKVKDFANLIPGHGGVTDRMD <b>CQ</b> ..			
<i>DmCDS</i>	..PFGGGFFASGFKRAFKIKDFGDMIIPGHGGIMDRFD <b>CQ</b> ..			
<i>HsCDS1</i>	..PFGGGFFASGFKRAFKIKDFANTIPGHGGIMDRFD <b>CQ</b> ..			
<i>HsCDS2</i>	..PFGGGFFASGFKRAFKIKDFANTIPGHGGIMDRFD <b>CQ</b> ..			
<i>CgCDS</i>	..PFGGGFFASGLKRAFKVKDFGHSIPGHGGITDRVDC <b>Q</b> ..			
<i>ScCDS</i>	..PFGGGFFASGLKRTFKVKDFGHSIPGHGGITDRVDC <b>Q</b> ..			
<i>SpCDS</i>	..PFGGGFFASGLKRAFKIKDFGASIPGHGGLTDRMD <b>CQ</b> ..			
<i>CrCDS1</i>	..PFGGGFFASGFKRAFKHMKDFGDTIPGHGGVTDRFD <b>CQ</b> ..			
<i>OtCDS1</i>	..PFGGGFFASGFKRAFKIKDFAETIPGHGGVTDRLD <b>CQ</b> ..			
<i>AtCDS1</i>	..PFGGGFFASGFKRAFKIKDFGDSIPGHGGITDRMD <b>CQ</b> ..			
<i>AtCDS2</i>	..PFGGGFFASGFKRAFKIKDFGDSIPGHGGITDRMD <b>CQ</b> ..			
<i>AtCDS3</i>	..PFGGGFFASGFKRAFKIKDFGDSIPGHGGFTDRMD <b>CQ</b> ..			
	640		675	
<b>EfCDS2</b>	..V <b>T</b> GDLTASLLKRDAGVKD <b>S</b> ALLPGHGGWLDRTDAH..			
<i>TgCDS2</i>	..V <b>L</b> GDLTASLVKRDAGVKD <b>S</b> GTLLPGHGGWLDRTDSY..			
<i>NcCDS2</i>	..V <b>L</b> GDLTASLVKRDAGVKD <b>S</b> GTLLPGHGGWLDRTDSY..			
<i>TcCDS2</i>	..V <b>V</b> GDLLQSLLKRTARIKD <b>S</b> GYLMPGHGGVLDRIDGL..			
<i>LmCDS2</i>	..V <b>C</b> GDLLQSLLKRAARVKD <b>S</b> GFIIPGHGGILDRVDGM..			
<i>CcCDS2</i>	..L <b>C</b> GDLFESCFKRDGVWKD <b>S</b> GSLEPGHGGMLDRADSY..			
<i>GsCDS2</i>	..L <b>L</b> GDLTASLFKRDAGFKD <b>S</b> GNIIIPGHGGILDRTDSY..			
<i>MvCDS</i>	..L <b>L</b> GDLTESMMKRDAGVKD <b>S</b> QLIPGHGGILDRTDSY..			
<i>SsCDS</i>	..L <b>L</b> GDLTESMMKRDAGVKD <b>S</b> QLIPGHGGILDRTDSY..			
<i>TeCDS</i>	..L <b>L</b> GDLTESMMKRDAGVKD <b>S</b> QLIPGHGGILDRTDSY..			
<i>AtCDS4</i>	..V <b>F</b> GDLTESMIKRDAGVKD <b>S</b> SLIPGHGGILDRTDSY..			
<i>AtCDS5</i>	..V <b>F</b> GDLTESMIKRDAGVKD <b>S</b> SLIPGHGGILDRTDSY..			
<i>CrCDS2</i>	..L <b>F</b> GDLIESIMKRDAGMKD <b>S</b> GLIPGHGGLLDRFD <b>S</b> Y..			
<i>OtCDS2</i>	..I <b>F</b> GDLLESVMKRNADM <b>K</b> D <b>S</b> GNLIPGHGGLLDRFD <b>S</b> Y..			
<i>BsCDS</i>	..Q <b>L</b> GDLVESALKRHYDV <b>K</b> D <b>S</b> GNILPGHGGILDRTFDSF..			
<i>EcCDS</i>	..V <b>L</b> GDLTESMFKREAG <b>I</b> KD <b>S</b> GHЛИPGHGGILDRIDSL..			
<i>HpCDS</i>	..V <b>F</b> GDLYESYLKR <b>K</b> AG <b>I</b> KD <b>S</b> ГKILPGHGGVLDRLDSM..			


**(D)** Alignment of conserved motifs of phospholipase-D-type PGPSS and CLSs from selected organisms (see Figure 7D for phylogenetic tree). See Appendix 3I For CDP-alcohol-phosphotransferase-type PGPSS and CLSs. The residues identical across all sequences are shaded with black color, while those identical in more than half of the sequences are shaded in grey. The residues only conserved in PGPSS or CLS sequences were shaded with purple and orange, respectively. The putative catalytic sites are marked with stars on top of the alignment. Sequence information including accession numbers and full organism names are shown in Appendix 5.



(E) Alignment of conserved motifs of PSDs from selected organisms (see Figure 7E for phylogenetic tree). The residues identical across all sequences are shaded with black color, while those identical in more than half of the sequences are shaded in grey. The cleavage residues at the catalytic sites are marked with stars on top of the alignment. Sequence information including accession numbers and full organism names are shown in Appendix 5.



(F) Alignment of conserved motifs of base-exchange-type PSSs and PTSs from selected organisms (see Figure 7F for phylogenetic tree). See Appendix 3I For CDP-alcohol-phosphotransferase-type PSSs. The residues identical across all sequences are shaded with black color, while those identical in more than half of the sequences are shaded in grey. The residues only conserved in PSS or PTS sequences were shaded with blue and green, respectively. The putative catalytic site (ECWWD) is marked with stars on top of the alignment, which was deleted in the  $\Delta tgpts$  mutant (see Figure 9A). The substrate-binding residue is highlighted with arrow. Sequence information including accession numbers and full organism names are shown in Appendix 5.




**(G)** Alignment of conserved motifs of PAPs from selected organisms (see Appendix 4A for phylogenetic tree). The residues identical across all sequences are shaded with black color, while those identical in more than half of the sequences are shaded in grey. The PAP active residues are marked with stars on top of the alignment. Sequence information including accession numbers and full organism names are shown in Appendix 5.

	166	*	177	217	***	224	289	*	*	304
<b>EfPAP</b>	..LKEVVGSLRPHF..SFPSGHSS..TRVLDHYHHVRDVVG..									
<i>TgPAP</i>	..AKICVGRLRPHF..SFPSGHSS..SRIKDKFHHPSDVMAG..									
<i>NcPAP</i>	..AKICVGRLRPHF..SFPSGHSS..SRIKDKFHHPGDVVAG..									
<i>CpPAP</i>	..LKNIFKSPRPPN..GMPSGHCV..ARWYVEDHTIPQCIWG..									
<i>PfPAP</i>	..LKRIFKKPRPIN..GMPSGHSS..SRVEVEDHTVLQIVG..									
<i>TbPAP1</i>	..LKVVAGRLRPDF..SFPSGHSS..SRTRDNRHHFADIVAG..									
<i>TbPAP2</i>	..LKIYAGRLRPDF..SFPSGHSS..SRTRDNRHHFSDILGG..									
<i>TbPAP3</i>	..LKVVAGVLRPDF..SFPSGHSG..SRLRDRNRHHSGDVVAG..									
<i>TcPAP1</i>	..LKIYAGRIRPDY..SFPSGHSS..SRTRDYWHHFDDIVAG..									
<i>TcPAP2</i>	..CKLYAGRLRPDF..SFPSGHAS..SRTRDNKHHFSDIVGG..									
<i>TcPAP3</i>	..TKLYAGRLRPDF..SFPSGHAA..SRTRDNRHHFSDVLAG..									
<i>LmPAP</i>	..IKVYAGRLRPDF..SFPSGHSS..SRTRDNRHYFDDIVAG..									
<i>CmPAP1</i>	..LKLLIGKPRPYF..SFPSGHAA..SRVLDHHHDVVVDVLGG..									
<i>CmPAP2</i>	..IKLYAGSLRPDF..SFVSGHTS..SRIVDNRHFPADVVGG..									
<i>GsPAP1</i>	..GKLSVGMLRPDF..SFPSGHAC..TRITDHRQHHSSVVAG..									
<i>GsPAP2</i>	..GKWWVGYLRPDF..SFPSGHAS..SRIVDNRHHPADVVAG..									
<i>OtPAP</i>	..MKNIIIGNIRPDF..SFPSGHTS..TRIRDYWHHWEDVLVG..									
<i>VcPAP</i>	..LKLPVGRLRPNF..SWPSGHSS..TRVLDYWHFTSDVLTG..									
<i>AtPAP1</i>	..IKNAVGRPRPDF..SFPSGHTS..SRVDDYWHHWQDVFAG..									
<i>AtPAP2</i>	..IKVATGRPRPNF..SFPSGHTS..SRVDDYWHHWQDVFAG..									
<i>AtPAP3</i>	..IKDAVGRPRPNF..SFPSGHTS..SRVDDYWHHWTDVFAG..									
<i>AtPAP4</i>	..IKDAVGRPRPDF..SFPSGHTS..SRVDDYWHHWQDVFGG..									
<i>AtPAP5</i>	..LKRILNQERPTT..GMPSSHAQ..LRVSQKLHTSSQVVVG..									
<i>AtPAP6</i>	..IKTSVEQARPET..GWPSSHSQ..SRVYLGYHTVAQVFAG..									
<i>AtPAP7</i>	..VKLIFRRARPAY..SFPSGHAS..SRILLGRHYVLDVAAG..									
<i>CgPAP1</i>	..IKNWIGRLRPDF..TTPSGHSS..SRTQDYRHHFIDVIIG..									
<i>CgPAP2</i>	..LKLVIGNFRPDF..STPSGHSS..SRITDHRHHWYDVSG..									
<i>ScPAP1</i>	..IKNWIGRLRPDF..TTPSGHSS..SRTQDYRHHFVDVILG..									
<i>ScPAP2</i>	..LKLIIIGNLRPDF..STPSGHSS..SRVIDHRHHWYDVSG..									
<i>HsPAP1</i>	..AKYSIGRLRPHF..SFYSGHSS..SRVSDYKHHWSDVLTG..									
<i>HsPAP2</i>	..AKVSIGRLRPHF..SFFSGHAS..SRVSDHKHHPSDVLAG..									
<i>HsPAP3</i>	..AKYMIGRLRPNF..SFYSGHSS..TRVSDYKHHWSDVLVG..									
<i>HsPAP4</i>	..IKLIVGRPRPDF..SFPSIHSS..SRMCDYKHHWQDSFVG..									
<i>HsPAP5</i>	..IKLIVGRPRPDF..SFPSGHSS..SRTCDYKHHWQGPFW..									
<i>HsPAP6</i>	..IKGLVRRRRPAH..SFPSGHAT..SRVMLGRHNVTDVAFG..									
<i>HsPAP7</i>	..VQKLICKRRGPYE..AFPAGHAS..SRVMIGRHVTDLVSG..									
<i>HsPAP8</i>	..GQVVTGHLTPYF..SFPSKHAA..NRVSEYRNHCSDVIAG..									
<i>HsPAP9</i>	..GQVVTGNPTPHF..AFPCKDAA..VRVAEYRNHWSDVLAG..									
<i>HsPAP10</i>	..IQLATGYHTPFF..TFPSQHAT..TQITQYRSHPVDVYAG..									
<i>HsPAP11</i>	..IQLSTGYQAPYF..SFPSQHAT..TRITQYKNHPVDVYCG..									
<i>HsPAP12</i>	..GQVVTGNLAPHF..TFPSKEAA..NRVAEYRNHWSDVIAG..									
<i>HpPAP</i>	..LKLLVARPRPAT..SFPSGHAL..DRVYLGHVHYPSDVLGG..									
<i>SePAP</i>	..AKKYYMRTRPFV..SYPSGHTA..SRVICGAHWQSDVDAG..									
<i>CePAP</i>	..LKELFARSRPQL..SFPSGHAM..SRLYFGVHWPTDVIAG..									
<i>MvPAP</i>	..LKKLFARARPQL..SFPSGHAM..SRLYLGVHWPTDVIAG..									


**(H)** Alignment of conserved motifs of DGKs from selected organisms (see Appendix 4B for phylogenetic tree). The residues identical across all sequences are shaded with black color, while those identical in more than half of the sequences are shaded in grey. Sequence information including accession numbers and full organism names are shown in Appendix 5.

	DGK Catalytic Domain																			DGK Accessory Domain								
	167	168	221	232	253	269	270	301	325	350	359	360	367	375	431	445	473	477	489	509	563	569	601					
<b>Efdgk1</b>	..FVNPTSGG..RVLVAGGGDCITVMW..PYGT-GNDPSNAFGWN..DLW..NYFSMGVES..FDRFR..NKMRYGIEG..NIPSFSCGNDIW..DGKLE..RLHS..QTGDFE..																											
<b>Efdgk2</b>	..IANPRTSGS..RVIAVGGDCAFAC..PSGT-GNDLDAHTYGVW..DSW..NYFCIGCFDG..VEKFR..NRAMYGF..NSRTIMCGVELW..DGKIE..RVMO..QVDGEF..																											
<i>TgDGK1</i>	..FINPTS GG..RVLVAGGGDCITVMW..PYGT-GNDFAQAFGWK..DLW..NYFSMGVES..FDRFR..NKMRYGIEG..NIPSFSCGNDIW..DRELE..RINO..QVDGEF..																											
<i>TgDGK2</i>	..FVNVRKAGG..RVIAVGGDCTVMW..PYGT-GNDFAQAFGWK..TIY..NYFSMGVES..FDRFR..NKMRYGMEG..NIPSFSCGNDIW..DGELE..RINO..QVDGEF..																											
<i>Ncdgk1</i>	..FINPTS GG..RVLVAGGGDCITVMW..PYGT-GNDFAQAFGWK..TIY..NYFSMGVES..FDRFR..NKMRYGMEG..NIPSFSCGNDIW..DGELE..RINO..QVDGEF..																											
<i>Ncdgk2</i>	..FVNVRKAGG..RVIAVGGDCTVMW..GFGT-GNDFAQSYGWA..DLW..LYLGICFDA..FDRFR..NRIMYGVAF..NNRSMIGCIPLW..DTKIE..RLSQ..QTGDFE..																											
<i>Cpdgk1</i>	..FVNPTS GG..YIIAAGGGDCITLNW..PFGT-GNDFAQAFGWK..DYN..NYFSIGEES..EDTFR..NKMRYALEG..NIPSFSCGNDIW..DEIIE..RVFO..QVDGEF..																											
<i>Cpdgk2</i>	..FVNPTS GG..YIIAAGGGDCITLNW..PFGT-GNDFAQAFGWK..DYN..NYFSIGEES..EDTFR..NKMRYALEG..NIPSFSCGNDIW..DGVLE..RIBQ..QVDGEF..																											
<i>Pfdgk1</i>	..FVNPTS GG..YIIAAGGGDCITLNW..PFGT-GNDFAQAFGWK..DYN..NYFSIGIDS..FERFR..NKMVYAIEG..NIPSYSSGNDIW..DGILE..RVHQ..QVDGEY..																											
<i>Lmdgk1</i>	..FINLNGSE..TVVVCGGDCITVSP..PLGT-GNDYSNCVGF..DRW..NYLVGCFD..FDDTR..NKAVYGVFM..NVNCYSACTHPW..DCAFE..KLIO..QIDGES..																											
<i>Lmdgk2</i>	..LVNLRSGG..YIVVAGGGCTISF..PLGT-GNDFSRTLGF..DRW..NYFSIGFDA..LNRRR..VKLWYAAFA..NMLTYAGAVAW..DGRVE..KLAQ..QFDGEE..																											
<i>Tbdgk</i>	..IVNPPLAGE..TVVVCGGDCITVSP..AFGT-GNDFSNCVGF..DRW..NYVSVCVGS..FDTFR..NKAVYAGTKPW..DRKLE..KTSQ..QIDGEP..																											
<i>Tcdgk1</i>	..IVNPVSGE..TVVVCGGDCITVSP..AIGT-GNDYSNCVGF..DRW..NYFSIGFDA..FDDFR..NKLVYGVVG..NVCSYACCTRWP..DHKME..KLAQ..QIDGEP..																											
<i>Tcdgk2</i>	..LINTRS GE..VVIVAGGGCTVSL..PMGT-GNDLSRTLGF..DRW..NYFSIGFDA..FGDFR..NKLWYCFG..NVKTYAGAVFW..DGLLE..KVAQ..QIDGEP..																											
<i>CmDgk</i>	..CVNPKSGG..RIILICGGDCITISR..PIGT-GNDLARLTLGWG..DTW..SMLSICCD..FNSR..NYISHALFG..NIPSYGAGADPG..DGRLD..RLRN..QCDGEA..																											
<i>Gsdgk1</i>	..LINRTSGS..KILVCGGGDCITCNL..PIGT-GNEELARSLGWG..DVW..GFLSICIDA..FNESR..NIAKYGVW..NIPSYGACAFPI..DRVLE..KLCQ..QVDGEP..																											
<i>Gsdgk2</i>	..FVNCKSGG..RALICGGDCITFSW..PLGT-GNDLSRSLGWG..DVW..NSLSIGVDA..FNEER..NVFLHWHG..NIPSYAGGLPY..DGLLE..KLAQ..QVDGEP..																											
<i>Crdgk</i>	..QQQGPAGG..RVLVAGGGDCITVGW..SAGSRGNDLARLGVWL..DRW..NYLGVGIDS..FHRFR..NRAWYTCVG..NIASYMCGVDLW..DGVLE..RLCQ..QVDGEP..																											
<i>Otdgk1</i>	..FVNKRSGG..RGLVAGGGDCITVAL..PLGT-GNDLARLGVWL..DRW..NYMGIICVDA..FDLAR..NKLLYAVF..NINPSFSCGVRMW..DGLLE..QIAQ..QIDGEP..																											
<i>Otdgk2</i>	..FVNKS CGG..RILVAGGGDCITVAM..PLGT-GNDLSRVLNWG..DRW..NYLGIICVDA..FHRFR..NKLLYGAFG..NINPSFAGVVRM..DGLVD..RLCQ..HVDP..																											
<i>Atdgk1</i>	..FINKSKGA..RVLVAGGGDCITAGW..PLGT-GNDLSRVLNWG..DRW..NYIGVGCDA..IHNR..NKLYAREG..NICSYMCGVDLW..DKIVE..RLAQ..QIDGEP..																											
<i>Atdgk2</i>	..FINKSKGG..RILVCGGGDCITVAM..PLGT-GNDLSRVLQWG..DRW..NYLGIICDCA..FMMR..NKLRYAKE..NIPSYMCGVDLW..DGLLE..RLAQ..QIDGEP..																											
<i>Atdgk3</i>	..FINPNSGG..RIMVAGGGDCITVGW..PLGT-GNDLSRSFGWG..DSW..NYLSIGMDA..FHHFR..NKIIYSSFG..NLHSYGSGSHPW..DGLLE..HIAQ..QMDGEP..																											
<i>Atdgk4</i>	..FVNPKSGG..RIVVAGGGDCITVGW..PLGT-GNDLSRSFGWG..DSW..NYFSIGMDA..FHHFR..NKIIYSSGY..NLHSYGSGRNPW..DGLLE..HIAQ..QMDGEP..																											
<i>Atdgk5</i>	..FINSKSGG..KIIIVAGGGDCITAGW..PLGT-GNNLPFAFGWG..DNW..NYFSIGMDA..FHSR..NQSTYVKKL..NLPFSFGCLNPW..DGLLE..RLAQ..RMGEP..																											
<i>Atdgk6</i>	..FINSKSGG..KIIIVAGGGDCITAGW..PLGT-GNNLPFAFGWG..DNW..NYFSIGMDA..FHSR..NQSTYVKKL..NLPFSFGCLNPW..DGLLE..RLAQ..RIDGEP..																											
<i>Atdgk7</i>	..FVNPKSGG..RIMVAGGGDCITVGW..PLGT-GNDLARVLRW..DRW..NYFSIGVDA..FHM..NKLWYFEFA..NIPSMHCGSNLW..DKRLE..RLAK..QIDGEP..																											
<i>Hsdgk2</i>	..FVNPKSGG..RVLVACGGDCITVGW..PLGT-GNDLARLWRG..DRW..NYFSIGVDA..FHM..NKLWYFEFA..NIPSMHCGSNLW..DQLLE..RLAQ..QIDGEP..																											
<i>Hsdgk3</i>	..LVPNPKSGG..RVLVACGGDCITVGW..PLGT-GNDLARLWRG..DRW..NYFSIGVDA..FHM..NKLWYFEFA..NIPSMHCGSNLW..DQLLE..RLAQ..QIDGEP..																											
<i>Hsdgk4</i>	..FVNPKSGG..RILACGGDCITVGW..PLGT-GNDLARLWRG..DRW..NYFSIGVDA..FHM..NKLWYFEFA..NIPSMHCGSNLW..DQLLE..RLAQ..QIDGEP..																											
<i>Hsdgk5</i>	..FVNPKSGG..RILACGGDCITVGW..PLGT-GNDLARLWRG..DRW..NYFSIGVDA..FHM..NKLWYFEFA..NIPSMHCGSNLW..DQLLE..RLAQ..QIDGEP..																											
<i>Hsdgk6</i>	..FVNPKSGG..RILACGGDCITVGW..PLGT-GNDLARLWRG..DRW..NYFSIGVDA..FHM..NKLWYFEFA..NIPSMHCGSNLW..DQLLE..RLAQ..QIDGEP..																											
<i>Hsdgk7</i>	..FVNPKSGG..RILACGGDCITVGW..PLGT-GNDLARLWRG..DRW..NYFSIGVDA..FHM..NKLWYFEFA..NIPSMHCGSNLW..DQLLE..RLAQ..QIDGEP..																											
<i>Hsdgk8</i>	..FVNPKSGG..RILACGGDCITVGW..PLGT-GNDLARLWRG..DRW..NYFSIGVDA..FHM..NKLWYFEFA..NIPSMHCGSNLW..DQLLE..RLAQ..QIDGEP..																											
<i>Hsdgk9</i>	..FVNPKSGG..RILACGGDCITVGW..PLGT-GNDLARLWRG..DRW..NYFSIGVDA..FHM..NKLWYFEFA..NIPSMHCGSNLW..DQLLE..RLAQ..QIDGEP..																											
<i>Hsdgk10</i>	..FINSKSGD..RILVCGGGDCSVGW..PLGT-GNDLARLWRG..DRW..NYFGJGLDA..FNTRR..NKMWYGLL..NITYAGINFW..DGKLE..RIAQ..QVDGEA..																											
<i>Pfdgk2</i>	..FVNVKSGG..ILLICGGDCITISI..PLGT-GNDLSISLWG..DVW..NYFDIGITA..FDNIR..NKILYGEV..NIPYFLCGIKIW..DKVIE..KLCQ..QYDGE..																											
<i>Pfdgk2</i>	..FVNVRSGG..IIIFLCGGDCITISI..PLGT-GNDLCISLWG..DVW..NYFDIGLIS..FDNIR..NKILYGEIG..NIPYILCGHNIW..DKLIE..KLCQ..QYDGE..																											
<i>Cpdgk3</i>	..FVNPKSGG..MIDIICGGDCITVWR..PLGT-GNDLSRTLGD..DIN..NYLDIGIAA..FHNR..NQLVYGEVG..NIPSFSCGVNLW..DGLIE..KLCQ..QVDGE..																											
<i>Ncdgk3</i>	..FVNVKSGG..RVLVCGGGDCITVGW..PLGT-GNDLSNVLWG..DLW..NYLDVGVA..FHKLR..NKFLYGEVG..NIPSFAGCVELW..DOLIE..RLCQ..QIDGEP..																											
<i>Tgdgk3</i>	..FVNVKSGG..RVLVCGGGDCITVGW..PLGT-GNDLSNVLWG..DLW..NYLDVGVA..FHKLR..NKFLYGEVG..NIPSFAGCVELW..DOLIE..RLCQ..QIDGEP..																											
<i>Efdgk3</i>	..FVNPKSGG..RVVVCCGGDCITVGW..PLGT-GNDLSNVLWG..DLW..NYLDVGVA..FHKLR..NKFLYGEVG..NIPSFAGCVELW..DOLIE..RLCQ..QIDGEP..																											

(I) Alignment of conserved motifs of CDP-alcohol-phosphotransferase-type enzymes (CEPTs, PISs, CDP-DAG-dependent PSSs, as well as some PGPSs and CLSs) from selected organisms (see Figure 7D, 7F and Appendix 4C-E for phylogenetic trees). The residues identical across all sequences are shaded with black color, while those identical in more than half of the sequences are shaded in grey. The residues only conserved in one group of enzymes were shaded with different colors. The three residues only identical in CEPT3s from coccidian parasites and different from other CEPTs are highlighted with blue boxes. Sequence information including accession numbers and full organism names are shown in Appendix 5.



## Appendix 4. Phylogeny of selected lipid synthesis enzymes.



Phylogenetic trees show the evolutionary relationships of PAP (A), DAG (B), CEPT (C), PIS (D) and CDP-alcohol-phosphotransferase-type enzymes including CEPT, PIS, CDP-DAG-dependent PSS, as well as some PGP S and CLS enzymes (E) in *E. falciformis* and various organisms representing major tree of life. Branch support was estimated by 100 bootstrap replicates. See Figure 7 for phylogeny trees of other enzymes. Sequence information including accession numbers and full organism names are shown in Appendix 5. Abbreviations: CEPT, choline ethanolamine phosphotransferase; CLS, cardiolipin synthase; DGK, diacylglycerol kinase; PAP, phosphatidic acid phosphatase; PGP S, phosphatidylglycerol phosphate synthase; PIS, phosphatidylinositol synthase; PSS, phosphatidylserine synthase.

## Appendix 5. Sequences used for phylogenetic analysis.

Sequences from apicomplexan and kinetoplastid parasites are shown with EuPathDB accession numbers, while the rest are provided with NCBI accession numbers. See Appendix 1 for the Genbank accession numbers of *E. falciformis* sequences.

	Designation	Species	Accession No.
<b>Glycerol 3-Phosphate Acyltransferase (G3PAT)</b>			
Apicomplexans	<i>CpG3PAT</i>	<i>Cryptosporidium parvum</i>	cgd6_1270
	<i>EfG3PAT1</i>	<i>Eimeria falciformis</i>	EfaB_PLUS_45924.g2677
	<i>EfG3PAT2</i>	<i>Eimeria falciformis</i>	EfaB_MINUS_3469.g362
	<i>NcG3PAT1</i>	<i>Neospora caninum</i>	NCLIV_029980
	<i>NcG3PAT2</i>	<i>Neospora caninum</i>	NCLIV_035870
	<i>PbG3PAT1</i>	<i>Plasmodium berghei</i>	PBANKA_1428500
	<i>PbG3PAT2</i>	<i>Plasmodium berghei</i>	PBANKA_1416700
	<i>PfG3PAT1</i>	<i>Plasmodium falciparum</i>	PF3D7_1212500
	<i>PfG3PAT2</i>	<i>Plasmodium falciparum</i>	PF3D7_1318200
	<i>TgG3PAT1</i>	<i>Toxoplasma gondii</i>	TGGT1_256980
	<i>TgG3PAT2</i>	<i>Toxoplasma gondii</i>	TGGT1_270910
Kinetoplastids	<i>LmG3PAT</i>	<i>Leishmania major</i>	LmjF.03.0080
	<i>TbG3PAT</i>	<i>Trypanosoma brucei</i>	Tb927.10.3100
	<i>TcG3PAT</i>	<i>Trypanosoma cruzi</i>	TcCLB.510943.150
Bacteria	<i>BsG3PAT</i>	<i>Bacillus subtilis</i>	AIY97425
	<i>EcG3PAT</i>	<i>Escherichia coli</i>	WP_001272797
	<i>HpG3PAT</i>	<i>Helicobacter pylori</i>	ALM81555
Cyanobacteria	<i>MvG3PAT</i>	<i>Microcoleus vaginatus</i>	EGK86078
	<i>PmG3PAT</i>	<i>Prochlorococcus marinus</i>	KZR82092
	<i>SsG3PAT</i>	<i>Synechocystis sp. PCC6803</i>	ALJ67680
	<i>TeG3PAT</i>	<i>Trichodesmium erythraeum</i>	WP_011612551
Red Algae	<i>CcG3PAT</i>	<i>Chondrus crispus</i>	CDF35600
	<i>CmG3PAT</i>	<i>Cyanidioschyzon merolae</i>	BAM80174
	<i>GsG3PAT</i>	<i>Galdieria sulphuraria</i>	EME29189
Green Algae	<i>ApG3PAT1</i>	<i>Auxenochlorella protothecoides</i>	XP_011399328
	<i>ApG3PAT2</i>	<i>Auxenochlorella protothecoides</i>	KFM27021
	<i>CrG3PAT1</i>	<i>Chlamydomonas reinhardtii</i>	EDP02129
	<i>CrG3PAT2</i>	<i>Chlamydomonas reinhardtii</i>	AFC93411
Plants	<i>AtG3PAT1</i>	<i>Arabidopsis thaliana</i>	Q9SHJ5
	<i>AtG3PAT2</i>	<i>Arabidopsis thaliana</i>	Q9FZ22
	<i>AtG3PAT3</i>	<i>Arabidopsis thaliana</i>	Q9SYJ2
	<i>AtG3PAT4</i>	<i>Arabidopsis thaliana</i>	Q9LMM0
	<i>AtG3PAT5</i>	<i>Arabidopsis thaliana</i>	Q9CAY3
	<i>AtG3PAT6</i>	<i>Arabidopsis thaliana</i>	O80437
	<i>AtG3PAT7</i>	<i>Arabidopsis thaliana</i>	Q9LHS7
	<i>AtG3PAT8</i>	<i>Arabidopsis thaliana</i>	Q5XF03
	<i>AtG3PAT9</i>	<i>Arabidopsis thaliana</i>	AED 97358
	<i>AtG3PAT10</i>	<i>Arabidopsis thaliana</i>	Q43307
Fungi	<i>CgG3PAT1</i>	<i>Candida glabrata</i>	KTB24783
	<i>CgG3PAT2</i>	<i>Candida glabrata</i>	KTB25967
	<i>ScG3PAT1</i>	<i>Saccharomyces cerevisiae</i>	P32784
	<i>ScG3PAT2</i>	<i>Saccharomyces cerevisiae</i>	P36148
Animals	<i>HsG3PAT1</i>	<i>Homo sapiens</i>	NP_065969
	<i>HsG3PAT2</i>	<i>Homo sapiens</i>	NP_997211
	<i>HsG3PAT3</i>	<i>Homo sapiens</i>	NP_116106
	<i>HsG3PAT4</i>	<i>Homo sapiens</i>	NP_848934
<b>Lysophosphatidic Acid Acyltransferase (LPAAT)</b>			

APPENDICES

Apicomplexans	<i>CpLPAAT</i>	<i>Cryptosporidium parvum</i>	cgd8_1400
	<i>EfLPAAT1</i>	<i>Eimeria falciformis</i>	EfaB_MINUS_17400.g1567
	<i>EfLPAAT2</i>	<i>Eimeria falciformis</i>	EfaB_MINUS_12065.g1058
	<i>NcLPAAT1</i>	<i>Neospora caninum</i>	NCLIV_017010
	<i>NcLPAAT2</i>	<i>Neospora caninum</i>	NCLIV_006550
	<i>PbLPAAT</i>	<i>Plasmodium berghei</i>	PBANKA_1308200
	<i>PfLPAAT</i>	<i>Plasmodium falciparum</i>	PF3D7_1444300
	<i>TgLPAAT1</i>	<i>Toxoplasma gondii</i>	TGGT1_240860
	<i>TgLPAAT2</i>	<i>Toxoplasma gondii</i>	TGGT1_297640
Kinetoplastids	<i>LmLPAAT</i>	<i>Leishmania major</i>	LmjF.32.1960
	<i>TbLPAAT</i>	<i>Trypanosoma brucei</i>	Tb927.11.15150
	<i>TcCLPAAAT</i>	<i>Trypanosoma cruzi</i>	TcCLB.510723.29
Bacteria	<i>BsLPAAT</i>	<i>Bacillus subtilis</i>	O07584
	<i>EcLPAAT</i>	<i>Escherichia coli</i>	P26647
	<i>HpLPAAT</i>	<i>Helicobacter pylori</i>	O25903
Cyanobacteria	<i>MvLPAAT</i>	<i>Microcoleus vaginatus</i>	WP_006633731
	<i>SsLPAAT</i>	<i>Synechocystis sp. PCC6803</i>	WP_010873224
	<i>TeLPAAT</i>	<i>Trichodesmium erythraeum</i>	WP_011611451
Red Algae	<i>CmLPAAT1</i>	<i>Cyanidioschyzon merolae</i>	BAM82661
	<i>CmLPAAT2</i>	<i>Cyanidioschyzon merolae</i>	BAM80575
	<i>CmLPAAT3</i>	<i>Cyanidioschyzon merolae</i>	BAM78739
	<i>GsLPAAT</i>	<i>Galdieria sulphuraria</i>	EME27983
Green Algae	<i>ApLPAAT</i>	<i>Auxenochlorella protothecoides</i>	KFM23593
	<i>OtLPAAT</i>	<i>Ostreococcus tauri</i>	CEF98793
Plants	<i>AtLPAAT1</i>	<i>Arabidopsis thaliana</i>	Q8GXU8
	<i>AtLPAAT2</i>	<i>Arabidopsis thaliana</i>	Q8LG50
	<i>AtLPAAT3</i>	<i>Arabidopsis thaliana</i>	Q9SYC8
	<i>AtLPAAT4</i>	<i>Arabidopsis thaliana</i>	Q8L4Y2
	<i>AtLPAAT5</i>	<i>Arabidopsis thaliana</i>	Q9LHN4
Fungi	<i>CgLPAAT</i>	<i>Candida glabrata</i>	KTB01584
	<i>ScLPAAT</i>	<i>Saccharomyces cerevisiae</i>	P33333
Animals	<i>HsLPAAT1</i>	<i>Homo sapiens</i>	NP_006402
	<i>HsLPAAT2</i>	<i>Homo sapiens</i>	NP_006403
	<i>HsLPAAT3</i>	<i>Homo sapiens</i>	NP_064517
	<i>HsLPAAT4</i>	<i>Homo sapiens</i>	NP_064518
	<i>HsLPAAT5</i>	<i>Homo sapiens</i>	NP_060831
	<i>HsLPAAT6</i>	<i>Homo sapiens</i>	AAP21893
<b>CDP-Diacylglycerol Synthase (CDS)</b>			
Apicomplexans	<i>CpCDS</i>	<i>Cryptosporidium parvum</i>	cgd7_450
	<i>EfCDS1</i>	<i>Eimeria falciformis</i>	EfaB_PLUS_1048.g115
	<i>EfCDS2</i>	<i>Eimeria falciformis</i>	EfaB_PLUS_36188.g2485
	<i>NcCDS1</i>	<i>Neospora caninum</i>	NCLIV_023660
	<i>NcCDS2</i>	<i>Neospora caninum</i>	NCLIV_024160
	<i>PbCDS</i>	<i>Plasmodium berghei</i>	PBANKA_1032600
	<i>PfCDS</i>	<i>Plasmodium falciparum</i>	PF3D7_1409900
	<i>TgCDS1</i>	<i>Toxoplasma gondii</i>	TGGT1_281980
	<i>TgCDS2</i>	<i>Toxoplasma gondii</i>	TGGT1_263785
Kinetoplastids	<i>LmCDS1</i>	<i>Leishmania major</i>	LmjF.26.1620
	<i>LmCDS2</i>	<i>Leishmania major</i>	LmjF.32.2870
	<i>TbCDS</i>	<i>Trypanosoma brucei</i>	Tb927.7.220
	<i>TcCDS1</i>	<i>Trypanosoma cruzi</i>	TcCLB.511237.40
	<i>TcCDS2</i>	<i>Trypanosoma cruzi</i>	TcCLB.508707.140
Bacteria	<i>BsCDS</i>	<i>Bacillus subtilis</i>	KFF57052
	<i>EcCDS</i>	<i>Escherichia coli</i>	P0ABG1
	<i>HpCDS</i>	<i>Helicobacter pylori</i>	WP_029567400
Cyanobacteria	<i>MvCDS</i>	<i>Microcoleus vaginatus</i>	WP_006633099
	<i>PmCDS</i>	<i>Prochlorococcus marinus</i>	WP_011130437

## APPENDICES

	SsCDS	<i>Synechocystis sp. PCC6803</i>	P73548
	TeCDS	<i>Trichodesmium erythraeum</i>	WP_011611001
Red Algae	CcCDS1	<i>Chondrus crispus</i>	XP_005717743
	CcCDS2	<i>Chondrus crispus</i>	XP_005711550
	GsCDS1	<i>Galdieria sulphuraria</i>	EME30016
	GsCDS2	<i>Galdieria sulphuraria</i>	EME29594
Green Algae	ApCDS1	<i>Auxenochlorella protothecoides</i>	XP_011399129
	ApCDS2	<i>Auxenochlorella protothecoides</i>	XP_011400015
	CrCDS1	<i>Chlamydomonas reinhardtii</i>	EDP04329
	CrCDS2	<i>Chlamydomonas reinhardtii</i>	EDP05553
	OtCDS1	<i>Ostreococcus tauri</i>	CEF98602
	OtCDS2	<i>Ostreococcus tauri</i>	CEF97647
Plants	AtCDS1	<i>Arabidopsis thaliana</i>	O04928
	AtCDS2	<i>Arabidopsis thaliana</i>	O49639
	AtCDS3	<i>Arabidopsis thaliana</i>	Q1PE48
	AtCDS4	<i>Arabidopsis thaliana</i>	Q94A03
	AtCDS5	<i>Arabidopsis thaliana</i>	Q9M001
Fungi	CgCDS	<i>Candida glabrata</i>	KTB16840
	NcCDS	<i>Neurospora crassa</i>	EAA29473
	ScCDS	<i>Saccharomyces cerevisiae</i>	P38221
	SpCDS	<i>Schizosaccharomyces pombe</i>	Q9P381
Animals	DmCDS	<i>Drosophila melanogaster</i>	P56079
	HsCDS1	<i>Homo sapiens</i>	NP_001254
	HsCDS2	<i>Homo sapiens</i>	NP_003809
<b>Phosphatidylglycerophosphate Synthase (PGPS)</b>			
Apicomplexans	EfPGPS	<i>Eimeria falciformis</i>	EfaB_MINUS_17907.g1626
	NcPGPS	<i>Neospora caninum</i>	NCLIV_063320
	PbPGPS	<i>Plasmodium berghei</i>	PBANKA_0710600
	PfPGPS	<i>Plasmodium falciparum</i>	PF3D7_0820200
	TgPGPS	<i>Toxoplasma gondii</i>	TGGT1_246530
Kinetoplastids	LmPGPS	<i>Leishmania major</i>	LmjF.07.0200
	TbPGPS	<i>Trypanosoma brucei</i>	Tb927.8.1720
	TcPGPS	<i>Trypanosoma cruzi</i>	TcCLB.505071.100
Bacteria	EcPGPS	<i>Escherichia coli</i>	AAA98754
	HpPGPS	<i>Helicobacter pylori</i>	EIE30130
Cyanobacteria	MvPGPS	<i>Microcoleus vaginatus</i>	WP_006632349
	SsPGPS	<i>Synechocystis sp. PCC6803</i>	ALJ68109
	TePGPS	<i>Trichodesmium erythraeum</i>	ABG49777
Red Algae	CmPGPS	<i>Cyanidioschyzon merolae</i>	BAM80263
Green Algae	CrPGPS	<i>Chlamydomonas reinhardtii</i>	EDO97733
Plants	AtPGPS1	<i>Arabidopsis thaliana</i>	O80952
	AtPGPS2	<i>Arabidopsis thaliana</i>	Q9M2W3
	OsPGPS	<i>Oryza sativa</i>	XP_015630365
Fungi	CgPGPS	<i>Candida glabrata</i>	CAG58076
	ScPGPS	<i>Saccharomyces cerevisiae</i>	CAC42966
	SpPGPS	<i>Schizosaccharomyces pombe</i>	Q9HDW1
Animals	DmPGPS	<i>Drosophila melanogaster</i>	NP_650751
	DrPGPS	<i>Danio rerio</i>	XP_003199680
	HsPGPS	<i>Homo sapiens</i>	AAI08733
<b>Cardiolipin Synthase (CLS)</b>			
Apicomplexans	CpCLS	<i>Cryptosporidium parvum</i>	cgd3_2940
	EfCLS	<i>Eimeria falciformis</i>	EfaB_PLUS_56725.g2797
	NcCLS	<i>Neospora caninum</i>	NCLIV_054060
	PbCLS	<i>Plasmodium berghei</i>	PBANKA_0108000
	PfCLS	<i>Plasmodium falciparum</i>	PF3D7_0609400
	TgCLS	<i>Toxoplasma gondii</i>	TGGT1_309940
Kinetoplastids	LmCLS	<i>Leishmania major</i>	LmjF.34.2110

## APPENDICES

	<i>TbCLS</i>	<i>Trypanosoma brucei</i>	Tb927.4.2560
	<i>TcCLS</i>	<i>Trypanosoma cruzi</i>	TcCLB.506559.40
Bacteria	<i>EcCLS1</i>	<i>Escherichia coli</i>	ALZ68966
	<i>EcCLS2</i>	<i>Escherichia coli</i>	ALZ69100
	<i>EcCLS3</i>	<i>Escherichia coli</i>	WP_044697990
	<i>HpCLS</i>	<i>Helicobacter pylori</i>	AFI01980
Cyanobacteria	<i>MvCLS</i>	<i>Microcoleus vaginatus</i>	WP_006631652
	<i>SsCLS</i>	<i>Synechocystis sp. PCC6803</i>	AGF52708
	<i>TeCLS</i>	<i>Trichodesmium erythraeum</i>	WP_011611499
Red Algae	<i>CcCLS</i>	<i>Chondrus crispus</i>	XP_005712170
	<i>CmCLS</i>	<i>Cyanidioschyzon merolae</i>	BAM81296
Green Algae	<i>CrCLS</i>	<i>Chlamydomonas reinhardtii</i>	XP_001699073
	<i>OtCLS</i>	<i>Ostreococcus tauri</i>	XP_003082955
Plants	<i>AtCLS</i>	<i>Arabidopsis thaliana</i>	Q93YW7
	<i>OsCLS</i>	<i>Oryza sativa</i>	Q5N9A1
Fungi	<i>CgCLS</i>	<i>Candida glabrata</i>	KTB14470
	<i>ScCLS</i>	<i>Saccharomyces cerevisiae</i>	NP_010139
	<i>SpCLS</i>	<i>Schizosaccharomyces pombe</i>	CAB16578
Animals	<i>DmCLS</i>	<i>Drosophila melanogaster</i>	NP_651418
	<i>DrCLS</i>	<i>Danio rerio</i>	NP_998096
	<i>HsCLS</i>	<i>Homo sapiens</i>	ABD46888
<b>Phosphatidylserine Decarboxylase (PSD)</b>			
Apicomplexans	<i>CpPSD</i>	<i>Cryptosporidium parvum</i>	cgd3_2100
	<i>EfPSD1</i>	<i>Eimeria falciformis</i>	EfaB_MINUS_22450.g1948
	<i>EfPSD2</i>	<i>Eimeria falciformis</i>	EfaB_MINUS_1072.g165
	<i>NcPSD1</i>	<i>Neospora caninum</i>	NCLIV_047160
	<i>NcPSD2</i>	<i>Neospora caninum</i>	NCLIV_036570
	<i>PbPSD</i>	<i>Plasmodium berghei</i>	PBANKA_0828700
	<i>PfPSD</i>	<i>Plasmodium falciparum</i>	PF3D7_0927900
	<i>TgPSD1</i>	<i>Toxoplasma gondii</i>	TGGT1_225550
	<i>TgPSD2</i>	<i>Toxoplasma gondii</i>	TGGT1_269920
Kinetoplastids	<i>LmPSD</i>	<i>Leishmania major</i>	LmjF.35.4590
	<i>TbPSD</i>	<i>Trypanosoma brucei</i>	Tb927.9.10080
Bacteria	<i>EcPSD</i>	<i>Escherichia coli</i>	AAA83896
	<i>SePSD</i>	<i>Salmonella enterica</i>	CBY98536
	<i>YkPSD</i>	<i>Yersinia kristensenii</i>	AJJ36856
Cyanobacteria	<i>MaPSD</i>	<i>Microcystis aeruginosa</i>	WP_002731706
	<i>PmPSD</i>	<i>Prochlorococcus marinus</i>	ABM78815
	<i>XsPSD</i>	<i>Xenococcus sp. PCC 7305</i>	ELS02409
Red Algae	<i>CcPSD</i>	<i>Chondrus crispus</i>	CDF41167
	<i>CmPSD</i>	<i>Cyanidioschyzon merolae</i>	BAM80594
Green Algae	<i>ApPSD</i>	<i>Auxenochlorella protothecoides</i>	KFM28115
	<i>TsPSD</i>	<i>Tetraselmis sp. GSL018</i>	JAC78653
Plants	<i>AtPSD1</i>	<i>Arabidopsis thaliana</i>	Q84V22
	<i>AtPSD2</i>	<i>Arabidopsis thaliana</i>	F4KAK5
	<i>OsPSD1</i>	<i>Oryza sativa</i>	Q10T43
	<i>OsPSD2</i>	<i>Oryza sativa</i>	Q5JN42
Fungi	<i>CgPSD1</i>	<i>Candida glabrata</i>	KTB16854
	<i>CgPSD2</i>	<i>Candida glabrata</i>	KTB25137
	<i>ScPSD1</i>	<i>Saccharomyces cerevisiae</i>	P39006
	<i>ScPSD2</i>	<i>Saccharomyces cerevisiae</i>	P53037
Animals	<i>DmPSD</i>	<i>Drosophila melanogaster</i>	AAF56228
	<i>DrPSD</i>	<i>Danio rerio</i>	NP_001073170
	<i>HsPSD</i>	<i>Homo sapiens</i>	NP_001313340
<b>Phosphatidylserine Synthase (PSS) / Phosphatidylthreonine Synthase (PTS)</b>			
Apicomplexans	<i>CpPSS</i>	<i>Cryptosporidium parvum</i>	cgd1_1110
	<i>EfPSS</i>	<i>Eimeria falciformis</i>	EfaB_PLUS_1974.g212

## APPENDICES

	<i>EfPTS</i>	<i>Eimeria falciformis</i>	EfaB_MINUS_800.g81
	<i>NcPSS</i>	<i>Neospora caninum</i>	NCLIV_026010
	<i>NcPTS</i>	<i>Neospora caninum</i>	NCLIV_034110
	<i>PbPSS</i>	<i>Plasmodium berghei</i>	PBANKA_1142700
	<i>PfPSS</i>	<i>Plasmodium falciparum</i>	PF3D7_1366800
	<i>TgPSS</i>	<i>Toxoplasma gondii</i>	TGGT1_261480
	<i>TgPTS</i>	<i>Toxoplasma gondii</i>	TGGT1_273540
Kinetoplastids	<i>LmPSS</i>	<i>Leishmania major</i>	LmjF.14.1200
	<i>TbPSS</i>	<i>Trypanosoma brucei</i>	Tb927.7.3760
	<i>TcPSS</i>	<i>Trypanosoma cruzi</i>	TcCLB.509937.30
Bacteria	<i>BsPSS</i>	<i>Bacillus subtilis</i>	BAA07225
	<i>HpPSS</i>	<i>Helicobacter pylori</i>	AAC45587
	<i>MtPSS</i>	<i>Mycobacterium tuberculosis</i>	GAA44221
Green Algae	<i>ApPSS</i>	<i>Auxenochlorella protothecoides</i>	KFM28612
	<i>CvPSS</i>	<i>Chlorella variabilis</i>	EFN55835
Plants	<i>AtPSS</i>	<i>Arabidopsis thaliana</i>	AEE29266
	<i>OsPSS</i>	<i>Oryza sativa</i>	AAT58731
	<i>ZmPSS</i>	<i>Zea mays</i>	ACG35885
Fungi	<i>CgPSS</i>	<i>Candida glabrata</i>	KTB22122
	<i>ScPSS</i>	<i>Saccharomyces cerevisiae</i>	BAA00121
	<i>SpPSS</i>	<i>Schizosaccharomyces pombe</i>	O94584
Animals	<i>DmPSS</i>	<i>Drosophila melanogaster</i>	AAF51622
	<i>HsPSS1</i>	<i>Homo sapiens</i>	AAH04390
	<i>HsPSS2</i>	<i>Homo sapiens</i>	AAH01210
<b>Phosphatidic Acid Phosphatase (PAP)</b>			
Apicomplexans	<i>CpPAP</i>	<i>Cryptosporidium parvum</i>	cgd8_5200
	<i>EfPAP</i>	<i>Eimeria falciformis</i>	EfaB_MINUS_22960.g1971
	<i>NcPAP</i>	<i>Neospora caninum</i>	NCLIV_063870
	<i>PfPAP</i>	<i>Plasmodium falciparum</i>	PF3D7_0805600
	<i>TgPAP</i>	<i>Toxoplasma gondii</i>	TGGT1_247360
Kinetoplastids	<i>LmPAP</i>	<i>Leishmania major</i>	LmjF.18.0440
	<i>TbPAP1</i>	<i>Trypanosoma brucei</i>	Tb927.8.480
	<i>TbPAP2</i>	<i>Trypanosoma brucei</i>	Tb927.10.13930
	<i>TbPAP3</i>	<i>Trypanosoma brucei</i>	Tb927.10.13400
	<i>TcPAP1</i>	<i>Trypanosoma cruzi</i>	TcCLB.503809.110
	<i>TcPAP2</i>	<i>Trypanosoma cruzi</i>	TcCLB.511277.370
	<i>TcPAP3</i>	<i>Trypanosoma cruzi</i>	TcCLB.511277.359
Bacteria	<i>HpPAP</i>	<i>Helicobacter pylori</i>	EJB76973
	<i>SePAP</i>	<i>Salmonella enterica</i>	AFH43770
Cyanobacteria	<i>CePAP</i>	<i>Crinalium epipsammum</i>	WP_051035457
	<i>MvPAP</i>	<i>Microcoleus vaginatus</i>	EGK88082
Red Algae	<i>CmPAP1</i>	<i>Cyanidioschyzon merolae</i>	BAM82646
	<i>CmPAP2</i>	<i>Cyanidioschyzon merolae</i>	BAM82332
	<i>GsPAP1</i>	<i>Galdieria sulphuraria</i>	EME32237
	<i>GsPAP2</i>	<i>Galdieria sulphuraria</i>	EME28653
Green Algae	<i>OtPAP</i>	<i>Ostreococcus tauri</i>	CAL52864
	<i>VcPAP</i>	<i>Volvox carteri</i>	EFJ45722
Plants	<i>AtPAP1</i>	<i>Arabidopsis thaliana</i>	AEE73835
	<i>AtPAP2</i>	<i>Arabidopsis thaliana</i>	BAB47575
	<i>AtPAP3</i>	<i>Arabidopsis thaliana</i>	AEE76067
	<i>AtPAP4</i>	<i>Arabidopsis thaliana</i>	BAB47574
	<i>AtPAP5</i>	<i>Arabidopsis thaliana</i>	AEE78725
	<i>AtPAP6</i>	<i>Arabidopsis thaliana</i>	AED 90554
	<i>AtPAP7</i>	<i>Arabidopsis thaliana</i>	AEE84623
Fungi	<i>CgPAP1</i>	<i>Candida glabrata</i>	KTB24721
	<i>CgPAP2</i>	<i>Candida glabrata</i>	KTB19937
	<i>ScPAP1</i>	<i>Saccharomyces cerevisiae</i>	AAS56070

APPENDICES

	ScPAP2	<i>Saccharomyces cerevisiae</i>	AAT93210
Animals	HsPAP1	<i>Homo sapiens</i>	NP_003702
	HsPAP2	<i>Homo sapiens</i>	NP_003704
	HsPAP3	<i>Homo sapiens</i>	NP_003703
	HsPAP4	<i>Homo sapiens</i>	NP_001025230
	HsPAP5	<i>Homo sapiens</i>	AAI06015
	HsPAP6	<i>Homo sapiens</i>	AAH38108
	HsPAP7	<i>Homo sapiens</i>	AAH06362
	HsPAP8	<i>Homo sapiens</i>	Q8TBJ4
	HsPAP9	<i>Homo sapiens</i>	Q96GM1
	HsPAP10	<i>Homo sapiens</i>	Q6T4P5
	HsPAP11	<i>Homo sapiens</i>	Q7Z2D5
	HsPAP12	<i>Homo sapiens</i>	Q32ZL2
<b>Diacylglycerol Kinase (DGK)</b>			
Apicomplexans	CpDGK1	<i>Cryptosporidium parvum</i>	cgd4_4340
	CpDGK2	<i>Cryptosporidium parvum</i>	cgd8_2390
	CpDGK3	<i>Cryptosporidium parvum</i>	cgd3_2630
	EfDGK1	<i>Eimeria falciformis</i>	EfaB_MINUS_7048.g670
	EfDGK2	<i>Eimeria falciformis</i>	EfaB_MINUS_36188.g2575
	EfDGK3	<i>Eimeria falciformis</i>	EfaB_MINUS_11882.g1052
	NcDGK1	<i>Neospora caninum</i>	NCLIV_022470
	NcDGK2	<i>Neospora caninum</i>	NCLIV_027060
	NcDGK3	<i>Neospora caninum</i>	NCLIV_015910
	PbDGK1	<i>Plasmodium berghei</i>	PBANKA_1334600
	PbDGK2	<i>Plasmodium berghei</i>	PBANKA_0831200
	PfDGK1	<i>Plasmodium falciparum</i>	PF3D7_1471400
	PfDGK2	<i>Plasmodium falciparum</i>	PF3D7_0930500
	TgDGK1	<i>Toxoplasma gondii</i>	TGGT1_202460
	TgDGK2	<i>Toxoplasma gondii</i>	TGGT1_259830
	TgDGK3	<i>Toxoplasma gondii</i>	TGGT1_239250
Kinetoplastids	LmDGK1	<i>Leishmania major</i>	LmjF.16.1290
	LmDGK2	<i>Leishmania major</i>	LmjF.35.5370
	TbDGK1	<i>Trypanosoma brucei</i>	Tb927.8.5140
	TcDGK1	<i>Trypanosoma cruzi</i>	TcCLB.506575.60
	TcDGK2	<i>Trypanosoma cruzi</i>	TcCLB.510329.290
Bacteria	BsDGK	<i>Bacillus subtilis</i>	AAA70044
	EcDGK	<i>Escherichia coli</i>	CUU96332
	HpDGK1	<i>Helicobacter pylori</i>	EIE31169
	HpDGK2	<i>Helicobacter pylori</i>	KRV53075
Cyanobacteria	MvDGK	<i>Microcoleus vaginatus</i>	WP_039887027
	SsDGK	<i>Synechocystis sp. PCC6803</i>	ALJ68494
	TeDGK	<i>Trichodesmium erythraeum</i>	WP_011614234
Red Algae	CmDGK	<i>Cyanidioschyzon merolae</i>	BAM80462
	GsDGK1	<i>Galdieria sulphuraria</i>	EME26535
	GsDGK2	<i>Galdieria sulphuraria</i>	EME28250
Green Algae	CrDGK	<i>Chlamydomonas reinhardtii</i>	EDP07029
	OtDGK1	<i>Ostreococcus tauri</i>	CEF97562
	OtDGK2	<i>Ostreococcus tauri</i>	CEF98712
Plants	AtDGK1	<i>Arabidopsis thaliana</i>	CAB62604
	AtDGK2	<i>Arabidopsis thaliana</i>	AAR28755
	AtDGK3	<i>Arabidopsis thaliana</i>	AEC06799
	AtDGK4	<i>Arabidopsis thaliana</i>	AED 96936
	AtDGK5	<i>Arabidopsis thaliana</i>	AEC07096
	AtDGK6	<i>Arabidopsis thaliana</i>	AEE85443
	AtDGK7	<i>Arabidopsis thaliana</i>	AEE85754
Fungi	CgDGK	<i>Candida glabrata</i>	KTB25101
	ScDGK	<i>Saccharomyces cerevisiae</i>	DAA11076

APPENDICES

	<i>SpDGK</i>	<i>Schizosaccharomyces pombe</i>	P87170
Animals	<i>HsDGK1</i>	<i>Homo sapiens</i>	P23743
	<i>HsDGK2</i>	<i>Homo sapiens</i>	Q9Y6T7
	<i>HsDGK3</i>	<i>Homo sapiens</i>	P49619
	<i>HsDGK4</i>	<i>Homo sapiens</i>	Q16760
	<i>HsDGK5</i>	<i>Homo sapiens</i>	P52429
	<i>HsDGK6</i>	<i>Homo sapiens</i>	Q13574
	<i>HsDGK7</i>	<i>Homo sapiens</i>	Q86XP1
	<i>HsDGK8</i>	<i>Homo sapiens</i>	P52824
	<i>HsDGK9</i>	<i>Homo sapiens</i>	O75912
	<i>HsDGK10</i>	<i>Homo sapiens</i>	Q5KSL6
<b>Choline/Ethanolamine Phosphotransferase (CEPT)</b>			
Apicomplexans	<i>CpCEPT1</i>	<i>Cryptosporidium parvum</i>	cgd4_2790
	<i>CpCEPT2</i>	<i>Cryptosporidium parvum</i>	cgd4_390
	<i>EfCEPT1</i>	<i>Eimeria falciformis</i>	EfaB_MINUS_56725.g2919
	<i>EfCEPT2</i>	<i>Eimeria falciformis</i>	EfaB_MINUS_15745.g1427
	<i>EfCEPT3</i>	<i>Eimeria falciformis</i>	EfaB_MINUS_25458.g2174
	<i>NcCEPT1</i>	<i>Neospora caninum</i>	NCLIV_029590
	<i>NcCEPT2</i>	<i>Neospora caninum</i>	NCLIV_025720
	<i>NcCEPT3</i>	<i>Neospora caninum</i>	NCLIV_006960
	<i>PbCEPT</i>	<i>Plasmodium berghei</i>	PBANKA_1127000
	<i>PfCEPT</i>	<i>Plasmodium falciparum</i>	PF3D7_0628300
	<i>TgCEPT1</i>	<i>Toxoplasma gondii</i>	TGGT1_257510
	<i>TgCEPT2</i>	<i>Toxoplasma gondii</i>	TGGT1_261760
	<i>TgCEPT3</i>	<i>Toxoplasma gondii</i>	TGGT1_276190
Kinetoplastids	<i>LmCEPT</i>	<i>Leishmania major</i>	LmjF.36.5900
	<i>TbCEPT</i>	<i>Trypanosoma brucei</i>	Tb927.10.8900
	<i>TcCEPT</i>	<i>Trypanosoma cruzi</i>	TcCLB.509791.150
Red Algae	<i>GsCEPT1</i>	<i>Galdieria sulphuraria</i>	EME27119
	<i>GsCEPT2</i>	<i>Galdieria sulphuraria</i>	EME32110
Green Algae	<i>OtCEPT1</i>	<i>Ostreococcus tauri</i>	XP_003080347
	<i>OtCEPT2</i>	<i>Ostreococcus tauri</i>	CEF97354
Plants	<i>AtCEPT1</i>	<i>Arabidopsis thaliana</i>	O82567
	<i>AtCEPT2</i>	<i>Arabidopsis thaliana</i>	O82568
	<i>ZmCEPT1</i>	<i>Zea mays</i>	XP_008649197
	<i>ZmCEPT2</i>	<i>Zea mays</i>	AFW69854
Fungi	<i>CgCEPT1</i>	<i>Candida glabrata</i>	KTB18544
	<i>CgCEPT2</i>	<i>Candida glabrata</i>	KTB25778
	<i>ScCEPT1</i>	<i>Saccharomyces cerevisiae</i>	P22140
	<i>ScCEPT2</i>	<i>Saccharomyces cerevisiae</i>	AAA63571
Animals	<i>DrCEPT</i>	<i>Danio rerio</i>	NP_001103187
	<i>HsCEPT1</i>	<i>Homo sapiens</i>	NP_006081
	<i>HsCEPT2</i>	<i>Homo sapiens</i>	AAH50429
<b>Phosphatidylinositol Synthase (PIS)</b>			
Apicomplexans	<i>EfPIS</i>	<i>Eimeria falciformis</i>	EfaB_PLUS_6035.g572
	<i>NcPIS</i>	<i>Neospora caninum</i>	NCLIV_002660
	<i>PbPIS</i>	<i>Plasmodium berghei</i>	PBANKA_1414100
	<i>PfPIS</i>	<i>Plasmodium falciparum</i>	PF3D7_1315600
	<i>TgPIS</i>	<i>Toxoplasma gondii</i>	TGGT1_207710
Kinetoplastids	<i>LmPIS</i>	<i>Leishmania major</i>	LmjF.26.2480
	<i>TbPIS</i>	<i>Trypanosoma brucei</i>	Tb927.9.1610
	<i>TcPIS</i>	<i>Trypanosoma cruzi</i>	TcCLB.503925.80
Red Algae	<i>CcPIS</i>	<i>Chondrus crispus</i>	CDF39583
	<i>CmPIS</i>	<i>Cyanidioschyzon merolae</i>	BAM80990
	<i>GsPIS</i>	<i>Galdieria sulphuraria</i>	XP_005703945
Green Algae	<i>ApPIS</i>	<i>Auxenochlorella protothecoides</i>	KFM23061
	<i>CrPIS</i>	<i>Chlamydomonas reinhardtii</i>	EDP06395

## APPENDICES

---


	<i>OtPIS</i>	<i>Ostreococcus tauri</i>	CAL56685
Plants	<i>AtPIS</i>	<i>Arabidopsis thaliana</i>	Q8LBA6
	<i>OsPIS</i>	<i>Oryza sativa</i>	CAC37011
	<i>ZmPIS</i>	<i>Zea mays</i>	NP_001105559
Fungi	<i>CgPIS</i>	<i>Candida glabrata</i>	KTB24417
	<i>ScPIS</i>	<i>Saccharomyces cerevisiae</i>	AAA34876
	<i>SpPIS</i>	<i>Schizosaccharomyces pombe</i>	Q10153
Animals	<i>DmPIS</i>	<i>Drosophila melanogaster</i>	AAF48491
	<i>DrPIS</i>	<i>Danio rerio</i>	AAT68039
	<i>HsPIS</i>	<i>Homo sapiens</i>	AAB94860

## Appendix 6. *TgCDS2* harbors bipartite signal and transit peptides.

The positions of nucleotides and amino acids of *TgCDS2* N-terminal extension are indicated along both margins. All methionine residues are marked in bold. The bipartite peptide sequence starts from the second methionine located in the extended N-terminus. The putative signal and transit peptides are depicted in green and yellow colors, respectively.

**Appendix 7. Phospholipid profiles of the  $\Delta tgcds1_r$  and  $\Delta tgcds1_r/\Delta tgcds2$  mutants.**

Lipids isolated from tachyzoites were analyzed by HPLC/MS. Major phospholipids identified were PtdCho, PtdEtn, PtdThr, PtdIns, PtdSer and PtdGro. (A) Cumulative sum of all lipids in the indicated strains cultured with or without ATc. Other panels illustrate PtdCho (B), PtdEtn (C) and PtdThr (D). PtdIns, PtdSer and PtdGro are depicted in Figure 14. Values are means with SEM from six independent assays (\*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001).



## Appendix 8. Vector sequences.

### (A) pGRA1-UPKO-EfPTS

Function: Ectopic expression of selected *E. falciformis* enzymes in *T. gondii* tachyzoites.

*EfPTS-HA* could be replaced with other *E. falciformis* enzymes of interest.



**NsiI** and **PacI** sites for inserting ORF-HA of selected enzymes

```

CCACCGGTACCTGGTTAGCGCAAAGGACGCGAAATGGTGGGAGCAGCAAGACAGCTAAAAGCCACAGCATTAAATATTCTCCATTA
AGACTCATATGCCGAAGAAAGATGCAGTGTAGAAACCTGTGAAGTCCGTATTCTCATCTGTAAACAGAGAGACTAGCTTAGTTAGTTCTCC
CACGTCTGGATCACCGCGTTACTTGTCTTAACCGTCTGTCACTACTGGCTCTCCCTGAGCTGACGTGACTCATGCTGGAGCTTC
GTATGGTAGGGTACCGTACACTCGAAATGTTCTGTGAACCGGGCTGTGTTGAGCTCCAGGTGCTTGTCCCTGGGTGTTCTCCCTCC
ACGTGTTTTCTGCTTCTGCCTGCCCAGTGTGAAAGCTGCTGTGAGCTGCTCTCCAGGTGCTTGTCCACTCTCCAGTCC
GCTTCGACACACCCCCAACGACTTGTGAAGGCTCTGGCCCTGTTGAGCTGACAGGCTCTCCAGGTGCTTGTGACTCTCCAGTCC
AGCTGGTGTATAGAACCGTATCTCTAGAGTGGCCCTCTATGCTGATGAGAAACCTGAGCTTGTGAGCTTGTGAGCTTGTGAGCT
TTCTTGCTTGGGGTAGCCCTTGTGACCTTGTGCTCTATGCTGAGCTTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCT
GATACTCTCCCAGACGGCACAGAAAGCTGAGCCCTGAGCTTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCT
TCATAGCGTGGTACTGTCACGAATACCAATCGCTGGGGTGCAGGGAGGAATATGCTGTTGACCATACGATCAGCTGAACGAAAC
ATGGTATGAGACGCGTAAGCGGGCACAGGTTGTTGCCCTCGTCATTGCGGACCAATTCCCGTCCACCGCTGCGTCTGACTCGACGGTT
GTGACCACCCCACCTCGCATGGGAGCTGGTAAAGCCACAACATTACTTGAATTTATCGTTGAAACTGCGAGCTCTGCGAGCTTGTGAGCT
GGTGTATCTCTCCACCTTATCAAGTTAGCTGAGCTGAGCTTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCT
GTTGGTAGGGTGGCTGGCAATCAAGGCTATTGCTTCTGCTGTTGAGAAATCAAGCAGATTCGAGGAAACCTGAGCTTGTGAGCTTGTGAGCT
CAAGCTGAGGAAACCTGGCAGCGAGGGCACAGGCTGGCAGACTTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCT
ACGGTGGCTGGATGCTTCTCGCTACAAGTAGCTGGTGGAGCTTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCT
GGATTTCTGAAGAAGTCCGGGCAATTGCTTGGCCACGGTTGAAGGCGAGACTGCTGAAGTTCTGGGTATGGCTTTGGGGCTCTT
GTGCTGTGCTCTGGAGAAGTAGAGAAAGACATGCTGTTGACACGCCCTTGAAGAGCTCAGCACACAGGCCAGCAAGAGTTGCGATTCC
GGCTTCAGGTTTGGCTTGGCAATCGCTTACTGGTACTGCTGTTGAGAAACAGACGGATTGCTTGTGCTCTCATCCCTGGATT
CTGAGGGCTTGTGATGGTGAAGATTTCAGTCTGACTTCTGATTCTGTTCTGTAACATTACATCGGTCGATGCCGATTCTTCTCGA
GTGTTAGTCCCTGGCTTCTGCTTGAAGAAAAAACGTTCTGCTTCTGGAGCTGCTGTTGAGCTTGTGCTTGAAGGAGCTTGTGAGCTTGTGAGCT
ACGCTGAAGTGTGCTGTTTACAGCAGCTAATAGGATGTTGCAAGATGTCATTTTCCAGTGGTGAAGAGCTTGTGAGCTTGTGAGCTTGTGAGCT
CTTCTCGAATTTCGCACTGTCACTTCAGTGGCTCATCCCGAGTTCCAGGAATGCTGTTGAGAGCTTGTGAGCTTGTGAGCTTGTGAGCT
AATCTCATGGGTATGATTTCGGATGTCGGTGATGCCCTGGGAGAACACCACATTGATTGGCTGGGAGCATATCCGATGAATCAGAATG
TTTATTAAAGTTATGCCCTTTCAAGCTGCAATACGAATTTCCTTCTTCGACGCCCTGGCACTTGTGTTTACGGGTGTTCTCTGTT
TTTCCCTTCTGGCGAGGCTAATGTTCTCTGCTTGAATGTCCTGGGACATTCCCGCCGTCATTGGTGAATCTGGTCAAGTCTGACTTGTGCTT
TTGGGATTAGTGGCTTCTGGCGAGGCTTCTACAGTGGGAGCTTCTACAGTGGGAGCTTCTACAGTGGGAGCTTCTACAGTGGGAGCTTCT
TGATTGTTGAGTGTGAGGTGCTACTCACGATTTACAGTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCT
ATTGGCGGAGTGTGTTTGGGGTGTGCGCTGTTACTTGCAAGGCTCCCGGAACAGGAAAGGAAGCAGTGTGAAAGGAGCTTGTGAGCTTGTGAGCT
GCAAAGGAAGAAACGGAAAAGCACAGCCACAACATTGCAAGAGAGAGCATGTGAAATGCTTGTGAGCTTCCACCTCAGGCGTCTTGTGAGCT
CGCTGCTTACCTGCCAACGAGTACTACAGGATCTACCCATACGATGTTCCAGATTACGGTAAATTAAAGACTACGACGAAAGTGATGCG
AGCCTGGAAAGGGAGCTGAGCTACAAAGCGCATAGTGTGAGAAAGCTGAGGAGCTTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCT
GCATCGTGTGCTGAGCTGCTGAGCTTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCT
GACGATGGTCAAAACTGGTATGTCAGCTGCAATGCCGAGCTGAGCTTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCT
GCTGGGATGCAAGTTTGTGCTGAGCTTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCT
AAACACCGTAGTTCCAGTCGACGGATCCACCGCGGTGGCGGCCAGTACCAAGTCTGCTGAGCTTGTGAGCTTGTGAGCTTGTGAGCT
TCGCTCCACGAGGGTGGAAACCTCTAGCACACAACCTCTCTGAGGGTGGAAAAGCTGCTGAGCTTGTGAGCTTGTGAGCTTGTGAGCT
GGGACCAACGGCAGAGACTGTTTACTCGGATGTCGCTACAGTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCT
GTCATCGGCTTACCCACAGTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCT
GAAACGCGAGCTTGTGCTTACAACGAATTTCATCCACCGGAGACGAGGGCTGATTCCCGTGGCAATCTGCAAGGCTTGTGAGCTTGTGAGCT
CGTAGGCAATATCGAAATAGATCCAGTGTGCTATGCAAGCTGCTGAGCTTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCT
GGTGGGTGTGCTGAAGACGTATTCCAAGATAACAAACCTCCCTGCAAGCTGAGCTTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCT
AGGTGCTTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCT
GTTCTGGGAGGACTCTCAAGGAAGCCCTGCTGAGGTTCTGAGGTTTAATGCGCTTGGCTGAGCTTGTGAGCTTGTGAGCTTGTGAGCT
GCAAGGGCCCCCTACCCAGCTTGTGAGGTTTAATGCGCTTGGCTGAGCTTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCT
TTATCCGCTCACAATTCCACACAAACATAGCGAGCCGAAGCTAATGCTGAGGCTGGGAGCTTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCT
TTGGGCTTACGCTGCCGCTTCCAGCTGGAGAACCTGTGCTGAGCTTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCT
GGCCTCTCCGCTTCTCGCTACTGACTCGCTGCCGCTGGCTGAGCTTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCT
ATCCACAGAATAGGGATAACCGAGAAAGACATGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCT
TTCCATAGGCTCCGCCCCCTGACGACCATCACAAAATCGACGCTCAAGTCTGAGGCTTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCT
TTCCCCCTGGAGCTTCTCTGCTGCTCTGCTTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCT
TTCTGAGCTTACGCTGCCGCTTCCAGCTGGAGAACCTGTGCTGAGCTTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCT
TGCCCTTACTCCGGTAACATCGCTTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCT
CGAGGTATGTAAGGCGCTGCTACAGTGGTCTGAGCTTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCT
GCCAGTTACCTCGGAAAAGAGTTGGTAGCTCTGAGCTTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCT
ACGGCAGAAAAAAAGGATCTCAAGAAGATCTTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCT
TCATGAGATTACAAAAGGATCTTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCT
TGACAGTACCGGAGGGCTTACCATCTGGCCCCAGTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCT
ACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCT
AGCCAGCCGGAGGGCCGAGCGCAGAAGTGGCTCTGCAACTTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCT
TTCGCGCTTACGCTGCCGCTTCCAGCTGGAGAACCTGTGCTGAGCTTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCT
TCCAACGATCAAGGCGAGTACATGATCCCCATGTTGTGAGGGAGAGCTTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCT
CCGAGTGTGTTACACTCATGTTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCT
AACCAAGTCTGAGAATAGTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCTTGTGAGCT

```

AAAGTGCTCATCATTGGAAAACGTTCTCGGGGCGAAAAACTCTAAGGATCTTACCGCTGTTGAGATCCAGTCGATGTAACCCACTCGTCGAC  
CCAACGTCTTCAGCATTTTACTTCAACCAGCGTTCTGGGTGAGCAAAAACAGGAAGGCAAATGCCAAAAAAGGAAATAAGGGCGAC  
ACGGAAATGTTGAATACCTCATCTTCTTCAATTATTATGAAAGCATTTACAGGGTTATGTCATGAGCGGATACATATTGAAATGT  
ATTAGAAAAAAACAAATAGGGGTTCCGGCAGCATTTCCCCAAAAGTGCACCTGAGCGCCCTGTAGCGGCCATTAGCGGCCGGTGTG  
TGGTGTACCGCAGCGCTGACCGCTACATTGCGACGCCCTAGCGCCCTTCTCGCTTCTCCCTTCGCACTGGCG  
CTTTCCCGCTAACGCTAAATCGGGGCTCCCTTAGGGTCCGATTAGTGTCTTACGGCACCTGACCCAAAAGTGTATTAGGGTGTAT  
GGTTCACGTAGTGGGCCATGCCCTGATAGACGGTTTTCGCCCTTGACGTTGGAGTCCACGTTCTTAATAGTGGACTCTGTTCAAACGT  
GAAACAACACTCAACCCATTCTCGGTATTCTTGTATTAAAGGATTGCGCATTGCTTAAAGGCTGATTAA  
AAAATTTAACGCAATTAAACAAAATTAAACGCTTACATTCCATTGCCATTAGCGTGCACATTGTTGGGAAGGGCATTGTCGCGG  
CCTCTCGCTATTACGCCAGCTGGCAAGGGGGATGTCGCAAGGGGATTAAGTGGTCAAGCGAGGTTTCCCACTGACGACGTTGAA  
AACGACGGCCAGTGAGCGCGTAATACGACTCATATAGGGCAATTGGAGCTTCAAGGCTGTAGTACTGGTGTCTGCTATGCCACACGCCGA  
TTCAAGGGCTATGCGACAAGCGGGATTGCTGATGAGCGTCGTTCCCACTGAAGCGCGGAGTGGTGGCGA

**(B) pG152-TgCDS1**

Function: 3' HA tagging of *TgCDS1*.

*TgCDS1-3COS* HA *TgSAG1-3UTR* p*TgDHFR-TS* *TgHXGPRT-ORF* *TgDHFR-TS-3UTR*

Nael site for linearizing the vector before transfection

## **APPENDICES**

CAGTTGATGTAACCCACTCGCACCCAACTGATCTTCAGCATTTTACTTCAACAGGTTCTGGGTGAGCAAAAACAGGAAGGCCAAATGCCCAAAAAGGAAATAAGGGCAGACGGAAATGTTGAATACTCATACTCTTCTTTCAATATTATGAAAGCATTATCAGGGTTATTGTCATGAGCGGATACATATTGATTTAGAAAAAATAAACAAATAGGGGCTCCCGCAGCATTTCGGCAAAGTGCACCTGACGTCAAGAACCATTTATCATGACATTAACCTATAAAAATAGGCGTACAGGGCCCTTCGTCGCGCTTCTGGTATGACGGTAAACCTCTGACATCGAGCTCCGGAGACGGTCAACGTTGTCGAAGGGATGCCGGGAGCAGACAAGCCCGTCAGGGCGCTCACGGGGTGTGGGGTGTGGGGCTGGCTTAACATGCGGCATCAGGAGCAGATTGACTGAGAGTGCACCATATGCGGTGAAATACCGCAGACATGCGTAAGGAGAAAATACCGCAGTCAGGCCATTGCCATTCAAGGCTGCGCAACTGTGGGAAGGGCAGTCGGTGCAGGCCCTTCGCTATTACGCCAGCTGGCGAAAGGGGATGTGTCGAAGGCGATTAAGTGGTAAACGCCAGGGTTCCAGTCAGACGTTGTAACAGCAGGCCAGTGAATTGGAGATCGGTACTTCGCGAATGCGTCGAGATCGTACCCGTACTTCAATCCAATTAA

(C) pG152-TgCDS2

## Function: 3' HA tagging of *TgCDS2*.

*TgCDS2-3COS* HA *TgSAG1-3UTR* p*TgDHFR-TS* *TgHXGPRT-ORF* *TgDHFR-TS-3UTR*

**Xhol** site for linearizing the vector before transfection

## **APPENDICES**

ACTCGTGCACCCAACTGATCTTCAGCATTTACTTCAACAGCCTTCTGGGTGAGAAAAACAGGAAGGCAAATGCCGAAAAAAGGGAA  
TAAGGGCGACACGGAAATGTTGAATACTCATACTCTTCCTTTCAATTATTGAAGCATTATCAGGGTTATTGTCATGAGCGGATAACAT  
ATTTGAATGTTATTAGAAAATAAACAAATAGGGCTTCCGCGCACATTCCCGAAAAGTGCCACCTGACGCTCAAGAAACCATTATTATCATG  
ACATTAACATCTAAAAATAAGGCGTATCAGGAGGCCCTTCTCGTCGCGCTTCCGTTGATGACGGTAAACCTCTGACACATGCGACTCCCG  
AGACGGTCACAGCTTGTGTAAGGGATGCCGGAGACAGACAAGGGCTCAGGGCGCTCAGGGGTGTGGCGGGTCTGGCTTAA  
CTATCGGCATCAGAGCAGATTGTAAGACTGACCATATGCCGTGTAAGAACAGTCAGATGCTAAGGGAAAATAACGCCATCAGGC  
CATTGCCCCATTCAAGGCTGCCAACTGTTGGAAAGGGCGATGGTGCAGGGCTTCTCGTATTACGCCAGTGGCGAAAGGGATGTGCTGCAA  
GGCGATTAAGTGGGTAACGCCAGGGTTTCCCAGTCAGCACGTTGTAACAGCAGGCCAGTGAATTGGAGATCGGTACTCGCGAATCGCTG  
AGATCGTACCCCTGTACTCCAATCCAATTAA

(D) *pG152-TgPGPS*

Function: 3' HA tagging of *TgPGPS*.

*TgPGPS-3COS* **HA** *TgSAG1-3UTR* **pTgDHFR-TS** *TgHXGPRT-ORF* **TgDHFR-TS-3UTR**

**SacI** site for linearizing the vector before transfection

## **APPENDICES**

CCAGTCGATGTAACCCACTCGCACCCAACTGATCTTCAGCATCTTACTTTACCCAGCCTTCTGGGTGAGCAAAACAGGAAGGCAAA  
TGCCGAAAAAAGGGATAAGGGCGACAGGAATGTTGAATACTCATACTCTTCCTTTCAATATTATTGAAGCATTATCAGGGTTATTGT  
CTCATGAGCGGATACATATTGATGTTAGAAAATAAACAAATAGGGGTTCCGCACATTTCCCGAAAAGTGCCACCTGACGCTCAAG  
AAACCATTTATCATGACATAACCTAAAAATAAGGGCTATCAGCAGGGCCCTTCGTCGCGCTTCGCTGATGACGGTAAACCTCTG  
ACACATGCACTCCGGAGACGGTCAACAGCTGTCGTAACGGGATGCCGGGAGCACAGACAAGCCCTGCAAGGGCCGTCAGGGGTCTGGGG  
TGTGCGGGCTGGCTTAACATGCGGCATCAGAGCAGATTGTCAGAGTGCACCATATGCGGTGTAACACCAGCAGTCGTAAGGAGAA  
AATACCGCATCAGGGCCATTGCCATTAGGCTGCGCAACTGTTGGGAAGGGCATCGGTGCGGCCCTTCGCTATTACCCAGTCGGA  
AGGGGGATGTCGCAAGGCATTAAAGTGGGTAACGCCAGGGTTCCCAAGTCAGCAGCTGTAACACGCGCAGTGAATTGGAGATCGGT  
ACTTCGCGAATGCGTCGAGATCGTACCCGTACTCCAATCCAATTAAAT

**(E) pTKO-CAT-TgCDS1<sup>398-1068</sup>-Myc**

Function: Ectopic expression of *TgCDS1* without N-terminal extension and with C-terminal Myc tag.

*TgGRA1-5UTR* *TgCDS1*<sup>398-1068</sup>-Myc *TgGRA2-3UTR* *TgSAG1-3UTR* *CAT-ORF* *TgTub8-5UTR*

**Nsil** and **PacI** sites for inserting *TgCDS1<sub>398-1068</sub>*-Myc  
**NotI** site for linearizing the vector before transfection

TTGGTATCTGCCTCTGTAAGCCAGTTACCTCGAAAAAGACTGGTAGCTCTGATCCGCCAACAAACCACCGCTGGTAGCGGTGTT  
 TTTGTTGCAAGCAGCAGATTACGCCAGAAAAAGGACTCAAGAAGATCCTTGATCTTCTACGGGCTGACGCTCAGTGGAAACGA  
 AACTCACGTTAAGGGATTGGCATGAGATTATCAAAAAGGATCTCACCTAGATCCTTAAATTAAAATGAAGTTAAATCAATCTAAA  
 CTATATATGAGTAAACTTGGCTGACAGTACCAATGTTAATCAGTGAGGACCTATCTCAGGATCTGCTATTCGTCATCCATAGTGC  
 CTGACTCCCCGTCGTAGATAACTACGATACGGGAGGGCTTACCATCTGGCCCAGTGCCTGAATGATACCGCAGACCCACGCTCACCG  
 CCAGATTATCAGATAAACCAAGGCCAGCGGAAGGGCAGCGCAGAAGTGGCTGCAACTTATCCGCCATCCAGTCTATTAAATTGTT  
 GCCGGAGGCTAGACTAGTGGCTGTTAATGTTGCCAACGTTGAGGCTTGCATTGCTACAGGCATGTTGTCACGCTCGCTTGG  
 TATGGCTCATCGTCCGGTCCCAAGCAGTCAAGGGAGTACAGTGGCTATGATCCCCATGTTGCAAAAAGGGCTTAGCTCTCGGTCTCC  
 ATCGTTGTCAGAGTAAGTGGCCGAGTGTATCACTATGGTTATGGCAGACTGCATAATTCTTACTGTCATGCCATCCGTAAGATGCT  
 TTCTGTGACTGGTAGACTCAACAAAGTCAATTCTGAGAATAGTGTATGCGGCCACCGAGTTGCTTGCCTGGCTCAATACGGGATAAAC  
 CGGCCACATAGCAGAACTTAAAGTGTCTCATGGAAAAGCTTCTCGGGGCAAACCTCTCAAGGATCTTACCGTGTGAGATCCAGT  
 TCGATGTAACCCACTCGCACCCAACTGATCTCAGCATCTTACTTCACCAAGCCTTCTGGTGAGCAGGAAACAGGAAAGGCAAATGCC  
 CAAAAAAGGAAATAAGGGCAGACCGAAATGTTGAATACTCATACTCTCCCTTTCATATTGAAGCATTATCAGGGTTATTGCTCAT  
 GAGCGGATACATATTGAATGTTAGAAAATAACAAATAAGGGGTTCCCGCACATTTCCCGAAAAGTGCACCTGACGCCCTGCTAGC  
 GGCCTTAAAGCGCCGGGGTGGTGGTACCGCAGCGTACATGGCCAGGCCCTAGCGCCCGCTCCTTCGCTTCTCCCT  
 CCTTCTGCCAACGTTGCCGCTTCCCGTCAAGCTTAAATGGGGCTCCCTTGGGTTCTGATTAGTGTCTTACGGCACCTCGACCC  
 CAAAAAAGTGAATTAGGGTGTGGTACGTAGTGGGATCAGCCTGATAGACGGTTTTCGCCCCCTTGACGTTGGAGTCCACGTTTTAAT  
 AGTGGACTCTTGTCCAACACTGGAACAACACTCAACCCATCTCGGTCTATTCTTGTATTATAAGGGATTGCGCTTACGTTGCTATTGGT  
 TAAAAAATGAGCTGATTTAACAAAATTAACGCAATTAAACAAATAACGCTTACAATTCCATTGCCATTAGGCTGCGCAACTGT  
 TGGGAAGGGCGATCGGTGCGGGCTTCTCGCTATTACGCCAGTGGCGAAAGGGGATGTGCTGCAAGGCGATTAGTGGTAACGCCAGGG  
 TTTCCAGTCAGCACGTTGAAAAGACGCCAGTGAGGCCGCTAACGACTACTATAGGCGAATTGGAGCTCGAAGGCTGTAGTACTG  
 GTGCTGTATGCCACGCCGATTACGCCGATGCGACAAGCGGGATTGCTGAGCGTCTCCCACTGAAGCGCAGTGGGGAGTGGTGGCG  
 A

### (F) pTKO-DHFR-TS-TgCDS2<sup>527-1044</sup>-Myc

Function: Ectopic expression of TgCDS2 without N-terminal extension and with C-terminal Myc tag.

- **TgGRA1-5UTR** | **TgCDS2<sup>527-1044</sup>-Myc** | **TgGRA2-3UTR** | **TgDHFR-TS-3UTR** | **TgDHFR-TS-ORF** | **TgDHFR-TS-5UTR** -

**NsiI/SbfI** and **PacI** sites for inserting TgCDS2<sup>527-1044</sup>-Myc

**NotI** site for linearizing the vector before transfection

CCACCGGTACCTGGCTCTAGCTGCCGAGGCACCCCTCATAGCGTGTACTCGTCACGAATACCAATCGCTGGGTCGGCGGGAGGA  
 ATATGCTTTGTTGACCATACGATCACGCTGAACGAAAATGGTATGAGACGCCGTAAGCGGGCACAGGGTTGTTGCCCTCGTCTATTGCG  
 GACCAATTCCGGTCCACCGCTGCTCGACTCGACGGTTGTCGACGCCACCCACTCGCATTGGCAGTCGGTAAAGCCACAAACATTCTTGC  
 AATTTCGACACGGTCTGTTAGACGCACTGGTTGCTGTTGGTGGCCAAATCAAGGCTATTCTGCTTACGTTGCTATTGAGTGTACAGT  
 TGGTGGCTACGCTTCTGAGTGGGTTGCTTCCAGTCTCCTGTCGATAAAAGAATTCTCAGACCTCTGCATGCCGCGGATCTTCACCT  
 TCTCTCAAAGTATGCCCTCACCTCCGCCAGTCTTGTCTGCCCTCCGCCAACACCCAACCTCATCTCTGGCTCTCCGGT  
 CTGTCGCTTCTGCTAGTCGCTCTCTCACCCTCGACGAGACCCATCGCAGACATTTCAGCATCCATCTTCCCTGATTGCTG  
 TGTCGCTTCTCCCTCTGGGTTACGCTGGTTTCTCCGATCTTGCCTGAGATGCTTCTCTCCCTGCCCTCGGCCGCTGCCCTCTCT  
 TCCGCCCTCCGGCTCTCTCTCCGCTGGCTGCCCTGGGCTGCTGCCCTGGGCTGCTGCCCTGGGCTGCTGCCCTGGGCTATG  
 CGCCCTCTCTCTGCTGGCTCTCCGCTTCTCAGACACCTTCGCGTACTTGTGGGATCGCTCTGGGATCTTCCGAAAT  
 CTCTCTCTCTGCTTCTCCCTCTCTGCTGCCCTCCCTGCCGCTGCTCTCCGCCAGGAGGCTCTTCCCTGCCGCTGCTGCCCTGGG  
 GCGGCTGCAAGGCTGCCGGCTCGTTGCTGCTGTTGATTGAGAGGTGCGCTGCCCTCGAGCGCTTGGAGAGACGAAAAGATGTA  
 CGCGCTGCCCTGCCGGCAGGCATGGCTCCGCTTGGAGATGCATGCCAAGAAAGGCGTCGACCTCGTCGCAAAAGAGCCTTGC  
 CGCAACAGCGACGCCAGCCCCCAAGACGCCGAGCTTCCGGAGACAGCTACCTCTCTCCGCCCTTCTCCGCCGCTGCCCTCC  
 CGCTTCCGCAAGCTGCGCCTGCTGCTGCCCTCGCCATCTGCTGCCCTGCTGCTGCCCTGCTGCTGCCCTGGGCT  
 CGACCTCGGCATGCCAGCGCGCAGCGCTGCTGCCCTGCCATTCCATTCAAGAACGCTGCCACAGGCTGCTTCCGCCCTGCT  
 GTCTCCCTCCGCTGCTTCGCTCTCTGCTCTCCGCTTCTGCTGCCCTGCTGCTGCCCTGGGCTGAGAGGATCGGG  
 GTCCCTCTGGGAGTTCTTCTCGCTGTTGGGGACTTGACGCCAGTTAGTGAAGGCCGACGCCGGTGTGAAGGACAGTGG  
 CTCCTGTCGCCGAGGATGGCTGCCGGACAGACTCTACCTGCTGCCGCGCTTCCGCTATGTCATGACTCTTCACTAAAG  
 GTCTGTCGCCGAGGATGGCTGCCGGACAGACTCTACCTGCTGCCGCGCTTCCGCTATGTCATGACTCTTCACTAAAG  
 TCCGAAGAAGACCTCTGATAATTAAAGTACGACGAAAGTGTGCCAGGCCGAGCTCCGCCAGAGGCCGAGCTCCGCCAGGCC  
 ACTGGGATGCCATTGCT  
 AAAAATGTTGGGGAGGGTGGCTTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT  
 CACTGCTCAATGTTAAGAACCTGTTCTCCGTTAGAGAGGACAAAAGACGATTGCAAAACTGGTATGACGCAATAGCC  
 CAATGCCGACGCT  
 CAGTTGGTTGATGTCAGCCTCCAGTGTCAATGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT  
 ACAGTGGCAGACGAATTATTGACATGATACAAGGACGAGAAAGGAACAAACACCGTAGTTCCAGTCAGCGGATCCACCGCG  
 ACTGCAGGGTACCCCTCGAGGATATGCAATTCTACACTTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT  
 AAAGCCGCTGAAGGGAGGAGCTACAAAGCCGATCAGTGGAAAGATGTTGGGGAGGGTGTCTGCTGCTGCTGCTGCTGCTGCT  
 GTTCGAATGCACTGCT  
 GCAAAACTGGTATGTCAGCAATGCCCAATGCCGAGCTCAGTGGTTGATGTCAGCCTCCAGTGTCAATGCTGCTGCTGCTGCT  
 ATGCAAGTTTGGTGTGCT  
 GTAGTCCAGTCGACGGATCCTAGTGGATCGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT  
 CGCCAGACAGCACAGCTCCAGCAGCTACAGAACGATAACGCAATTGCGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT  
 TTTGCTCTGATGACAAAAGAAAAGGCCGAGGGTGTGAGACTGTGTTGAAATGCCACATGAAGGCTACCTCCCTTCGATA  
 GGGTCTCTGGCACCCCTCGTCAGCTCTCCGACCCGGACTCTCCCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT  
 CTATTCCGCTAGCAGCCATCTCCATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT  
 TTGATGCT  
 CATGCGTGTGCT  
 GAAGGGGAGGCCGAGCCGACATGCCACGCCGCTGATGACGACGCCGCTGATGACGACGCCGCTGCTGCTGCTGCTGCT  
 CAAGGCCGAGGCCGAGCCGACATGCCACGCCGCTGATGACGACGCCGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT  
 CATTCTCAGCTGGTCGACGCCGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT  
 GCCGATGTCCTGCCACCTCTCGGTGGGGAGATTGCGCAATCGAGGAACCTCGCGTCACTTGTGCTGCTGCTGCTGCTGCT

AGATGGTTGCGTTCGTGCGCAATGAACACCAGCAACTCTCGAGGACCCCTTCCAGAACACACGCCTTGTGGTGAGAAGTGGAAAGG CCTGATCCAGCAGTAGGCCATAGTCAGCGAATTGGAGATGACACCAACGCCGTCGTCATCCATTGCTCCATTGTTAATAATGTC GCAATGAGATCAAGGTACTGGAATTCTCATGGCCTAAAGTGAACATGCGAACGCCGAACTCAGTCTCTTGTGCGTTTTCGG TCTCTCGTCATCCACGCCAACCCGGCAATGGCGGGCAAGAAGGAGCCTGCAACCCGCTGCAAGGGAGTTGCTCCCTCGGACG TCAAGGAGCTCATTGCGTCCGTCAGTGGCTCGTCAGTCTCCTCTCTCAGAACACCAGAACAGTGTAGGGTACCCGTT GTCTGAGAAGGTCTGGAATGAAGATGGTCGATACGTCGTCATTGTCCTCTCTCCAGGGACAAAAGGGAACGAACACAGAC TCGCAGGAGCTGCGAGCAGTGTGATTGTTGAAAGAATGTCATCTCGGGGAACCCAGGGAAAGAAAAGCTGCAACGGAAACTCGC GGGCATCACCGCTGATGACAGGTGAGGCAACGCCAGACGCCGCTGTCAGTCCCCTCCACGACAAAATCTGGTCGAC AGAATCTTGTACTCTCTCCAGAAGGCTGAGGCTGGAGTGAAGCAGACTCGGACGCTGTCGCTGCGCTCAGCTGAGGCTCTCC CCCAATGTCCTCTTGGAGGAAAGGAAACGACGATGTCATCTGTCACAGGGGCTAAACCTTCGAGGATGCTTCCCAGGTT TCCGTCCTGACAACGGCGTGAATCTTGCAGTGTGGAGAGGGAAAGTCCAGAGTCGCCGCTTGTCAAATTCTGGGAAGCCACCC GTTCAGGCAGTGGCTCTCGGGCTGTTGTCAACAGAGAAAAGTGTGAAATCTGTCAGTGGGGCACGGGAGGCGTTGTG ATGCCATGCCCTCTGGGGCATCGGACGACAGCACCCGGTTCTGCACTCTCCAGACAGACAACGCCGTAAGAGCAGACGC ACTACTAAAGGCAAATTCACCCGCTCTGCACTCAGAGCAGTGTCTCCGACTGCCGCTGTTGAAATGAAAAGGTTCTACGAGACACGC TCTCGGATCGACAAGGAGATCTGCAACACTGGCTGATGTCGAAACAAAGCACGGAGAGACGCCAAGGAAAGTGTACATCGAACACGGT ATCAAACCCGAGAAAAGAAACGAACAGAGAAAAGGAAACCTCCGACATTTAAAGAATGAATGAACTTCCCAGATTTCACAAAATGGCTC ATTTTCGCGACGGCAGTCAGATAACAGGTGTAGCGGCTGCCACCAACAGAGACGGCGGCCACAGGACGCTACTGGGACTGCGAACAGCA GCAAGATCGGATCTCCGCGGGGGTTGAATGCAAGGTTCTGTCGTCGAAAAGAGAAATGAAACTTAATGTCACGTAGTCGCGCATGA AAAGCGTCTAACCAACTAAAAAGACAAAAACCGCACTCGGGCGTGAATGTCGGGGGAACGGATGGCTCTCTTTTGAAAGGCAATGCA AAAAGAACAGACGACGACGATACAACGCTAGTCCCCTGGCACAGAGAGATAGAGGCTGTCGTTGAGTACCGCTCAT GGAGGAGATCTCCGGAGCTGTCCTCTGGAAAGTGTGAAACAGGTGCGCTCCGAGAAATCGCACGGGCTAATACGTTGTAAGACAAAAGACAGCCGCTGCG GATTAGAAGTCGTGGACTACATACGGACCTCTGTCAGAGACATGCCATGCCAAGGGCTTATCTGGCTGTGACGCCAGTTCAAGA GTACCGCTACTAAGTTGAAACGATATGACCGTTCTGCGTTACATTCTGCAACTGTCAGGATTGCGTGAAGGAGACAGGAG CGCCCTCGTGTACTTCCAACGAAATTATCGAGTAACCAACTCTACCCACGGACATCCCTACGGCTTCTCGTGTAGGGCTAGGAAA TGATCCGATATGGTACACGTGACACAGGAAAGTAAAGGAAATTGACAATACAGTCAGGCTGCTCCCTGAGGACACCTGCTGTGATGATG TTGAGGAGCAGTACCGGATTACGCTGGCAAGCTGTTGCTAGCGTTACGGGCTACCCAGCTTGTGTTCTTAGTGAGGTTAA TTGCGCGTGGCTAATCATGGTACAGTGTGTTCTGTCGAAATTGCTCACAACTCCACACACATCGAGCGGAAGCATAAA GTGTAAGCCTGGGTGCTAATGAGTGAAGCTAACTCACATTATGCGTTGCGCTACTGCCGTTTCCAGTCGGAAACCTGTCGCG CTCGATTAATGAATCGCCAACCGCGGGAGAGGCGTTGCGTATTGGCGCTTCCGCTCTCGCTACTGACTCGCTCGCTCG TTCGGCTCGGGGACCCGATCGCTACTCAAAGGCGTAATACGTTATCCACAGAAATCAGGGATAACCGAGGAAAGAACATGTGACCAA AGGGCAGCAAAGGCGAGAACCGTAAAGGCGCTGTCGCTTCCCTAGGCTCCGGCCCCCTGACGAGCATCACAAAATGACGC TCAAGTCAGGGTGGCAACCCGAGAGACTATAAGAATACCGGGCTTCCCTGGAAAGCTCTCGTGTGCTCTGTGACCCGACCG CCCTTACCGATACTGTCGCCCTTCTCGGAAACGGTGGCGCTTCTCATAGCTCACCGTGTAGGATATCTGAGTTCGTTGAGGCTGT TCGCTCAAGCTGGCTGTCAGAACCCCCCGTTCAGCCGACCCGCTCGCCATTCCGTAATCTGAGTCAACACTCGCTTGTGAGTCAACCCGTAAGA CACGACTTATGCCACTGGCAGCCACTGGTAACAGGATTAGCAGAGCAGGATGTAGCGGCTACAGAGTTCTGAGTGGTGGCTA ACTACGGTACACTAGAAGGACAGTATTGGTATCTGCCCTCTGTCGAAGCAGTACCTTCGAAAAGAGTTGGTAGCTTGTGATCCGAA ACAAAACCCGGCTGGTAGCGGTTTTGGTTCAGCAGGATTACGCGAGAAAAGAGATCTCAAGAATGATCTTGTGATCTTCT ACAGGGCTGACGCTACTGGTAAGGATTGGTCAATGAGATTCTGAGTACAGTCTTACCATAGCTTACCGTGTAGGATCTTGTGATCTTCTT AAAAAAGTAAGTTTAAATCAATCTAAAGTATATGAGTAAACTTGGTCTGAGCTTACCATGCTTACAGTGTGAGGACACTATCTACCGAT CTGCTATTGCTCATCCATAGTGTGCTACTCCCGCTGTGAGATAACTACGATAACGGGAGGGCTTACCATCTGGCCCTAGTGTGCAATG ATACCGCGAGACCCACGCTCACCGCTCAGATTACGAAATAACCAGCCAGCCGAAGGGCGAGCGCAGAGTGGCTCTGCAACTTAT CCCCTCCATCCAGCTATTGTTGCTGGGAAAGCTAGTAAGTGTGAGTGGCTTACCTGAGTGGCTCTGCAACTGAGTGGCTCTGCAACCT CATCGTGTGTCAGCTCGTGTGTTGCTAGCTGAGTGGCTTACCTGAGTGGCTCTGCAACTGAGTGGCTCTGCAACCT CCCCTCCATCCAGCTATTGTTGCTGGGAAAGCTAGTAAGTGTGAGTGGCTTACCTGAGTGGCTCTGCAACTGAGTGGCTCTGCAACCT AAAGCGGTTAGCTCCTCGGCTCGATGTTGTCAGAAGTAAGTGTGAGTGGCTTACCTGAGTGGCTCTGCAACTGAGTGGCTCTGCAACCT TTACTGTCATGCCATCCGTAAGATGCTTCTGTCAGTGTGAGTACTCAACCAAGTCTGAGAATAGTGTATGCCGAGCGAGTGTCTC TTGCCCCGGCTCAACAGGGATAATACCGGCCACATAGCAGAACTTAAAGTGTCTCATCTGGAAAACGTTCTCGGGGCAAAACTCTCA AGGATCTACCGCTGTTGAGATCCAGTGTAAACCAACTGTCACCCAACTGATCTTCAGCATCTTACTTCACTTACCCAGCGTTCTGGGT GACCAAAACAGGAAGGCAAAATGCCAAAAAGGGAAATAGGGGACACGGAAATGTTGAATACTCATACTCTCTTTCAATATTATTG AACGATTATCACGTTTGTCTCATGAGCGGATACATATTGTAAGTGTGTTGAAAATAACAAATAGGGGCTCGGCACATTTCCCGA AAAGTGCCACCTGACGCCCTGTAGCGCGCATAAGCGCGGGGGTGTGTTGCTACGCGCAGCGTACACTTGGCAGCGAGCTCTC CGCCCGCTCTTCTCCCTCTCGCCACGCTTCCCGCTCAAGCTTAAATCGGGGCTCCCTTAGGGTCTCG ATTAGTGTGTTACGGCACCTCGACCCAAAAACTGATTAGGGTGTAGGTTACGTTAGGGCTAGTGGCCATCGCCCTGATAGACGGTTTCTGCCCT TTGACGTTGGAGTCCACGTTCTTAATAGTGGACTCTGTCAGGAAACACACTCAACCTATCTGGCTTACCTTGTGATTTGATTATAAG GGATTTGCGGATTTGGCTATTGGTAAAAAGAGCTGATTTAACAAAATTAAACGCAATTGTTAACAAATATTAAACGCTTACAATTTC CATTGCCATTAGGCTGCCACTGGTGGAAAGGGGAGCGTGGCTGGGGCTCTCGCTATTACGCCAGCTGCGCAAGGGGATGTGTCGCAA GGCAGTAAAGTGGTAAACGCCAGGGTTTCCCTGAGTACGACGTTGAAACGCGCCAGTGGCGCAGTAAACGACTCACTAGGGCA ATTGGAGCTCGAAGGCTGAGTAGTACTGTCGCTGATGCGACACGGGATTACGGCTATGCCAAGCGGGATTGCTGAGCGTCTGCC CCACTGAAGCGCGGGAGTGGTGGCGA

### (G) pTETO7SAG1-UPKO-Myc-TgCDS1-HA (partial)

Function: Ectopic expression of *TgCDS1* with N-terminal Myc tag and C-terminal HA tag.

**TgUPRT-5UTR** **pTETO7SAG1** **Myc-TgCDS1-HA** **TgNTP3-3UTR** **TgUPRT-3UTR**

**Ncol/BspH1** and **PacI** sites for inserting Myc-TgCDS1-HA

**NotI** site for linearizing the vector before transfection

TGACGAGGGGGAAAGGCCCTGGAATCTAACGTCGTTGCGGCCACCTGACTTGAGGTGGATAGGATGCTGTCAAGGGGGCGAGCCTATGAA AACGCCAGCACCGCTTTACGGTCTGCTTGTGCTCACATGTTCTCTGCGTATCCCTGATCTGTTGAGTACGCTATGCTGAG TGAGCTGATACGCTGCCGAGACGACGCCAGCGAGCGACTGAGTGGCTACAGGCGAGAAGCGAACGCCAAATCGAACACGCCCTCTCCCG CGCGTGGCCGATTCAATGCACTGGCACGAGCGAGCGACTGGAAAGCGGGAGCTGAGGCGAACGCCAAATTAGTGAGTTAGCTCAC TCATTAGGCACCCAGGCTTACACTTATGCTCCGCTGATGTTGAGGAAATTGAGGCTAACATTCACACAGGAAACAGCT GACCATGATTACGCCAAGCTGCAAAATTACCCCTACTAAAGGGAAACAAAAGCTGTTACCGGGCCCTTGTAAAGCGGCAAAGGACGCGAAAATGG

## **APPENDICES**

(H) pTETO7SAG1-UPKO-Myc-TgCDS2-HA (partial)

Function: Ectopic expression of *TgCDS2* with N-terminal Myc tag and C-terminal HA tag.



**Ncol/BspHI** and **PacI** sites for inserting Myc-*TgCDS2-HA*  
**NotI** site for linearizing the vector before transfection

(I) *pTETO7SAG1-UPKO-TgPIS-HA* (partial)Function: Ectopic expression of *TgPIS* with C-terminal HA tag.

<i>TgUPRT-5UTR</i>	<i>pTETO7SAG1</i>	<i>TgPIS-HA</i>	<i>TgNTP3-3UTR</i>	<i>TgUPRT-3UTR</i>
--------------------	-------------------	-----------------	--------------------	--------------------

*Ncol* and *PacI* sites for inserting *TgPIS-HA**NotI* site for linearizing the vector before transfection

TGACGAGGGGGAAACGCCCTGGAATCTAACGTGTTGCGGTGCCACCTGACTTGAGGTGGATAGGATGCTGTCAGGGGGCGGAGCCTATGAA  
 AACGCCAGCACCGCTTTACGGTCTGCTTGTGCTCACATGTTCTCTGCGTATCCCTGATCTGTTGAGTACGTATACGCTTGAG  
 TGAGCTGATACGCTGCCGCAGCGAACGACCAGCGAGCGACTGAGCGAGAAGCGAAGAGCGCCAAATACGCAAACCGCCCTCTCCCCG  
 CGCGTGGCCGATTCAATCAGCTGGCACAGGGCTTCCCAGCTGGAAAGCGGGCAGTGAGCGCAACGCAATTAAATGAGTTAGCTCAC  
 TCATTAGGCACCCAGCTTACACTTTAGCTCCGGCTCGTATGTTGAGTACAGGGATAACAATTTCACACAGGAAACAGCTAT  
 GACCATGATTACGCAAGCTGAAATTACCCCTACTAAAGGGAAACAAAAGCTGTTACCGGGCCCTGTAAGCGCAAAGGAGCGAAAATGG  
 TGGGAGCAGCAAAGACAGCTAAACGCCACAGCATTAAATTCTCCTTAAGATTCAATGCGGAAGAAAGATGCACTGTGAGAAACCTGTGA  
 AGTCCTGATTCTCATCTGTAACAGAGAGACTAGCTTGTGTTTCCGACACATCTGGATCACCCGCGTTACTTTGCTCTAACCCTGTG  
 TCACACTGGCTCTCCCTGAGCTGAGCTGAGCTCATGCTGGATGAGCTTACCGGGATACCGGAAATGTTCTGAA  
 CGGGCTGGTGTGGCTTCTGCCCCGGTGTGCTTCTCCCTTCACCTCCGCTTGACACAGCTGTTCTGCTTCTGCGCCACCCGCTGCGTAG  
 TATCGAAAGCTGTAGAGTGGCACAGGCTCTCCAGGGCTCTGCACTCTCAGTGGTGTATAGAACCGTTATCTCTAGAGTGGCAGAAAGAG  
 CCCCTCCTTATTCTGTTTCCCTGGGTACGAGCTATCTGTTGCTTCTGCTGGGGATGACCTTGTGACCTTATGCTTC  
 TCGATGAGAAACCGTCGACTCTCGTTGATGCAGGGTTCTGCGCGAAGATACTCTCCCACAGGCCACAGAAAGTGGTAGCCGCTGTTTC  
 CAACGCAGCGTACCTGATCCGACTTCACTTCTATCACTGATAGGGAGTGGTAAACTCGACTTCACTTTCTCTATCACTGAT  
 TATCACTGATAGGGAGTGGTAAACTCGACTTCACTTTCTCTATCACTGATAGGGAGTGGTAAACTCGACTTCACTTTCTCTATCACTGAT  
 AGGGAGTGGTAAACTCGACTTCACTTTCTCTATCACTGATAGGGAGTGGTAAACTCGAGCTGAGCTGATCGAAACTCATGGGATACGTT  
 AAACCTGACTTTCACTTTCTCTATCACTGATAGGGAGTGGTAAACTCGAGCTGAGCTGATCGAAACTGTTCAATGTCACCTGAGGA  
 GTAGTCAGTGTGATTCTCACTGTTCTCGCAAGGGCCAGCAGCCGAGTACAGTTTGTTGCGCAGAGCCGTTGTCAGCTTCCGTTCT  
 CGGTTGTGTCACATGTCATTGTCGTAACACACAGGGTGTATGCGGTTTGCCTGACCAACTTCATTATTCTCTGAATTCCCTTT  
 GACAAAC**CATGG**CGGGGACTCTGCAAGCCCGAGGCCAGCTCCCGCTCTGACAGAGACTGGGAGCGCTCTGGAGGCAAAGCTGT  
 CCAAGCGCGCTCAGATTCTGACCTTCTCATGACAGAAACAAATGGGCGGGAGTGGAAAGTTTCTCTACGTCGCAACATCATTGGGATACGTT  
 CGTATCGCGCTGCTGTGGCGCTGCTATTGCGTGGCGAGAAGCGTACACTCTCTCTTGTATGTCATCGCAATGCGCTGGAC  
 CAGTCGATGGCGCTGCCGACGCCGCTGGCCAAGTTCATTGTCGGCGCTGTCGACCAAGTTGTCGACCGGTTCAACATGTC  
 GTATGTTCTGAACGCCCTCGGTACCCGACTTGTGTTTGCCTTGCATCGCCTTTCTGGACATGGGGCCACTGGGTCACCTCTTC  
 GCCGGGGCGTCGTTGGCGCAAAGTCTCACAAAAGATGGATCCGAAGTGAATGCCATTCTCCGTACTACCGTTCTGCCCGGT  
 TTTGGCGATCGTGGCTTCTGAGGGTTCTCATGTCGTTCTTGGCATGCCGGTCTCAGGCTCAGTCCTCGCTGCTCG  
 ACTCTCGTCATGTCAGTCCTCCCTGATGTCATGTCCTTCAAGACGCGTACGAACTCTCCAAGGACTGTACGGAGCAGGGCT  
 GCGTGGCACATTGGTGGCCCTCTGTCACCCATAGATGTCGTTACAGT**TGA****TAA****TAA****GATCT**AATGTCGATTGAGTGGTC  
 CTATTATCGGAGAAAGTCGCTTGCACACAGTGTCTTCACTCTGTCATACAGTTCAGATGAGTCGAGGACTTGGGAGAGGAGT  
 TCTCTAGGGTGTACGCCGGGATCTGACCTTTTGTGCGCTATGTCGAGACCTGTCCTCCCGAGCAAGCGCCTACGTTGCTCTCGA  
 AGCGCTCTCGACGGAGCAAACTCATGCGGGATTATACCAATAGGGCGACTCGGAAGAAGTCGGACACCCATGTTTACGTC  
 CGATAACGTAACACCCGGTAGGCTGTTATCTCACTGTTTATTACAGGTTACCGTGTCTACAGTCCCCAGAAACCGCATGCGT  
 CTCATAGTGTGTCCTCAAGACGACCATCACAGCACGTCGCCCTAATGTCGTTGACAGCGCTCAATTCTGCTTATGCTCTG  
 TCGTTGATTGTTGTTGAAACTGAGCTGCAACAAACATTGATGGCTCGCTGATTAGCGGCCCTCAAGGATTCTGTTGAGACGCC  
 AGTACACGCCAGCTGTTTGTGATCGCAGCTCGCGCTGGTAGAACACTGAGCAGCATGTCGTTGAAACAATATAAGGCTGGAGCG  
 GAAACGGTCTCACGGACTTACGCAACGGTGTGCGCCAGATTGCGTTCTGATTTCAGCAGGGTTTGCACACTTGCAGCG  
 ACTCAGAAAAGGCTGGCAATCTATGTTAGGTCAGAGAAAAGGCTGGCAACTATGTTAGGTCACACAGCGCAGTGT  
 CATCATTAATTACATGTCCTGCCCATTTCATATTCAATCTATAGGGCAGCATGAGCAGAGACGCAAGACGCTAGGAGTCTG  
 ACCGGTGAAGGAAATATGGTAAACCTGTTTCTACCCGAGCAGCTTACCTGTTAATCTAAACTGAGCTCTGAAAGGCCACATT  
 CATCGAACAGAAAGGCTGGCCATTCAACACAGCAAGGGAGGAAACAAAGACGGGAGCAGCACGTTCTACAGGAGGGAAATCGA  
 TACTTCGAGTTGCGCGTAGGGACAATGCTGTCGCTGCACTGCAAGCGCTGGGCCACACTAGT**TCTAGACAGTACCAAGTGT**  
 TGATGAAAGTGCACCGACATTCTGTTCTGCTCCACAGGGTGGACCTCTAGCACACAATTCTCTCTGAGGGTGC  
 GTCTGCTAATTATCGAGTTATTGAACTACGGGACCAACGGGAGAGACTGTTTCACTCGGATGTCGACAGTTGACGTC  
 ACAGGAAAGGCACATTCTGTTTATTCGTTCATCCGCTATCACCAGTGTGCTCGGATCGAACGCCAGAAACCAAACACCTGT  
 TAGTAACATGTCACCGAGTGTGCAACCTGAAAGAACGACAGCTGTTGCTTACACAGGAAATTTCATTCCACCGGAGACGAGGG  
 TGCACTGTCATGCAAGGAGCTGGCTGAGGAGCTGTCGAGGAGCTGTCGAGGAGCTGTCGAGGAGCTGTC  
 CATCTGTGAAACATTGCCAGGAGCTGCAACGGTGTGCTGAGGAGCTGTCGAGGAGCTGTCGAGGAGCTGTC  
 CTGGCGATCAGATGTCGTTGACGGATAGCAGGGTGTGCTGAGGAGCTGTCGAGGAGCTGTCGAGGAGCTGTC  
 CCTGGGTAACGGCTGGTAAACACGCAACGGAGGTTCTGGGAGGTTCTCAAGGAAGCCTGTTCCGCTCAGGATTCCGAGTGG  
 GCTACACTGCATTCTCGGAAAGTGTAAAGCAG**GGGGCGC**

(J) *pTETO7SAG1-UPKO-TgCDS1-HA* (partial)Function: Ectopic expression of *TgCDS1-HA* under the control of *pTETO7SAG1* promoter.

<i>TgUPRT-5UTR</i>	<i>pTETO7SAG1</i>	<i>TgCDS1-HA</i>	<i>TgNTP3-3UTR</i>	<i>TgUPRT-3UTR</i>
--------------------	-------------------	------------------	--------------------	--------------------

*Ncol/BspHI* and *PacI* sites for inserting *TgCDS1-HA**NotI* site for linearizing the vector before transfection

TGACGAGGGGGAAACGCCCTGGAATCTAACGTGTTGCGGTGCCACCTGACTTGAGGTGGATAGGATGCTGTCAGGGGGCGGAGCCTATGAA  
 AACGCCAGCACCGCTTTACGGTCTGCTTGTGCTCACATGTTCTCTGCGTATCCCTGATCTGTTGAGTACGTATACGCTTGAG  
 TGAGCTGATACGCTGCCGCAGCGAACGACCAGCGAGCGACTGAGCGAGAAGCGAAGAGCGCCAAATACGCAAACCGCCCTCTCCCCG  
 CGCGTGGCCGATTCAAT**TGAGCTGCCACGACAGGTTCCCGACTGAGAAAGCGGGAGTGAAGCGCAACGCAATTATGAGTTAGCTCAC**

TCATTAGGCACCCCAGGCTTACACTTATGCTCCGGCTCGTATGTTGTGGAATTGTGAGCGGATAACAATTTCACACAGGAAACAGCTAT  
 GACCATGATTACGCCAAGCTCGAAATTAAACCTCACTAAAGGGAACAAAAGCTGGTACCGGGCCCTTGTAAAGCGCAAAGGAGCGAAAATGG  
 TGGGAGCAGCAAAGACAGCTAAACGCCAACGCAATTAAATTCTCATTAAAGATTATGCGGAAGAAAGATGCACTGTGAGAAACCTGTGA  
 ACTTCGTATTCTCATCTGTAAACAGAGACTAGCTTATGTTCCGACACATCCTGGATCACCGCGTTACTTGTCTTAACCGTCTG  
 TCACTACTGGCTCTCCCTGAGCTGACGTGAGCTCATGCTGGAGCTTGTATGGATAGGGTACCCCTGGTACACTCGGAAATGTTCTGAA  
 CGCGGCTGGTGTGGCTCTTGTCCTGGTCTTCTCGACACGTGTTTTCTGCTTCTGCGCCACCGCTGTGCTAG  
 TATCGAAAGCTGAGCTTGTGAGCTTGTGACAGGCCACTTGTGACTCTCCAGCTTGTGACTCTCCAGCTGGTGTATAGAACCGTTACTTGTCT  
 CCTGTTCTGGTGTGGCTTCTCCCTGGTACGAGCTTGTGTTCTGGTGTGGCTTCTGGTGTGGGATGACCTTGTGACCTTCTATGCGTT  
 TCGATGAGAAACCGTCACTCTCGTGTGACAGGGTTCTGCGCGAAGATACTCCACAGGCCACAGAAAGCTGTAGCCGTGTTTC  
 CAACCGCAGCGTACGTGATCCGTACCGAGCTGACTTCACTTTCTATCACTGATAGGGAGTGGTAAACTCGACTTCACTTTCTATCACTGAT  
 TATCACTGATAGGGAGTGGTAAACTCGACTTCACTTTCTATCACTGATAGGGAGTGGTAAACTCGACTTCACTTTCTATCACTGATAGGGAGTGGT  
 AAAGCTGACTTCACTTTCTATCACTGATAGGGAGTGGTAAACTCGACGGTGTACGCTATGATAAGCTTCAATGTCACCTGTAGGAAGAG  
 GTAGTCAGTGTGATTCTCATCTGGTGTGGCTTCTGGGAGTACAGTTGTGGTGTGGGAGTACCCCTGGTGTGGCAGCTTCCGTTCT  
 CGGGTGTGTACATGTGTCATTGTGTCATAACACACGGTGTATGTGGTGTGGCTGACCAACTTCAATTATTCTTCTGAAATTCCCTTTC  
 GACAAA**CCATGA**AACCCCCGTCGCCGATACCAGATGCGTAAAGGTGGAGATTGGTACACTCCAGTCATTTCGTCGCGTGTCCAC  
 CAACGATGTTGTCGAAGGACAAAGCAGGGAGAGGTAGAGAATGCGGAGTACGTACCCAAGGTGCTTTTCTCCACTCTCCCTCGTGTG  
 TATTCCCTCGGGCTCTTCTCCGCTCTCTCGTGTGCGCGAGTCCCGAGTGGCTTCTGGCTGCGTGTGGCCACTCAAACCGTCTCCC  
 ATGAAATGCGTACAGCGATGAGTCGTCGGTACGCCAGAAATGTAGGAAACCCCGATTTCTGGTGTGGCTGCGTGTGGCCACTCGAATC  
 GGAAGCCCGAGCTGGAAAGACACTCGGGGAGTGGGGGGCGAGATTGTCTCTGGACCTCTACGGACGGCGTGTAGCCAGCAACAGGGC  
 CATCGCACTGGGAGCTATGGGACCTCTGAAAGACAGCGAGGGAGAGAACACTCGCACGGAGTGGGTTGGATACCGATCCGAAGCTGAGT  
 CGTAGCAGCCGGAGATGGGGGGCGAGATTGTCTCTGGACCTCTACGGACGGCGTGTAGCCAGCAACAGGGCAGAAGCAGTAGAGGAGT  
 GATGACAGAGAGCAGGGAGCGGCTGAATCCCGCTCACATGTGCCAGCGCTCGAAAGGGCAGAAGCAGTAGAGGAGTGTGTTGAT  
 GAATTGGATGCGTAGCAGGCTATCCCCCCCCGTGCTGTTCTGCCAGGCTGCGTGTGCGACAGCGGCAATCAGCCGACAGATC  
 ACCAGGTGGCTCTGCGGAGCGGGCGCAGTCCGCTCAGTCGACCTCGTCTCGGTCGCTGCTGCGTGTGGCTCTCCGCTCC  
 AGTTCTGGTGAACCACTTAAGTATTGGCCCTCTGGTGGCTTATGGTGGAGTACGTCGCTGCTGCTGCTGCTGCTGCT  
 CATGGTGGTGGCGACGGCCGGCGGGCTCTCAGGGATACCGGGGAGACTCTCAGGGCCTCTGCGCAGCTGAGTACCTCGTCCATT  
 TGCCGCTGTGGTCACTCTCCGTCAGTGGAAAGCCGACAGGGCGCTCGAAAGAAGCTCGAGACAGCTCCGCTCGTGTGGAGC  
 GATTCTCGTCTCATCTCGGGTACATCTGGCTGCCGACAGTGTACAGCGCCGCTGGTCTGGTCTGCCCTGTGGCTGATGTACTGGAG  
 ATTATCGCGGTCAGCAGAGGCGAGGCGCCGCTCCCGACTCTACCTGCAAGTGGTATTGGTCTCTCATACCATCATGGTTCG  
 GCCTGCCTTCCGCTGCGGATGCCCTGGCGCCCTGCGCTCCCTGACCGACTCGCTCGGCGGGCTGGGACACTTCCGGAGATACGAGA  
 AGCCGGTCCGCTGCGAGTCCCATTTGGCCGACAGGGCGCCGCTCTGGAGCGCCCTGCTCACGTTCCACAGTCGTCACGTACACTGCG  
 GGTTCATCGGCGCTCGTGTGTTCACTATCGCGGAGGGTTCAGTGGCTCACAGGTTCTCCAGGCTGGCGTGTGCGTACGTCG  
 TCTCATCGTGGCAGGCCGCTGAGCAGATCGGAACATTACTCGGGCTCATCTGGTCTATCTCCCAACCTCGCTGATGTCACAGA  
 CGTCTAGCCTACATCTGTGGCATGCTCTTGGCGCACCGGGCTCATCCGCTTCTGCCGAAGAAGACTGTCGAAGGATTGTCGGCGCTCG  
 TTCATCACGCTCTCTGGCGGTACATGTCGAAACAGCTCAAGAGTACAAAGTCTTGTCTGCCGCCGCGCATGTCGACTTCCGACCC  
 TCCCATGTCGACGACTCTGACTGAAAGCTCCCGACCCCTCGTCCCTGCTACGACGAGGAAATCAGAGTTCCTCGGACTCAAAGG  
 CTGCGTCAGCGCCCGACTCCGGCTCGTTGCGCTGCGCTGCGTTCTATTCTCTCCGTTCACTGTCGTTCCAGCATGTCGTT  
 GAGGCTCTGCGAAGGGAGCGGGTGGAAAGGACAGGACGGTAAGGAGCGAGGGACTCCGTAGGTGGGAGAGTCCAGGAGG  
 CAGACTTGGCGTAAGTCGCAAGCCCAGGGAGGACAGCGAGGGAGGGAGACTCCGTAGGTGGGAGAGTGGAAAGCCGAGGAGACCGA  
 GGTGAGCCTGTTGCGAGCAAGCAACAGGGCGTCGCGGTGCGAGGGAGTTCCAGGAGGGAGGTCTGCAAGGCTGCTCTGGGT  
 CGCGCTCCGAGCTCCGGCTCGTTGCGCTGCGCTGCGTTCTATTCTCTCCGTTCACTGTCGTTCCAGCATGTCGTT  
 GCTCCCTGCCCTTGGCGCTCTTGGCGAGCGGGTCAACAGCGCCGCCGATCAAGGACTTGGGAAATCATCCCTGCCACCGGG  
 CGTCACCGATGCTGACTGCCAGATTCTAAGGAACTGGTACCGCATCTCAACTACAGGACTTGGGAAATCATCCCTGCCACCGGG  
 GAGGGGGAGCCCCGGCGCCCTCCCCCGCACACCTCGCGCGACACCGCTACTCTCGGAGGAGACTGGAGAAGACGACTGCGGACT  
 CTGAGGGCGGGTCACTCCACGCCCCACATTCCATCGCGAGAAAATACCGGGAGGCTTACGGCGCAGCCCCCACAGCCCCCAGAG  
 CTGTCGCAAGATGCTGGGACAGACTGGGGGAATCCGAGGCCGCGCTGGCAAGCTGTCAGAGTGGAGGCGAAGACGGCG  
 CTCAAAGTAAATAATCGAAAAGCTCGGCAACTGCTGCCAGGTTGATGTCAGAGACAAGGAAAAATGGTCTCGGGCGTGC  
 AGGACGCGGAAGAACTCGAACCGCGTAAGGCACTCGCTGCGAGACTCGAGACTTGAAGAGGAGGAGGAATGACGCACTCGTCA  
 ACAAAACCGAATTTCGGTACCCATACGATGTTCCAGATTACGCT**TGA**TTAATTAAGATC**TAT**TCGATTGTTGTCGCC  
 TATTATCGGAGAA**GAT**CT**AAT**TCGATTGTCGATTGTCGCCATTATCGGAGAA  
 GATCGTGTGTTGTCACACAGGCTCTGTCATACAGTTCAGATGAGTCGAGGACTCTGCGAGGGAGTAGTTCTCTAGTG  
 ACCCGGGGAGTCACCTTTGTTGTCGAGCTGTCAGACGACTCTCCGAGGAGCTACGCGCTTACGTTGTCCTCGAAGCGCT  
 CGGCAAAATTCTGCGGGATTATACCAATAGGGCGACTCGGAAGAAGATCGACACCCATGTTTACGTCGACTTGC  
 GATAACGTAACAA  
 CCCGGTAGGCTGTTACTCAACTGTTTATTACAGGTTACCGTGTGCTACAGTCCCGAGAACAGCGATGCGTCTCTCATAGTGT  
 CTCAGACGACCATACAAGCACGCGCTCTAATGTCGTCAGAACATGTCGCGCTCAATTCTGCTTATGCTCTGTTGTTG  
 TGTGAAACTGAGCTGCGAACAAACATTGATGGCTCCGTCATTAGGCCGCCCTCAAGGATTCTGTGTAGAGACCCAGT  
 GACACGCCGAC  
 GTCGTTGTTTTCATCGTCCGGAGTCGTCGGTTAGAACACTGACAGCATGCGTGTAAACAATATAATGCTGGAAGCGTT  
 GAGCGTGTGAAACCGTGGCAACTAACAGCAAGGGAGGAACAAAGAACGGGGACGCACAGTTCTACAGAGGAGGAATCGA  
 GTCGTTGCTGGCCACTAAACAGCAAGGGAGGAACAAAGAACGGGGACGCACAGTTCTACAGAGGAGGAATCGA  
 GCGAG  
 ACCAGCATTCTGTTTCTGGCTCCCGACAGGGTGGAAACCTCTGACACACAATTCTCTCTGAGGGTGGCGAAAAACTG  
 CTGCTGCT  
 CGAGTTATTGAAACTACGGGACCAACGGGAGAGACTGTTTCACTCGGATGTCGACAGTTGAGCTCGCGACGAAAGGC  
 ATTTTTTTATTCTGGTTCATCCGGCTATCCACCGAGTGTGCTCGGTCGATCGAACGCCAGAAACCAACACTGTTAG  
 TAACATCTGAC  
 CAGTCGACACTGGAAGAACCGCAGCAGTTGCTTACACAGAAATTTCATCCACCGAGACGAGGGTCTGATTCC  
 AGGACATCCCGTAGGAAAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG  
 TTGCCAGGAGCTGAACGGGGTGGTGTGAAGACGTTTCAAGATAACAAACCTCCCGCAGGGTCACTGTTGCTTCC  
 CGGAGATCAGATG  
 TCGTGTACGGAGTACGGAGTCTCTCGGGTCAATTCTCTCCTCGGTGACACAGAAAAGAGGAGGAGGAGGAGGAG  
 AAAACACGCAACCGAGGAGGTTCTGGGAGGACTTCAAGGAAGCCGTTCCGCTCAGGATTCCGAGTGGCATTCT  
 CCTCGGCAAAAGTGTAAAGCAG**GC**  
**GGCCCG**

## (K) pTKO-DHFR-TS-TgCDS1-KO

Function: Deletion of *TgCDS1* locus by double homologous recombination.

**Xcm1** and **Spel** sites for inserting *TgCDS1-5UTR*  
**HindIII** and **Apal** sites for inserting *TgCDS1-3UTR*  
**Apal** site for linearizing the vector before transfection

CCACCGGTCACTGG CGAATCGT TTTCTCTTACAGTACCGTGGCAGTGACAGGCAACTCTCGGAACATTAAAGTCGCTATGCAGT  
 ACTGTGGCTGGAGAACGATCGAGCTCGGCACGGAGTCACGAATTTCGGGGGGTACGTGTTTACACAGGCCACTCGCTGACTCG  
 CGTATGTATTTGTGATACGGTGGCAGACGCATGATCACATTCTCCGTCTCCCTCTGTTACATCCCACCGCTCCCTGATTCTG  
 TTTATGCGGGTGAAGTGTGAGCTCTGCATCTTCGCATCGCGCTTGTCTGGGGTTGTAAGGCTCCACATCTCAGAGGGCAGCGGG  
 AAACAACGCCGCCAACCGAGTCTACTGCACCTCAATCGTGGCTCATCGCCGTTCTGAAACGGAAGTCGAGGCTCAGGAAACTTCGC  
 CTCGCAGACCCGATTTCTGCTGCGCTCGGAACCGTCTGTTACCAAGGGGGAGGCCACACATTACTCACAAGGTT  
 CAGTGCAGGAGAGAGAATCTGGTCTGAGAAAAGGGAGGCCACTCGCTGGCATGGTGGTACAGTCTCAAGGGAGTGTAAA  
 CGCATCAGCTCTGGGAACGAAACGGAGATGTGTTTTCCAACCAGCGCGCTCCCGCAGCGTAGCCAGCGAGACGTGAACCTCAGTCAG  
 TTCTTTGTCTCCGTTCTGAAACGAGCCATTTCTGTAAGGGTCAAACCCGGA **ACTAGT** GGATCGATCCCCCGGGCTCAGGAA  
 TTCATCCTGCAAGTGCATAGAAGGAAAGTGTCTGCTGCTGGCAGACAGAACAGTCCAGCACTCTAGCGGCATACAGAACGATAACGCAT  
 TCACGAGTGGATACACGCACATCTGCTCACCCGCAACTCGCTTCTGTTCTGATGACAAAAAGAAAACAAGGGCAGCTGAGACTGTGAAAT  
 GCCACATGAAGAGTCATCCCTTTCTGATAAAGGACACAGGGGCTCTGCGCACCCCTCGTCAGCTCTCCGACCCGAGGCCACTCTCCTG  
 ATCCCTCCGAAAGAGGAGAAAACGAGACAGGGCAGCTCTGATTCTCGTAGACAGACAGCATCTCCATCTGATTCTCCGTCGGGACCTAG  
 CCCACGACCTCAAATCCTCGCGGTAAATCGCAGTTCTGATGCGTTCTGTTGAGGATGTTCAAAATGGGAACGGTCTCGGTTCTC  
 TCCGAGCTGCTCTTTAAAGCCTGCACATGGTCGTAGACATGGCTGTTCCCATGAAAGTGAATGAACCTCTTAGGTTAGGTTGAGAC  
 GTGTCAACCAGTGGCTCAAAGCGAATAGGAAGCGATGTTGAAGGGGACGCCAGGCCACATCGCACGACCGCTGATACATGATGACGAC  
 AGCTCCTCTGTCGTTACGAGTAACTGGCACAACAGTACAAGGCGGACGCCATTCTGTCAGCGCTGTCAGGATTCCAGGAGTCATGA  
 GCATGCGACGATCTGGTGAAGTCTCGTCACTGATCACATTCTCGTCACTGTCAGCGCTGTCAGCGCTGTCAGGATTCTCGTCTT  
 GTATGCGCCGGCAAGTGTCTCCACTGGAAGCGCTAGGGCCGATGTCGCTCCGACCTCTCGGCTCGTGTGCGGAATCGAGGAACCTG  
 CGTGTACATTCTGCTCCAGATCTCACCGCCCTTCTCAGAAAGATGGTTCTGCTGTCGCGCCGAATGAACACAGCAACTCTCAGGA  
 CCCCTTCCAGAACACACGCTTGTGGTGAAGTGGAAAGGCCGATCCAGCAGTAGCGCATAGTGCAGCGGAATTGGAGATGACACCAAC  
 GCCCGTCCGTCATCCATTGCTCTCATGTTAATAATGCGGCAATGAGATCAAGGTACTGGAATTCTCATGGCCTCTAAAGTGAACATGC  
 GGAACGGCCGAATCAGTCTTCTGCGTTTTCTCCGTTCTCGTCATCCACGCCAACCGGGCAATGGCTGCGCCGAAGAAG  
 GAGCCTGCAACCGCTGACGGAGTGTCTCCCTCGTGGACGCTCAAGAGGCTACTGCGTTCCGAGCTGCTGCGTGTGAGTCAGTCTT  
 CCTCTCTCTGAGAACACAGGAGAACACAGACTCGCAGGAGCTGCAAGCTGCGTGTGAGTTGTTGAGGAGATGAGTCC  
 TTCTCTCTCCGAGCTCCGGAAAAGGAGAACACAGACTCGCAGGAGCTGCAAGCTGCGTGTGAGTTGTTGAGGAGATGAGT  
 CTCCGGGGAACCGAGGGAGAAAACGTCACGGAAACTCGCGGCTACACCGTGTACAGTGTACAGGTGAGAGGCAACGCCAGAGACAGCGCTG  
 CTCGTACAGTCCCCTCCACGACAAAATCTGGTCACTGACAGAATCCTGTACTCTCCTCCAGAAGGCTGAGAGTGTGCGGAGTGAAGCA  
 CAGACTCGGACCGCTGCTGCCCTCACCTGAGGCTTCTCCGCCGAATGCTCTTCTGAGGAAAGGAAACGACGATGTTCAATCTGT  
 CCACGGGGGCTAAACTTCTGAGAACACAGGAGCTTCCGAGGCTTCTCCGAGCTGCAACACGGGCTGTAATCTGCGACTGATGGAGAGGAAG  
 TCCAGAGTCGGGGCTTCTGGAAAATCTCTGGGAACGCCACCCGTTCAAGGAGCTGCTTCTCTGGGGCTGTTTGTCAACACGAGAAAAGTGT  
 TTGAAATCTGTGTCAGTGGGCCACGGAGGGCTGTGAGTGCATGCCCTTGGGGCATCGCAGACGACACAGGAACTACGCGGGGGTAAAATGAATG  
 GCATCTTCCCAGACACGACAACGCCCTAGAGCAGAAACGCACTACTAAAGCAGAACTTCAACCGCTCCGTCACTCAGAGCAGTCTCCG  
 CACTGCCGTGGTAAATGAAAAGGTTCTACGAGACACCGCTCCGGATCGACAAGCGAAGGATCTGCACACCTGGTCTGATGTCGAACAA  
 AGCACGGAGGAGAGACGAAAGTGTACATCGAACACCGTTATCAAACCCGAGAAAAGAAACGAAACAGAAAGAAAAGGAAACCTCCGATAC  
 TTTAAAGAATGAATTCTCCGATTTCTCCAAAATGGCTCATTTCTGCGCACGCTGAGTAAACAGGTGTAAGGCTGCCCACCAACAGA  
 GACGGGGGGGGGACAGGAGCGCTACTGGAGCTGCAAGCAGAGATCTCCGGGGGGGGGGTTGAATGCAAGGTTCTGCTGTG  
 AAAAGAGAATGGAATTATGCTCACGTAGTTCGCGCATGAAAAGGCTCTTACCACTCAAAAAAGACACAGCAGACGATCAGCGACTC  
 TGCGGGGGGACGGGATGGCTCTCTTTGGAAAGCGAATCTGACAAAAGACAGCAGACGATCACACGTTAGTCCCTGGCAGAGAGATAG  
 AGGTGCTGGGGGCAATTGCGGTGCTGGATTACAGTCATGGAGGAGATGTTCCGGAGCCTGTTCTGAGGAGATGAGTCTGAGGAGATAG  
 GAAAGTCACGACATGGAACACGACCCGGGGAGAGAGTGTCTGACAACAGAATGACACACAGGAACTACGCGGGGGTAAAATGAATG  
 ACATGCTAGCAGTCACTCTGAAAAGGGTGGCTCTGATCAGGAAACTCCGGTTCTAGTGTGAACAGGTGCGCTCCGAGAAATCCGAC  
 GCGGGCTAATACGTGGTAAGGACAAAAGCAGCAGCTGCGTCCGGGATTAGAAGTGTGGCACTACATCGGACTCTGTACGAGACATGCCATG  
 CCAAGGGCGTTATCTGGTCTGTGACCCGAGTTCTGAGACATACGGCTACTAAGTTGAAACGCACTATGACGCTTGTGTTACCA  
 TTCTCTCTGCAACTGCTCAGGCAATTGCGTGTGAGCAAAGCAGCGCTCGTGTAGTCCCAACTAATATTATGAGTAAGCACACTCTCAC  
 GGACATCCCTAGCGCTTACCTGTCAGGGCTAGAGAAATGATCGGATATGTTACACGTGACCACGCCAAAGTAGAAAGGAATTAGCAT  
 AACTCAGTCAGCAGTCTCCCTGAGGACACCTGCTGATGATTGAGGAGCACTCACGGGATTACAGCTGGG **AAGCTT** CATTGTAAGA  
 GTATGCAACAGTGAAGTAAAGCAGAAAAGGCTCGAATAGCCCGTAAGCTTCTACTACAGGACTTTTTCTCTCGCAATGAAAGAACCTGAT  
 CTTGGGAGAGCTGTCTGGGGGGGGAGAAGGCTGAGAAGAAGTGTGCTGATAATCTCATGGAAACCCCTCTGAAAAGCTCTTGTGCA  
 CTTCTCCGTCACTCTGCAAGAGTGCATCCCAACCTACATCGCAGCGTCCGGCTGCCACGCTTCTCTCCGAGCTGCTGGTGCAC  
 TGCCCTCTGCAAAATGCTGTTCTCTGAAACCTTCACTGATCGGCTCGTCAAGTGTGAGGCTGGTGTGAGGAGATGCTGAGTCT  
 CTGTGCAATCGGTTCTAGTGGCTGCAAGTCAAGGAGAGCTAGGCTGGTGTGAGGAGATGCTGAGGAGCTGTTCTGAGGAGATGCTC  
 GTAGAAATCGGACCGGACTTCTGCGCTGAACTTCTGACGTTCCGGAGTGCCTGTTGAGAAGACGCTGATTCCAGAGACGAGCTGAGT  
 GCGCGTGTCTCATCCAGGTTTGAACCTGGCTGCTGTTCTGCGCCCAAGTGTGATGTTGGAGACGGCCCTCACAAAGCGCTCAGG  
 AGGCTGAGGAAAGCACATGGTCTCCAGGGCTAGAGGGCGACTGTTTTCTCTAGGGTGTCTCTATAGTGTACTGTTGCTGTATAC  
 CAGGAGTCACGCTCATCCAGGCTGCAAGCGCCAGGCCAGGCCAGGCCAGGCCAGGCCAGGCCAGGCCAGGCCAGGCCAGGCCAGGCC  
 TAGCTGTTCTGTTGAAATTGTTATCCGTCACAACTTACACAGGCCAGGCCAGGCCAGGCCAGGCCAGGCCAGGCCAGGCCAGGCCAGGCC  
 TGAGCTAATGTT  
 GGGGAGAGGCGGGTTGCGTATTGGGCGCTTCCGCTCTCGCTCACTGACTCGCTCGCCTCGCTCGTGTGCGGAGCGGGTATCAGCT  
 CACTCAAAGGCCGTAATACGTTATCCACAGAATCAGGGATAACGCAAGGAAACATGTGAGCAAAAGGCCAGGCCAGGCCAGGCCAGGCC  
 AAAAGGCCGCTCTGGCTGGCTTTCCATAGGCTCCGGCCCTGACGAGCATCACAAAATCACGCTCAAGTCAAGTCAAGGAGGGCGAAACCGAC  
 AGGACTATAAGAATCACGGCGTCTCCCTGGAAAGCTCCCTGCGCTCTCCACCTAGTGTGCTGAGCTGCTGTTGTTGTTGTTGTTGTT  
 CTCCTCTGGAAAGCGCTGGCTCTCTCATAGCTCACCGCTGTAGGTTATCTCAGTCTGGGTGAGGCTGCTGCTGCTGCTGCTGCTG  
 AACCCCCCGTTCAGCCGACCGCTGCCCTATCGGTAACTATGCTCTGAGTCCAACCCGTTAACACGACTTATCGCACTGGCACAGC  
 CACTGGTAACAGGATTAGCAGAGCGAGGTATGAGGGCTGCTACAGAGTCTGAGTGGCTCAACTACGGCTACACTAGAAGGACAGTA  
 TTTGGTATCTGCGCTCTGCTGAGGCCAGTTACCTGCAAGGAGGTTGAGCTTGTGATCCGCAAACAAACCACCGCTGGTAGCGGTGGTT  
 TTTTTGTTGCAACGAGCAGATTACGCCAGAAAAAAAGGATCTCAAGAAGATCTTGTGATCTTCTACGGGGTCTGACGCTCAGTGGAAACGA  
 AAACTCAGCTTAAGGGATTGGTCTGAGGATCTCAAAAGGATCTTCACTAGCTCACCTAGTGTGTTAATGAAAGTTAAATCAATCTAA  
 AGTATATATGAGTAAACTGGTCTGACAGTACCAATGTTAATCTAGTGTGAGGACACTATCTCAGCGATCTGCTTATTCGTCATCATGTT  
 CCTGACTCCCCGGCTGTAGATAACTACGATACGGAGGGCTTACCATCTGGCCCTGCAACTTATCCGCTCCATCCAGTCTATTAAATTG  
 TCCAGATTATCAGCAATAAACCAGCCAGCCGAAGGGCCAGCGCAGAGTGGTCTGCAACTTATCCGCTCCATCCAGTCTATTAAATTG  
 TGCGGGAGCTAGAGTAAGTAGTTGCCAGTTAATAGTTGCGCAACGTTGTTGCTACAGGCATCGTGGTGTACGCTCGTCTGTTG

## **APPENDICES**

GTATGGCTCATTAGTCGGTCCCAACGATCAAGGCAGTTACATGATCCCCATGTGTGAAAAAAGCGGTTAGTCCTTCGGTCCCTCGATCGTTGCAGAAAGTAAGTGGCCGAGTGTATCACTCATGGTTATGGCAGCACTGCATAATTCTCTACTGTATGCCATCGTAAGATGCTTTCTGACTGGTAGACTCAACCAAGTCATTCTGAGAAATGTGTATGCCGACCGAGTTGCTCTGCCCGCGTAATACGGGATAATA CGCGGCCACATAGCAGAACCTTAAAGTGTCTCATGGAAACGTTCTCGGGCGAACCTCAAGGATCTTACCGCTGAGATCCAGTTCGATGTAACCCACTCTGCACCCAACTGATCTCAGCACCTTTACTTCAACAGCGTTCTGGTGAGCAAAAACAGGAAGGCAAAATGCCGAAAAAAGGGAATAAGGGCAGACCGGAACTGTAATACTCATCTCCCTTTCAATTATTGAAGGATTTATCAGGGTTATTGTCTCA TGACGGATACATATTGAATGATTAGAAAATAACAAATAGGGGTTCCGGCACATTCCCGAAAAGTGCACCTGACGCCCTGTAGCGGCATTAAGCGCGGGGTGTGGTGTACCGCAGCGTACACTGCCAGGCCCTAGGCCGCTCTTCGCTTCTCCCTTCCTTCTGCCACGTTGCCGGCTTCAAGCTCTAAATGGGGGCTCCTTAGGGTTCCGATTAGTGTCTTACGGCACCTCGACC CCAAAAACCTGATTAGGTGATGGTCACGTAGGGCCATGCCCTGATAGCGTTTTCGCCCTTGACGTTGGAGTCACGTTCTTAA TAGTGGACTCTGGTCCAAACTGGAAACAACACTCAACCCATCTCGGTCTATTCTTGTATTATAAGGGATTTCGCCATTGCGCTATTGGTTAAAAAAATGAGCTGATTAAACAAAATTTAACCGGAATTAAACGCTTACAATTCCATTGCCATTGCGCTGCGCAACT TTGGGAAGGGCGATCGGTGCCGCTTCTCGTATTACGCCAGTGGCGAACGGGGATGTCGCTGAAGGCATTAAGTGGTAAAGGCCAGGGTTTCCCAGTCAGCAGCTGTAACACGACGCCAGTGGAGCGCCGTAATACGACTCACTATAGGGCAATTGGAGCTTCAAGGCTGAGTACTGGTCTCGTATGCGACACGCCGATTACGCCGTATGCGACAAACGGGATTGCTGATGAGCGTCTCCCACTGAAGCGCCGGAGTGGTGGCGA

(L) *pTUB8-CAT-TgCDS2-KO*

Function: Deletion of *TgCDS2* locus by double homologous recombination.



## ***Apal* sites for inserting *TgCDS2-5UTR***

**Xhol** and **XbaI** sites for inserting *TgCDS2-3UTR*

**Xba**l site for linearizing the vector before transfection

GGGGCCAGTCCTGTCGATTTCTCCCGATGCGCAGTGGACAGAGCTGAAGAAAAACGCCAGACCGACGCCGGTCCAGCAGCAGCTTGTT  
ATTCTGGAGTTCAGTCTCATCGTGTGCTGGAGATATCCCTGGTTGGCAGAAAGACGAATTTCGCTGCTTCAGTGATACACT  
TCGTCGGTTCCAAGTCAGTCAGTCGGCTCTCCAGAAAATCGTCGGCTCTGTCGGCTGTGCTACGAGATTCTCAGCTGTTCAAAA  
AAGGCTGTCGTCCTCGCAGTTCCTCCGGAGACAGTCAGTCGTCCTTCCGGGACACAATGCCGCTTCGCCGGAGCGGCCAGTC  
CTTCGTTCTTCTTCTTCGTTCTCTCTGTCCTGGAGGCTGTCTGTCGGTGTCTTCACGCCGCTGAGAGCTTCCTCTGCA  
CTGCTGCTGACGAAGCTGATGGACATGCACATCGTCTCAGTCGACAGCAGCATTGACTCAGCTTTCTGATTGAAACCGTTCTGCA  
TCCTCCAACCTTTCAAGCTCGCTGAGACGAGAGAAACCGCTCAAGAAAAGGATCCATAAGAGACCTTCCGTACCCACCTCTCTG  
GGAGCAGTCAAACGACTGGCGTCTCGGCTCTCGGAGAAGAGAAAGCAAGGAAGGCAGACTCCGAAGAGAGAGTTGAGACCGGA  
AGCGAGAGGGATGACTCCCCGGAGGAAGAGGAGGGATGACTCGAGAAAGACGAGAAAGGAGAGCAGACTGGTAAAGAGAGAGAG  
GTGAGAGACCCGAAGGAACGGCGTGGCGAAAAAGCAGGAGAGGAGCAGTGAAGCAAAGCGTCTTGGCTGGAGCGAACGCAAAGATGCT  
CGTGAACACCCGAGGAAGAGGAGCAGAACAGCGGCTGGAGGACAAGAAAACTTCGAGCGCAGCAAAGGGCCGGCCCTCAGCGTAT  
CGATAAGCTTAACCAACACCTTGAGACCGCTGTCCAACCAACCCGACACCCCGTGTCCAACCCAGCACCTGAGACCGCTGTCTAAC  
CACCGACCCCTGAGACCGCTGTTCTAACACCGCACCCGTAGAGACCGCTGTTCAAGCTTGCCTGCAATTGGCTGGTGTGATCTGGTGGACCG  
GTGGAGATGCGCGCAGAAGGGGATGTCAGAAACATTGTTGTTCTGTGAACCTTATAGTGTAAAGGCCGAATATTAGCAG  
AGAGTCCTCTTGTTCCATTCTCTTGTGAATTGCCCTTCTCTTGTGAGTGTGTTAGAGAACAGCACTCGTCCCGTCCCTGACG  
ACGCCAACCGCGCAGAACACATCCACCAAACCGGTTACACATCACCTTGTGTAAGTCTTGTGCGAAAACACTACTCGTGGCATTTTCTG  
AATTCTCTTTTGACAAAATGAGGAGAAAATCACTGGATATACCACCGTTGATATATCCCAATCGTCAAGAACATTGAGGCA  
TTTCACTGAGTGTGCTACCTATAACCGACCGTTGACTGGATATTACGCCCTTTAAAGCCTAAAGAAAATAAGCACAAGTTT  
ATCCGGCTTATTACACATTCTGCCCCCTGATGAATGCTCATCCGAATTCCGTATGGAATGAAAGACGGTGAGCTGTGATATGGGATAG  
TGTTCACCCCTGTTACACCGTTTCCATGAGCAAACGTTTACATCGCTGGAGTGAATACCAAGCAGATTCCGGCAGTTCTAC  
ATATATTGCAAGATGTGGCTGTTACGGTAAAACCTGGCTATTCCCTAAAGGTTTATTGAGAATATGTTTCTGCTCAGCCAATCCCT  
GGGTGAGTTCCACAGGTTTGTATTAACCTGGCCAATATGGCAACTTCTGGCCCCCGTTTACCATGGGAAATTATACGCAAGGCGA  
CAAGGTGCTGATGCCCTGGCAGTTCAAGGTTCATGCGCTGTGATGGCTCATGCGCAAGATCTTAATGAAATTACACAGACTG  
GATGAGTGGCAGGGCGGCTTAATATCACCGTTGTCGTCATCTCCTAACATGCAAAAGGAAACACACTTCGTCGAGCATGCCCCATTAT  
AAAGAAAACTGAGTTCTCGCTGCTGGCTCAGGTGTCACATCCACAAAACCGCCGACTCTAAATAGGAGTGTTCGAGCAAGCAGCAGAA  
GTTTATGACTGGGTCGAATCTCTGAACGGATGTGGCGGACCTGGCTGATGTTGATGCCGTGACACACGGCCACATGGGTCAATACACA  
AGACAGCTATCAGTTGTTAGTCGAACCGTTAACGACGATAGAAACCGCTACTAAATGCATTACCTCGAGACGAGGGGGAGGGAGG  
GTCCCGCAGGGAGAGAAAGGAAACGGCAGGAGGAATGGGGGTCGAGAGACAAGGAACACTGCACAGTTG  
AGAGGAAGAGAGAAAGGAGGATGCAACCAAGGGTTCGAGTGGGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG  
GGTTTCCAAAGTCGACTGGAGACAGCAGACAACTCGGGGGAGGGTGAAGCGACCGCAGCGATTATGAGAAGGGGCTCTAAACAGGCTCTCCTT  
TCGCTGAGAGGGAAAGTACCTACCCCCACGAAAAGCAACGGCTCTTTCATCTGAGTGGAGGAGGCTCCACAGCCTCACTGGAGATAAGAAGG  
CAGCGCGACTGGTACGTAAGTCGCTGTGCTGTTTTTCCGCTGGCAACTCCCTTACGATTGCCCTCTGCGATGTTGCTATCCATT  
GTTTCGACTGGTCTGCTGACGCTGGCCTGCGACTGGACTGGAAGTTGTCGCTGCAAGCGAGAGCGCAGGGAACTGGAGAGAAGGCGAGA  
ACGGGGCAGGGTGTGCTGAGCTTCCGCTGTTCTCAACTGAAAAAAAGAGTCAAGAAGGAGTTCCAGTCTCCACTTGGGGGACACCGCG  
ACTCGAATGTTCCATCTGCCAGGCTCCAGTTCTGCTGGTGGAGAAAAGTGTGCTTCCCTCATTCGCTGCTCACTCCAGGCCAGTC  
GAACCGCAAGGGCAAGGGGTGCTCAGGAGCCTCTGCGAGGGAGTAGAGAACCCAGCGTACCTCTGCGCCACAGGGAAGGTAAATTCA  
GTACAACACTGGAAAGAAAAGGGGTTTCTGCACTGTCAGTTTAACTGGAAACCAACAGCTGGCAGCAGGTGAGAAGATTCTGTT  
TCAGTCCTCGCCGATTCTTCGCGAGCAAGAGCTTCTAGCGGCCGCCACCGCGGTGGAGCTCCAGTTTGTCCCTTGTGAGG  
GTTAATTGCCGCTTGGCTAATCATGGTCATAGCTTTCTGTGAAATTGTTATCCGCTCACAACTCCACACATACGAGCGGAAGC  
ATAAAAGTGTAAAGCTGGGTGCTAATGAGTGAAGCTAATCAGGTTCTGCTGAAACTTACATTGCGTTGCGCTCACTGCCCTTCCAGTGGAAACCTGCTG  
GCCAGCTGCTTAAATGAAATGCCAACCGCCGGGAGAGGGCGGTTGGCTATTGGCGCTCTCCGCTACTGACTCGCTGCGCTC  
GGCTGTTGGCTGCGGAGGGTATCAGTCACCTAACAGGCGTAAACAGGTTTACCGTTACAGGAAATCAGGGATAACCGCAGGAAAGAACATGTA  
GCAAAAGGCCAGAACAGGCGTGGCTGCTGGTTTCCATAGGCTCCGGCCCTGACGACATCACAAAATC  
GACGCTCAAGTCAGAGGTGGCAGAACCCGAGAGACTATAAAAGATACCGAGGCTTCCCTGGAGGCTCCCTGTCGCTCTCTGTTCCGAC  
CCTGCCGCTTACCGGATACCTGTCGGCTTCTCCCTCGGAAAGCGTGGCGCTTCTCATAGCTCACGCTGAGGTATCTCAGTCCGGTGTAG  
GTCGTTGCTCCAAGCTGGCTGTGCAAGAACCCCGTTCAGCCGACCGCTGCGCCTTATCGTAACTATCGTCTGAGTCACCCGG  
TAAGACACGACTTACCGCACTGGCAGGCCACTGGTAACAGGATTAGCAGAGGGAGGTATGAGGGCTGCTACAGGTTCTTGTGAGTGGTG  
GCTTAACACTGGCTACAGAAGGAGCAGTATTGGTATCTGGCTCTGCTGAGCCAGTACCTTGGGAAAGGAGTGTGAGCTTGTGATCC  
GGCAACAAACCCAGCTGGTGGCGTGGTTTGTGAGTGGCAAGCAGCAGATTACCGCAGAAAAGGATCTCAAGAAGATCTTGTGATCT  
TTCTACGGGTCTGAGCTCAGTGGAGGAAACTCACGTTAGGGATTGGTATGAGGATTATCAAAGGATCTTACCTAGATCTTGTGATCT  
TTCTACGGGTCTGAGCTCAGTGGAGGAAACTCACGTTAGGGATTGGTATGAGGATTATCAAAGGATCTTACCTAGATCTTGTGATCT

## APPENDICES

---

AAATTAAAAATGAAGTTTAAATCAATCTAAAGTATATGAGTAACCTGGCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCA  
GCGATCTGTCTATTCGTTCATCCATAGTGCCTGACTCCCCGTCGTGAGATAACTACGATAAGGGAGGGCTTACCATCTGGCCCCAGTGCTG  
CAATGATACCGCGAGACCCACGCTCACGGCTCCAGATTATCAGCAATAAACAGCCAGCCGAAGGGCCGAGCGCAGAAGTGGTCTGCAAC  
TTTATCCGCCCTCATCCAGTCTATTAAATGGTGCAGGAAAGCTAGAGTAAGTAGTCGCCAGTTAATAGTTGCGCAACGTGTTGCCATTGCT  
ACAGGCATCGTGGTGTACGCTCGTGGTATGGCTTATTCAAGCTCCGGTCCCAACGATCAAGGCAGTTACATGATCCCCCATGTTGT  
GCAAAAAGCGTTAGCTCCCGTCTCGATCGTTGTAGAAGTAAGTTGCCAGTGTATCACTCATGGTTATGGCAGCACTGCATAA  
TTCTCTTACTGTCTATGCCATCCGTAAGATGCTTTCTGTACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTCTATGCCGACCCAGT  
TGCTCTGCCGCCGCTCAATACGGATAATACCGCACATAGCAGAACTTTAAAAGTGCCTCATCATTGGAAAACGTTCTCGGGCGAAAAC  
TCTCAAGGATCTTACCGCTGGAGATCCAGTCGATGTAACCCACTCGTGCACCCAACTGATCTCAGCATTTCACCGCTTCAACCGCTT  
TGCGTGGAGCAAAAACAGGAAGGCAAATGCCGAAAAAAAGGAATAAGGGGACACGGAAATGTTGAATACTCATACTCTCCCTTTCAATAT  
TATTGAAGCATTATCAGGGTATTGTCTCATGAGCGGATACATATTGAATGTATTAGAAAATAACAAATAGGGGTTCCGCGCACATTTC  
CCCGAAAAGTGCCACCTGACGCCCTGTAGCGGCGCATTAAGCGCCGGGTGTGGTGGTTACCGCAGCGTACCGCTACACTTGCCAGCGC  
CCTAGCGCCCGCTCTTCGCTTCTCCCTTCTCGCCACGTTCGCCGGCTTCCCGTCAGCTCTAAATCGGGGCTCCCTTAGGG  
TTCCGATTTAGTGCCTTACCGCACCTCGACCCCCAAAAGCTTGATTAGGGTATGGTACGTAGGGCCATGCCCTGATAGACGGTTTTC  
GCCCTTGACGTTGGAGTCCACGTTCTTAATAGTGGACTCTGTTCCAAACTGGAAACAACACTCAACCCCTATCGGTCTATTCTTTGATTT  
ATAAGGGATTTGCCATTTCGGCTATTGGTAAAGATGAGCTGATTAAACAAAATTAAACCGAATTAAACAAATATTACGCTTACA  
ATTCCATTGCCATTCCAGGCTGCGCAACTGTTGGGAAGGGCAGTCGGTGCAGGCCAGTGTAAACGACGGCCAGTGAGCGCGTAAACGACTCACTATAG  
TGCAAGGCAGTTAAGTGGGTAACGCCAGGGTTCCAGTCACGACGTTGAAACGACGGCCAGTGAGCGCGTAAACGACTCACTATAG  
GGCGAATTGGGTACC

## References

- 1 Dubremetz, J. F., Achbarou, A., Bermudes, D. & Joiner, K. A. Kinetics and pattern of organelle exocytosis during *Toxoplasma gondii*/host-cell interaction. *Parasitol Res* **79**, 402-408 (1993).
- 2 Dobrowolski, J. M. & Sibley, L. D. *Toxoplasma* invasion of mammalian cells is powered by the actin cytoskeleton of the parasite. *Cell* **84**, 933-939 (1996).
- 3 Carruthers, V. B. & Sibley, L. D. Sequential protein secretion from three distinct organelles of *Toxoplasma gondii* accompanies invasion of human fibroblasts. *Eur J Cell Biol* **73**, 114-123 (1997).
- 4 Dobrowolski, J. M., Carruthers, V. B. & Sibley, L. D. Participation of myosin in gliding motility and host cell invasion by *Toxoplasma gondii*. *Mol Microbiol* **26**, 163-173 (1997).
- 5 McFadden, G. I., Reith, M. E., Munholland, J. & LangUnnasch, N. Plastid in human parasites. *Nature* **381**, 482-482, doi:DOI 10.1038/381482a0 (1996).
- 6 Wilson, R. J. M. et al. Complete gene map of the plastid-like DNA of the malaria parasite *Plasmodium falciparum*. *J Mol Biol* **261**, 155-172 (1996).
- 7 Kohler, S. et al. A plastid of probable green algal origin in Apicomplexan parasites. *Science* **275**, 1485-1489 (1997).
- 8 Janouskovec, J., Horak, A., Obornik, M., Lukes, J. & Keeling, P. J. A common red algal origin of the apicomplexan, dinoflagellate, and heterokont plastids. *P Natl Acad Sci USA* **107**, 10949-10954, doi:10.1073/pnas.1003335107 (2010).
- 9 Black, M. W. & Boothroyd, J. C. Lytic cycle of *Toxoplasma gondii*. *Microbiol Mol Biol Rev* **64**, 607-623 (2000).
- 10 Ajioka, J. W. The protozoan phylum Apicomplexa. *Methods* **13**, 79-80 (1997).
- 11 Chapman, H. D. et al. A selective review of advances in coccidiosis research. *Adv Parasitol* **83**, 93-171, doi:10.1016/B978-0-12-407705-8.00002-1 (2013).
- 12 Blake, D. P. & Tomley, F. M. Securing poultry production from the ever-present *Eimeria* challenge. *Trends Parasitol* **30**, 12-19, doi:10.1016/j.pt.2013.10.003 (2014).
- 13 Shirley, M. W. The genome of *Eimeria* spp., with special reference to *Eimeria tenella*--a coccidium from the chicken. *Int J Parasitol* **30**, 485-493 (2000).
- 14 Cai, X., Fuller, A. L., McDougald, L. R. & Zhu, G. Apicoplast genome of the coccidian *Eimeria tenella*. *Gene* **321**, 39-46 (2003).
- 15 Yan, W. et al. Stable transfection of *Eimeria tenella*: constitutive expression of the YFP-YFP molecule throughout the life cycle. *Int J Parasitol* **39**, 109-117, doi:10.1016/j.ijpara.2008.06.013 (2009).
- 16 Lai, L. et al. The role of sialyl glycan recognition in host tissue tropism of the avian parasite *Eimeria tenella*. *PLoS Pathog* **7**, e1002296, doi:10.1371/journal.ppat.1002296 (2011).
- 17 Blake, D. P. et al. Population, genetic, and antigenic diversity of the apicomplexan *Eimeria tenella* and their relevance to vaccine development. *Proc Natl Acad Sci U S A* **112**, E5343-5350, doi:10.1073/pnas.1506468112 (2015).
- 18 Stockdale, P. G., Stockdale, M. J., Rickard, M. D. & Mitchell, G. F. Mouse strain variation and effects of oocyst dose in infection of mice with *Eimeria falciformis*, a coccidian parasite of the large intestine. *Int J Parasitol* **15**, 447-452 (1985).

## REFERENCES

- 19 Barta, J. R. *et al.* Molecular phylogeny of the other tissue coccidia: *Lankesterella* and *Caryospora*. *J Parasitol* **87**, 121-127, doi:10.1645/0022-3395(2001)087[0121:MPOTOT]2.0.CO;2 (2001).
- 20 Zhao, X. & Duszynski, D. W. Phylogenetic relationships among rodent *Eimeria* species determined by plastid ORF470 and nuclear 18S rDNA sequences. *Int J Parasitol* **31**, 715-719 (2001).
- 21 Korenko, G. & Pakandl, M. Early events in the life cycle of the mouse coccidium *Eimeria falciformis* (Eimer, 1870) Schneider, 1875 in naive and immune hosts. *Parasite* **11**, 333-339 (2004).
- 22 Steinfelder, S., Lucius, R., Greif, G. & Pogonka, T. Treatment of mice with the anticoccidial drug Toltrazuril does not interfere with the development of a specific cellular intestinal immune response to *Eimeria falciformis*. *Parasitol Res* **97**, 458-465, doi:10.1007/s00436-005-1464-x (2005).
- 23 Pogonka, T. *et al.* CD8+ cells protect mice against reinfection with the intestinal parasite *Eimeria falciformis*. *Microbes Infect* **12**, 218-226, doi:10.1016/j.micinf.2009.12.005 (2010).
- 24 Wiedmer, S. *et al.* New insights into the excystation process and oocyst morphology of rodent *Eimeria* species. *Protist* **162**, 668-678, doi:10.1016/j.protis.2011.03.001 (2011).
- 25 Schmid, M., Lehmann, M. J., Lucius, R. & Gupta, N. Apicomplexan parasite, *Eimeria falciformis*, co-opts host tryptophan catabolism for life cycle progression in mouse. *J Biol Chem* **287**, 20197-20207, doi:10.1074/jbc.M112.351999 (2012).
- 26 Stange, J. *et al.* IL-22 mediates host defense against an intestinal intracellular parasite in the absence of IFN-gamma at the cost of Th17-driven immunopathology. *J Immunol* **188**, 2410-2418, doi:10.4049/jimmunol.1102062 (2012).
- 27 Takeo, T. *et al.* Molecular and phylogenetic characterizations of an *Eimeria kriegermanni* Yakimoff & Gouseff, 1938 (Apicomplexa: Eimeriidae) mouse intestinal protozoan parasite by partial 18S ribosomal RNA gene sequence analysis. *Parasitol Int* **63**, 627-630, doi:10.1016/j.parint.2014.04.004 (2014).
- 28 Heitlinger, E., Spork, S., Lucius, R. & Dieterich, C. The genome of *Eimeria falciformis*--reduction and specialization in a single host apicomplexan parasite. *BMC Genomics* **15**, 696, doi:10.1186/1471-2164-15-696 (2014).
- 29 Schmid, M. *et al.* *Eimeria falciformis* infection of the mouse caecum identifies opposing roles of IFNgamma-regulated host pathways for the parasite development. *Mucosal Immunol* **7**, 969-982, doi:10.1038/mi.2013.115 (2014).
- 30 Flegr, J., Prandota, J., Sovickova, M. & Israili, Z. H. Toxoplasmosis--a global threat. Correlation of latent toxoplasmosis with specific disease burden in a set of 88 countries. *PLoS One* **9**, e90203, doi:10.1371/journal.pone.0090203 (2014).
- 31 Cook, T. B. *et al.* "Latent" infection with *Toxoplasma gondii*: association with trait aggression and impulsivity in healthy adults. *J Psychiatr Res* **60**, 87-94, doi:10.1016/j.jpsychires.2014.09.019 (2015).
- 32 Kissinger, J. C., Gajria, B., Li, L., Paulsen, I. T. & Roos, D. S. ToxoDB: accessing the *Toxoplasma gondii* genome. *Nucleic Acids Res* **31**, 234-236 (2003).
- 33 Gajria, B. *et al.* ToxoDB: an integrated *Toxoplasma gondii* database resource. *Nucleic Acids Res* **36**, D553-556, doi:10.1093/nar/gkm981 (2008).
- 34 Donald, R. G. & Roos, D. S. Stable molecular transformation of *Toxoplasma gondii*: a selectable dihydrofolate reductase-thymidylate synthase marker based on drug-resistance mutations in malaria. *Proc Natl Acad Sci U S A* **90**, 11703-11707 (1993).

## REFERENCES

- 35 Kim, K., Soldati, D. & Boothroyd, J. C. Gene replacement in *Toxoplasma gondii* with chloramphenicol acetyltransferase as selectable marker. *Science* **262**, 911-914 (1993).
- 36 Donald, R. G. & Roos, D. S. Insertional mutagenesis and marker rescue in a protozoan parasite: cloning of the uracil phosphoribosyltransferase locus from *Toxoplasma gondii*. *Proc Natl Acad Sci U S A* **92**, 5749-5753 (1995).
- 37 Donald, R. G., Carter, D., Ullman, B. & Roos, D. S. Insertional tagging, cloning, and expression of the *Toxoplasma gondii* hypoxanthine-xanthine-guanine phosphoribosyltransferase gene. Use as a selectable marker for stable transformation. *J Biol Chem* **271**, 14010-14019 (1996).
- 38 Meissner, M., Schluter, D. & Soldati, D. Role of *Toxoplasma gondii* myosin A in powering parasite gliding and host cell invasion. *Science* **298**, 837-840, doi:10.1126/science.1074553 (2002).
- 39 Herm-Gotz, A. et al. Rapid control of protein level in the apicomplexan *Toxoplasma gondii*. *Nat Methods* **4**, 1003-1005, doi:10.1038/nmeth1134 (2007).
- 40 Huynh, M. H. & Carruthers, V. B. Tagging of endogenous genes in a *Toxoplasma gondii* strain lacking Ku80. *Eukaryot Cell* **8**, 530-539, doi:10.1128/EC.00358-08 (2009).
- 41 Foussard, F., Gallois, Y., Girault, A. & Menez, J. F. Lipids and fatty acids of tachyzoites and purified pellicles of *Toxoplasma gondii*. *Parasitol Res* **77**, 475-477 (1991).
- 42 Foussard, F., Leriche, M. A. & Dubremetz, J. F. Characterization of the lipid content of *Toxoplasma gondii* rhoptries. *Parasitology* **102 Pt 3**, 367-370 (1991).
- 43 Hsiao, L. L., Howard, R. J., Aikawa, M. & Taraschi, T. F. Modification of host cell membrane lipid composition by the intra-erythrocytic human malaria parasite *Plasmodium falciparum*. *Biochem J* **274 ( Pt 1)**, 121-132 (1991).
- 44 Sam-Yellowe, T. Y. et al. Proteome analysis of rhoptry-enriched fractions isolated from *Plasmodium* merozoites. *J Proteome Res* **3**, 995-1001, doi:10.1021/pr049926m (2004).
- 45 Welti, R. et al. Lipidomic analysis of *Toxoplasma gondii* reveals unusual polar lipids. *Biochemistry* **46**, 13882-13890, doi:10.1021/bi7011993 (2007).
- 46 Dechamps, S., Shastri, S., Wengelnik, K. & Vial, H. J. Glycerophospholipid acquisition in *Plasmodium* - a puzzling assembly of biosynthetic pathways. *Int J Parasitol* **40**, 1347-1365, doi:10.1016/j.ijpara.2010.05.008 (2010).
- 47 Botte, C. Y. et al. Atypical lipid composition in the purified relict plastid (apicoplast) of malaria parasites. *Proc Natl Acad Sci U S A* **110**, 7506-7511, doi:10.1073/pnas.1301251110 (2013).
- 48 Nebl, T., De Veer, M. J. & Schofield, L. Stimulation of innate immune responses by malarial glycosylphosphatidylinositol via pattern recognition receptors. *Parasitology* **130 Suppl**, S45-62, doi:10.1017/S0031182005008152 (2005).
- 49 Bhattacharjee, S., Stahelin, R. V., Speicher, K. D., Speicher, D. W. & Haldar, K. Endoplasmic reticulum PI(3)P lipid binding targets malaria proteins to the host cell. *Cell* **148**, 201-212, doi:10.1016/j.cell.2011.10.051 (2012).
- 50 Arroyo-Olarte, R. D. et al. Phosphatidylthreonine and Lipid-Mediated Control of Parasite Virulence. *PLoS Biol* **13**, e1002288, doi:10.1371/journal.pbio.1002288 (2015).
- 51 Charron, A. J. & Sibley, L. D. Host cells: mobilizable lipid resources for the intracellular parasite *Toxoplasma gondii*. *J Cell Sci* **115**, 3049-3059 (2002).
- 52 Coppens, I. Contribution of host lipids to *Toxoplasma* pathogenesis. *Cell Microbiol* **8**, 1-9, doi:10.1111/j.1462-5822.2005.00647.x (2006).

## REFERENCES

- 53 Caffaro, C. E. & Boothroyd, J. C. Evidence for host cells as the major contributor of lipids in the intravacuolar network of *Toxoplasma*-infected cells. *Eukaryot Cell* **10**, 1095-1099, doi:10.1128/EC.00002-11 (2011).
- 54 Nolan, S. J., Romano, J. D., Luechtfeld, T. & Coppens, I. *Neospora caninum* Recruits Host Cell Structures to Its Parasitophorous Vacuole and Salvages Lipids from Organelles. *Eukaryot Cell* **14**, 454-473, doi:10.1128/EC.00262-14 (2015).
- 55 Gupta, N., Zahn, M. M., Coppens, I., Joiner, K. A. & Voelker, D. R. Selective disruption of phosphatidylcholine metabolism of the intracellular parasite *Toxoplasma gondii* arrests its growth. *J Biol Chem* **280**, 16345-16353, doi:10.1074/jbc.M501523200 (2005).
- 56 Dechamps, S. et al. The Kennedy phospholipid biosynthesis pathways are refractory to genetic disruption in *Plasmodium berghei* and therefore appear essential in blood stages. *Mol Biochem Parasitol* **173**, 69-80, doi:10.1016/j.molbiopara.2010.05.006 (2010).
- 57 Bobenckik, A. M. et al. *Plasmodium falciparum* phosphoethanolamine methyltransferase is essential for malaria transmission. *Proc Natl Acad Sci U S A* **110**, 18262-18267, doi:10.1073/pnas.1313965110 (2013).
- 58 Sen, P., Vial, H. J. & Radulescu, O. Kinetic modelling of phospholipid synthesis in *Plasmodium knowlesi* unravels crucial steps and relative importance of multiple pathways. *BMC Syst Biol* **7**, 123, doi:10.1186/1752-0509-7-123 (2013).
- 59 Gulati, S. et al. Profiling the essential nature of lipid metabolism in asexual blood and gametocyte stages of *Plasmodium falciparum*. *Cell Host Microbe* **18**, 371-381, doi:10.1016/j.chom.2015.08.003 (2015).
- 60 Waller, R. F. et al. Nuclear-encoded proteins target to the plastid in *Toxoplasma gondii* and *Plasmodium falciparum*. *P Natl Acad Sci USA* **95**, 12352-12357, doi:DOI 10.1073/pnas.95.21.12352 (1998).
- 61 Mazumdar, J., E, H. W., Masek, K., C, A. H. & Striepen, B. Apicoplast fatty acid synthesis is essential for organelle biogenesis and parasite survival in *Toxoplasma gondii*. *Proc Natl Acad Sci U S A* **103**, 13192-13197, doi:10.1073/pnas.0603391103 (2006).
- 62 Ramakrishnan, S. et al. Apicoplast and endoplasmic reticulum cooperate in fatty acid biosynthesis in apicomplexan parasite *Toxoplasma gondii*. *J Biol Chem* **287**, 4957-4971, doi:10.1074/jbc.M111.310144 (2012).
- 63 Amiar, S. et al. Apicoplast-localized lysophosphatidic acid precursor assembly is required for bulk phospholipid synthesis in *Toxoplasma gondii* and relies on an algal/plant-like glycerol 3-phosphate acyltransferase. *PLoS Pathog* **12**, e1005765, doi:10.1371/journal.ppat.1005765 (2016).
- 64 Sampels, V. et al. Conditional mutagenesis of a novel choline kinase demonstrates plasticity of phosphatidylcholine biogenesis and gene expression in *Toxoplasma gondii*. *J Biol Chem* **287**, 16289-16299, doi:10.1074/jbc.M112.347138 (2012).
- 65 Gupta, N., Hartmann, A., Lucius, R. & Voelker, D. R. The obligate intracellular parasite *Toxoplasma gondii* secretes a soluble phosphatidylserine decarboxylase. *J Biol Chem* **287**, 22938-22947, doi:10.1074/jbc.M112.373639 (2012).
- 66 Hartmann, A., Hellmund, M., Lucius, R., Voelker, D. R. & Gupta, N. Phosphatidylethanolamine synthesis in the parasite mitochondrion is required for efficient growth but dispensable for survival of *Toxoplasma gondii*. *J Biol Chem* **289**, 6809-6824, doi:10.1074/jbc.M113.509406 (2014).
- 67 Lindner, S. E. et al. Enzymes involved in plastid-targeted phosphatidic acid synthesis are essential for *Plasmodium yoelii* liver-stage development. *Mol Microbiol* **91**, 679-693, doi:10.1111/mmi.12485 (2014).

## REFERENCES

- 68 van Schaijk, B. C. *et al.* Type II fatty acid biosynthesis is essential for *Plasmodium falciparum* sporozoite development in the midgut of *Anopheles* mosquitoes. *Eukaryot Cell* **13**, 550-559, doi:10.1128/EC.00264-13 (2014).
- 69 Shears, M. J. *et al.* Characterization of the *Plasmodium falciparum* and *P. berghei* glycerol 3-phosphate acyltransferase involved in FASII fatty acid utilization in the malaria parasite apicoplast. *Cell Microbiol*, doi:10.1111/cmi.12633 (2016).
- 70 Meissner, M., Brecht, S., Bujard, H. & Soldati, D. Modulation of myosin A expression by a newly established tetracycline repressor-based inducible system in *Toxoplasma gondii*. *Nucleic Acids Res* **29**, E115 (2001).
- 71 Besteiro, S., Brooks, C. F., Striepen, B. & Dubremetz, J. F. Autophagy protein Atg3 is essential for maintaining mitochondrial integrity and for normal intracellular development of *Toxoplasma gondii* tachyzoites. *PLoS Pathog* **7**, e1002416, doi:10.1371/journal.ppat.1002416 (2011).
- 72 Vollmer, M., Thomsen, N., Wiek, S. & Seeber, F. Apicomplexan parasites possess distinct nuclear-encoded, but apicoplast-localized, plant-type ferredoxin-NADP<sup>+</sup> reductase and ferredoxin. *J Biol Chem* **276**, 5483-5490, doi:10.1074/jbc.M009452200 (2001).
- 73 Plattner, F. *et al.* *Toxoplasma* profilin is essential for host cell invasion and TLR11-dependent induction of an interleukin-12 response. *Cell Host Microbe* **3**, 77-87, doi:10.1016/j.chom.2008.01.001 (2008).
- 74 Sibley, L. D., Niesman, I. R., Parmley, S. F. & Cesbron-Delaunay, M. F. Regulated secretion of multi-lamellar vesicles leads to formation of a tubulo-vesicular network in host-cell vacuoles occupied by *Toxoplasma gondii*. *J Cell Sci* **108** (Pt 4), 1669-1677 (1995).
- 75 Echeverria, P. C. *et al.* *Toxoplasma gondii* Hsp90 is a potential drug target whose expression and subcellular localization are developmentally regulated. *J Mol Biol* **350**, 723-734, doi:10.1016/j.jmb.2005.05.031 (2005).
- 76 Dubremetz, J. F., Rodriguez, C. & Ferreira, E. *Toxoplasma gondii*: redistribution of monoclonal antibodies on tachyzoites during host cell invasion. *Exp Parasitol* **59**, 24-32 (1985).
- 77 Aurrecoechea, C. *et al.* EuPathDB: a portal to eukaryotic pathogen databases. *Nucleic Acids Res* **38**, D415-419, doi:10.1093/nar/gkp941 (2010).
- 78 Schmatz, D. M., Crane, M. S. & Murray, P. K. Purification of *Eimeria* sporozoites by DE-52 anion exchange chromatography. *J Protozool* **31**, 181-183 (1984).
- 79 Bligh, E. G. & Dyer, W. J. A rapid method of total lipid extraction and purification. *Can J Biochem Physiol* **37**, 911-917 (1959).
- 80 Brouwers, J. F. *et al.* Distinct lipid compositions of two types of human prostasomes. *Proteomics* **13**, 1660-1666, doi:10.1002/pmic.201200348 (2013).
- 81 Smith, C. A., Want, E. J., O'Maille, G., Abagyan, R. & Siuzdak, G. XCMS: processing mass spectrometry data for metabolite profiling using nonlinear peak alignment, matching, and identification. *Anal Chem* **78**, 779-787, doi:10.1021/ac051437y (2006).
- 82 Agrawal, S., van Dooren, G. G., Beatty, W. L. & Striepen, B. Genetic evidence that an endosymbiont-derived endoplasmic reticulum-associated protein degradation (ERAD) system functions in import of apicoplast proteins. *J Biol Chem* **284**, 33683-33691, doi:10.1074/jbc.M109.044024 (2009).
- 83 Hager, K. M., Striepen, B., Tilney, L. G. & Roos, D. S. The nuclear envelope serves as an intermediary between the ER and Golgi complex in the intracellular parasite *Toxoplasma gondii*. *J Cell Sci* **112** (Pt 16), 2631-2638 (1999).

## REFERENCES

- 84 Tran, P. N. *et al.* Changes in lipid composition during sexual development of the malaria parasite *Plasmodium falciparum*. *Malar J* **15**, 73, doi:10.1186/s12936-016-1130-z (2016).
- 85 Carroll, M. & McCrorie, P. Lipid composition of bloodstream forms of *Trypanosoma brucei brucei*. *Comp Biochem Physiol B* **83**, 647-651 (1986).
- 86 Patnaik, P. K. *et al.* Molecular species analysis of phospholipids from *Trypanosoma brucei* bloodstream and procyclic forms. *Mol Biochem Parasitol* **58**, 97-105 (1993).
- 87 Gonzalez-Salgado, A. *et al.* myo-Inositol uptake is essential for bulk inositol phospholipid but not glycosylphosphatidylinositol synthesis in *Trypanosoma brucei*. *J Biol Chem* **287**, 13313-13323, doi:10.1074/jbc.M112.344812 (2012).
- 88 Oliveira, M. M., Timm, S. L. & Costa, S. C. Lipid composition of *Trypanosoma cruzi*. *Comp Biochem Physiol B* **58**, 195-199 (1977).
- 89 Kaneda, Y., Nagakura, K. & Goutsu, T. Lipid composition of three morphological stages of *Trypanosoma cruzi*. *Comp Biochem Physiol B* **83**, 533-536 (1986).
- 90 Wassef, M. K., Fioretti, T. B. & Dwyer, D. M. Lipid analyses of isolated surface membranes of *Leishmania donovani* promastigotes. *Lipids* **20**, 108-115 (1985).
- 91 Ramos, R. G. *et al.* Comparison between charged aerosol detection and light scattering detection for the analysis of *Leishmania* membrane phospholipids. *J Chromatogr A* **1209**, 88-94, doi:10.1016/j.chroma.2008.07.080 (2008).
- 92 Becker, G. W. & Lester, R. L. Biosynthesis of phosphoinositol-containing sphingolipids from phosphatidylinositol by a membrane preparation from *Saccharomyces cerevisiae*. *J Bacteriol* **142**, 747-754 (1980).
- 93 Lester, R. L. & Dickson, R. C. Sphingolipids with inositolphosphate-containing head groups. *Adv Lipid Res* **26**, 253-274 (1993).
- 94 Sperling, P. & Heinz, E. Plant sphingolipids: structural diversity, biosynthesis, first genes and functions. *Biochim Biophys Acta* **1632**, 1-15 (2003).
- 95 Futerman, A. H. & Hannun, Y. A. The complex life of simple sphingolipids. *EMBO Rep* **5**, 777-782, doi:10.1038/sj.embo.7400208 (2004).
- 96 Pratt, S. *et al.* Sphingolipid synthesis and scavenging in the intracellular apicomplexan parasite, *Toxoplasma gondii*. *Mol Biochem Parasitol* **187**, 43-51, doi:10.1016/j.molbiopara.2012.11.007 (2013).
- 97 Sonda, S., Sala, G., Ghidoni, R., Hemphill, A. & Pieters, J. Inhibitory effect of aureobasidin A on *Toxoplasma gondii*. *Antimicrob Agents Chemother* **49**, 1794-1801, doi:10.1128/AAC.49.5.1794-1801.2005 (2005).
- 98 Sutterwala, S. S. *et al.* Developmentally regulated sphingolipid synthesis in African trypanosomes. *Mol Microbiol* **70**, 281-296, doi:10.1111/j.1365-2958.2008.06393.x (2008).
- 99 Denny, P. W., Shams-Eldin, H., Price, H. P., Smith, D. F. & Schwarz, R. T. The protozoan inositol phosphorylceramide synthase: a novel drug target that defines a new class of sphingolipid synthase. *J Biol Chem* **281**, 28200-28209, doi:10.1074/jbc.M600796200 (2006).
- 100 Sevova, E. S. *et al.* Cell-free synthesis and functional characterization of sphingolipid synthases from parasitic trypanosomatid protozoa. *J Biol Chem* **285**, 20580-20587, doi:10.1074/jbc.M110.127662 (2010).
- 101 Ralph, S. A. *et al.* Tropical infectious diseases: metabolic maps and functions of the *Plasmodium falciparum* apicoplast. *Nat Rev Microbiol* **2**, 203-216, doi:10.1038/nrmicro843 (2004).

## REFERENCES

---

- 102 Mai, K. *et al.* Oocyst wall formation and composition in coccidian parasites. *Mem Inst Oswaldo Cruz* **104**, 281-289 (2009).
- 103 Martins-Duarte, E. S., Carias, M., Vommaro, R., Surolia, N. & de Souza, W. Apicoplast fatty acid synthesis is essential for pellicle formation at the end of cytokinesis in *Toxoplasma gondii*. *J Cell Sci*, doi:10.1242/jcs.185223 (2016).
- 104 Ramakrishnan, S. *et al.* The intracellular parasite *Toxoplasma gondii* depends on the synthesis of long-chain and very long-chain unsaturated fatty acids not supplied by the host cell. *Mol Microbiol* **97**, 64-76, doi:10.1111/mmi.13010 (2015).
- 105 Yu, M. *et al.* The fatty acid biosynthesis enzyme FabI plays a key role in the development of liver-stage malarial parasites. *Cell Host Microbe* **4**, 567-578, doi:10.1016/j.chom.2008.11.001 (2008).
- 106 Vaughan, A. M. *et al.* Type II fatty acid synthesis is essential only for malaria parasite late liver stage development. *Cell Microbiol* **11**, 506-520, doi:10.1111/j.1462-5822.2008.01270.x (2009).
- 107 Cobbold, S. A. *et al.* Kinetic flux profiling elucidates two independent acetyl-CoA biosynthetic pathways in *Plasmodium falciparum*. *J Biol Chem* **288**, 36338-36350, doi:10.1074/jbc.M113.503557 (2013).
- 108 Santiago, T. C., Zufferey, R., Mehra, R. S., Coleman, R. A. & Mamoun, C. B. The *Plasmodium falciparum* PfGatp is an endoplasmic reticulum membrane protein important for the initial step of malarial glycerolipid synthesis. *J Biol Chem* **279**, 9222-9232, doi:10.1074/jbc.M310502200 (2004).
- 109 Martin, D. *et al.* Characterization of *Plasmodium falciparum* CDP-diacylglycerol synthase, a proteolytically cleaved enzyme. *Mol Biochem Parasitol* **110**, 93-105 (2000).
- 110 Shastri, S. *et al.* *Plasmodium* CDP-DAG synthase: an atypical gene with an essential N-terminal extension. *Int J Parasitol* **40**, 1257-1268, doi:10.1016/j.ijpara.2010.03.006 (2010).
- 111 Lilley, A. C., Major, L., Young, S., Stark, M. J. & Smith, T. K. The essential roles of cytidine diphosphate-diacylglycerol synthase in bloodstream form *Trypanosoma brucei*. *Mol Microbiol* **92**, 453-470, doi:10.1111/mmi.12553 (2014).
- 112 Signorell, A., Rauch, M., Jelk, J., Ferguson, M. A. & Butikofer, P. Phosphatidylethanolamine in *Trypanosoma brucei* is organized in two separate pools and is synthesized exclusively by the Kennedy pathway. *J Biol Chem* **283**, 23636-23644, doi:10.1074/jbc.M803600200 (2008).
- 113 Martin, K. L. & Smith, T. K. Phosphatidylinositol synthesis is essential in bloodstream form *Trypanosoma brucei*. *Biochem J* **396**, 287-295, doi:10.1042/BJ20051825 (2006).
- 114 Baunaure, F., Eldin, P., Cathiard, A. M. & Vial, H. Characterization of a non-mitochondrial type I phosphatidylserine decarboxylase in *Plasmodium falciparum*. *Mol Microbiol* **51**, 33-46 (2004).
- 115 Gibellini, F., Hunter, W. N. & Smith, T. K. The ethanolamine branch of the Kennedy pathway is essential in the bloodstream form of *Trypanosoma brucei*. *Mol Microbiol* **73**, 826-843, doi:10.1111/j.1365-2958.2009.06764.x (2009).
- 116 Serricchio, M. & Butikofer, P. An essential bacterial-type cardiolipin synthase mediates cardiolipin formation in a eukaryote. *Proc Natl Acad Sci U S A* **109**, E954-961, doi:10.1073/pnas.1121528109 (2012).
- 117 Serricchio, M. & Butikofer, P. Phosphatidylglycerophosphate synthase associates with a mitochondrial inner membrane complex and is essential for growth of *Trypanosoma brucei*. *Mol Microbiol* **87**, 569-579, doi:10.1111/mmi.12116 (2013).
- 118 Bullen, H. E. *et al.* Phosphatidic acid-mediated signaling regulates microneme secretion in *Toxoplasma*. *Cell Host Microbe* **19**, 349-360, doi:10.1016/j.chom.2016.02.006 (2016).

## REFERENCES

- 119 Holthuis, J. C. & Levine, T. P. Lipid traffic: floppy drives and a superhighway. *Nat Rev Mol Cell Biol* **6**, 209-220, doi:10.1038/nrm1591 (2005).
- 120 Voelker, D. R. Bridging gaps in phospholipid transport. *Trends Biochem Sci* **30**, 396-404, doi:10.1016/j.tibs.2005.05.008 (2005).
- 121 Levine, T. & Loewen, C. Inter-organelle membrane contact sites: through a glass, darkly. *Curr Opin Cell Biol* **18**, 371-378, doi:10.1016/j.ceb.2006.06.011 (2006).
- 122 van Meer, G., Voelker, D. R. & Feigenson, G. W. Membrane lipids: where they are and how they behave. *Nat Rev Mol Cell Biol* **9**, 112-124, doi:10.1038/nrm2330 (2008).
- 123 van Dooren, G. G. et al. Development of the endoplasmic reticulum, mitochondrion and apicoplast during the asexual life cycle of *Plasmodium falciparum*. *Mol Microbiol* **57**, 405-419, doi:10.1111/j.1365-2958.2005.04699.x (2005).
- 124 Tomova, C. et al. Membrane contact sites between apicoplast and ER in *Toxoplasma gondii* revealed by electron tomography. *Traffic* **10**, 1471-1480, doi:10.1111/j.1600-0854.2009.00954.x (2009).
- 125 Sheiner, L., Vaidya, A. B. & McFadden, G. I. The metabolic roles of the endosymbiotic organelles of *Toxoplasma* and *Plasmodium* spp. *Curr Opin Microbiol* **16**, 452-458, doi:10.1016/j.mib.2013.07.003 (2013).
- 126 Nishi, M., Hu, K., Murray, J. M. & Roos, D. S. Organellar dynamics during the cell cycle of *Toxoplasma gondii*. *J Cell Sci* **121**, 1559-1568, doi:10.1242/jcs.021089 (2008).
- 127 van Ooij, C. et al. Identification of a *Plasmodium falciparum* phospholipid transfer protein. *J Biol Chem* **288**, 31971-31983, doi:10.1074/jbc.M113.474189 (2013).
- 128 Tran, P. N. et al. A female gametocyte-specific ABC transporter plays a role in lipid metabolism in the malaria parasite. *Nat Commun* **5**, 4773, doi:10.1038/ncomms5773 (2014).
- 129 Shen, H., Heacock, P. N., Clancey, C. J. & Dowhan, W. The CDS1 gene encoding CDP-diacylglycerol synthase in *Saccharomyces cerevisiae* is essential for cell growth. *J Biol Chem* **271**, 789-795 (1996).
- 130 Zhou, Y. et al. Extr plastidial cytidinediphosphate diacylglycerol synthase activity is required for vegetative development in *Arabidopsis thaliana*. *Plant J* **75**, 867-879, doi:10.1111/tpj.12248 (2013).
- 131 Halford, S., Dulai, K. S., Daw, S. C., Fitzgibbon, J. & Hunt, D. M. Isolation and chromosomal localization of two human CDP-diacylglycerol synthase (CDS) genes. *Genomics* **54**, 140-144, doi:10.1006/geno.1998.5547 (1998).
- 132 Inglis-Broadgate, S. L. et al. Isolation and characterization of murine Cds (CDP-diacylglycerol synthase) 1 and 2. *Gene* **356**, 19-31, doi:10.1016/j.gene.2005.04.037 (2005).
- 133 D'Souza, K., Kim, Y. J., Balla, T. & Epand, R. M. Distinct properties of the two isoforms of CDP-diacylglycerol synthase. *Biochemistry* **53**, 7358-7367, doi:10.1021/bi501250m (2014).
- 134 Tamura, Y. et al. Tam41 is a CDP-diacylglycerol synthase required for cardiolipin biosynthesis in mitochondria. *Cell Metab* **17**, 709-718, doi:10.1016/j.cmet.2013.03.018 (2013).
- 135 van Dooren, G. G. & Striepen, B. The algal past and parasite present of the apicoplast. *Annu Rev Microbiol* **67**, 271-289, doi:10.1146/annurev-micro-092412-155741 (2013).
- 136 Sheiner, L. et al. A systematic screen to discover and analyze apicoplast proteins identifies a conserved and essential protein import factor. *PLoS Pathog* **7**, e1002392, doi:10.1371/journal.ppat.1002392 (2011).

---

## REFERENCES

- 137 Cilingir, G., Broschat, S. L. & Lau, A. O. ApicoAP: the first computational model for identifying apicoplast-targeted proteins in multiple species of Apicomplexa. *PLoS One* **7**, e36598, doi:10.1371/journal.pone.0036598 (2012).
- 138 DeRocher, A., Gilbert, B., Feagin, J. E. & Parsons, M. Dissection of brefeldin A-sensitive and -insensitive steps in apicoplast protein targeting. *Journal of Cell Science* **118**, 565-574, doi:10.1242/jcs.01627 (2005).
- 139 Tonkin, C. J., Struck, N. S., Mullin, K. A., Stimmmer, L. M. & McFadden, G. I. Evidence for Golgi-independent transport from the early secretory pathway to the plastid in malaria parasites. *Mol Microbiol* **61**, 614-630, doi:10.1111/j.1365-2958.2006.05244.x (2006).
- 140 Bouchut, A., Geiger, J. A., DeRocher, A. E. & Parsons, M. Vesicles bearing *Toxoplasma* apicoplast membrane proteins persist following loss of the relict plastid or Golgi body disruption. *PLoS One* **9**, e112096, doi:10.1371/journal.pone.0112096 (2014).
- 141 Heiny, S. R., Pautz, S., Recker, M. & Przyborski, J. M. Protein Traffic to the *Plasmodium falciparum* apicoplast: evidence for a sorting branch point at the Golgi. *Traffic* **15**, 1290-1304, doi:10.1111/tra.12226 (2014).
- 142 Stewart, R. J. et al. Phosphorylation of SNAP is Required for Secretory Organelle Biogenesis in *Toxoplasma gondii*. *Traffic* **17**, 102-116, doi:10.1111/tra.12348 (2016).
- 143 DeRocher, A. E., Karnataka, A., Vaney, P. & Parsons, M. Apicoplast targeting of a *Toxoplasma gondii* transmembrane protein requires a cytosolic tyrosine-based motif. *Traffic* **13**, 694-704, doi:10.1111/j.1600-0854.2012.01335.x (2012).
- 144 Tawk, L. et al. Phosphatidylinositol 3-monophosphate is involved in *Toxoplasma* apicoplast biogenesis. *PLoS Pathog* **7**, e1001286, doi:10.1371/journal.ppat.1001286 (2011).
- 145 Daher, W. et al. Lipid kinases are essential for apicoplast homeostasis in *Toxoplasma gondii*. *Cell Microbiol* **17**, 559-578, doi:10.1111/cmi.12383 (2015).
- 146 Wichroski, M. J. & Ward, G. E. Biosynthesis of glycosylphosphatidylinositol is essential to the survival of the protozoan parasite *Toxoplasma gondii*. *Eukaryot Cell* **2**, 1132-1136 (2003).
- 147 Azzouz, N. et al. *Toxoplasma gondii* grown in human cells uses GalNAc-containing glycosylphosphatidylinositol precursors to anchor surface antigens while the immunogenic Glc-GalNAc-containing precursors remain free at the parasite cell surface. *Int J Biochem Cell Biol* **38**, 1914-1925, doi:10.1016/j.biocel.2006.05.006 (2006).
- 148 Debierre-Grockiego, F. & Schwarz, R. T. Immunological reactions in response to apicomplexan glycosylphosphatidylinositols. *Glycobiology* **20**, 801-811, doi:10.1093/glycob/cwq038 (2010).

## **List of conferences and courses**

### **Presentations in conferences**

- 04.2016, IRI Symposium: Molecular Interactions in Malaria, Berlin/Germany;
- 03.2016, 27th Annual DGP Meeting, Göttingen/Germany;
- 09.2014, 11th International Coccidiosis Conference, Dresden/Germany;
- 09.2014, 12th Euro Fed Lipid Congress, Montpellier/France;
- 05.2014, 3rd European Symposium on Microbial Lipids: Model Organisms and Biodiversity, Hamburg/Germany;
- 01.2014, ZIBI Graduate School Scientific Thinking, Berlin/Germany;
- 06.2013, 12th International Congress on Toxoplasmosis, Oxford/UK;
- 03.2013, IFoTox-2013 Interdisciplinary Form on Toxoplasmosis, Göttingen/Germany;
- 09.2012, 23rd Annual Molecular Parasitology Meeting, Woods Hole/USA;
- 03.2012, 23rd Annual DGP Meeting, Heidelberg/Germany;
- 2011-2015, ZIBI Graduate School Retreats, Berlin/Germany.

### **Practical and soft skill courses**

- 06.2013, Communication at Conferences;
- 03.2012, 6th Short Course for Young Parasitologists;
- 03.2012, FACS Calibur;
- 09.2011, Publishing Research Articles;
- 06.2011, Work-Life-Balance in the Academic World;
- 06.2011, Grant Application Writing;
- 05.2011, Analysis of Innate Immune Recognition in Bacterial Infections;
- 01.2011, Science-Ethics-Politics: Agenda Setting in Science;
- 09.2010, Presenting Professionally.

### List of publications

#### During PhD period:

**Kong P**, Ufermann CM, Zimmermann DL, Yin Q, Suo X, Helms BJ, Brouwers JF and Gupta N. Two phylogenetically and compartmentally distinct CDP-diacylglycerol synthases cooperate for lipid biogenesis in *Toxoplasma gondii*. *J Biol Chem.* 2017;292(17):7145-59.

**Kong P**, Lehmann MJ, Helms JB, Brouwers JF and Gupta N. Exclusive phospholipid expression and autonomous membrane biogenesis in *Eimeria* indicate a host-independent lifestyle of apicomplexan sporozoites. (in submission)

#### During master period:

**Kong P**, Wang L, Zhang H, Song X, Zhou Z, Yang J, Qiu L, Wang L and Song L. A novel C-type lectin from bay scallop *Argopecten irradians* (AiCTL-7) agglutinating fungi with mannose specificity. *Fish Shellfish Immunol.* 2011;30(3):836-44.

**Kong P**, Zhang H, Wang L, Zhou Z, Yang J, Zhang Y, Qiu L, Wang L and Song L. AiC1qDC-1, A novel gC1q-domain-containing protein from bay scallop *Argopecten irradians* with fungi agglutinating activity. *Dev Comp Immunol.* 2010;34(8):837-46.

**Kong P**, Wang L, Zhang H, Zhou Z, Qiu L, Gai Y and Song L. Two novel secreted ferritins involved in immune defense of Chinese mitten crab *Eriocheir sinensis*. *Fish Shellfish Immunol.* 2010;28(4):604-12.

Zhang H, **Kong P**, Wang L, Zhou Z, Yang J, Zhang Y, Qiu L and Song L. Cflec-5, a pattern recognition receptor in scallop *Chlamys farreri* agglutinating yeast *Pichia pastoris*. *Fish Shellfish Immunol.* 2010;29(1):149-56.

Wang L, Wang L, **Kong P**, Yang J, Zhang H, Wang M, Zhou Z, Qiu L, Song L. A novel C1qDC protein acting as pattern recognition receptor in scallop *Argopecten irradians*. *Fish Shellfish Immunol.* 2012;33(2):427-35.

Zhang H, Song X, Wang L, **Kong P**, Yang J, Liu L, Qiu L, Zhang Y, Qiu L and Song L. AiCTL-6, a novel C-type lectin from bay scallop *Argopecten irradians* with a long C-type lectin-like domain. *Fish Shellfish Immunol.* 2011;30(1):17-26.

Zhou Z, Wang L, Yang J, Zhang H, **Kong P**, Wang M, Qiu L and Song L. A dopamine beta hydroxylase from *Chlamys farreri* and its induced mRNA expression in the haemocytes after LPS stimulation. *Fish Shellfish Immunol.* 2011;30(1):154-62.

Zhang Y, Song L, Zhao J, Wang L, **Kong P**, Liu L, Wang M and Qiu L. Protective immunity induced by CpG ODNs against white spot syndrome virus (WSSV) via intermediation of virus replication indirectly in *Litopenaeus vannamei*. *Dev Comp Immunol.* 2010;34(4):418-24.

Wang L, Wang L, Yang J, Zhang H, Huang M, **Kong P**, Zhou Z and Song L. A multi-CRD C-type lectin with broad recognition spectrum and cellular adhesion from *Argopecten irradians*. *Dev Comp Immunol.* 2012;36(3):591-601.

Zhou Z, Wang L, Shi X, Zhang H, Gao Y, Wang M, **Kong P**, Qiu L and Song L. The modulation of catecholamines to the immune response against bacteria *Vibrio anguillarum* challenge in scallop *Chlamys farreri*. *Fish Shellfish Immunol.* 2011;31(6):1065-71.

Zhou Z, Yang J, Wang L, Zhang H, Gao Y, Shi X, Wang M, **Kong P**, Qiu L and Song L. A dopa decarboxylase modulating the immune response of scallop *Chlamys farreri*. *PLoS One.* 2011;6(4):e18596.

## Acknowledgements

Firstly, I would like to state my deep gratitude to Dr. Nishith Gupta for his constant support throughout my PhD period. I admire his profound scientific knowledge and diligent work attitude.

My sincere thanks to Prof. Dr. Richard Lucius for accepting me to work in his department and motivating me all these years through his enthusiasm for parasitology research.

Besides my supervisors, I want to thank Prof. Dr. Jos Brouwers for reviewing my thesis, as well as Prof. Dr. Kai Matuschewski and Prof. Dr. Christian Schmitz-Linneweber for being part of my thesis committee.

I am genuinely grateful to all the collaboration partners for their contribution to my projects, especially Jos Brouwers and Jeroen Jansen for their guidance with lipidomics research, as well as Prof. Dr. Xun Suo and Dr. Qing Yin for their excellent *in vivo* work.

I highly appreciate the productive and friendly environment in our lab, thanks to our brilliant technical assistants Grit Meusel and Manuel Rauch, as well as my PhD colleagues Anne, Ruben, Richard, Arun, Matthias, Laura, Özlem and Bingjian.

To Ines, Bernadette, Nicola, Christoph, Ludmila, Laura, Stefanie, Fatima, Diana, Lisa and Janina, I learned a lot as a supervisor for your projects or theses, and I am thankful for your efforts and the good time working together.

Special acknowledgments to Juliane, Andreas, Susanne, Martina and Christoph from the ZIBI graduate school for the support of funding.

Last but not least, “慈母手中线，游子身上衣，临行密密缝，意恐迟迟归”。感谢父母对我毫无保留的爱与支持。你们永远是我遇到困难时心中的基石，给我前进的动力和勇气。

## **SELBSTÄNDIGKEITSERKLÄRUNG**

### **Selbständigkeitserklärung**

Hiermit erkläre ich an Eides statt, die vorliegende Dissertation selbstständig und angefertigt und keine anderen als die angegebenen Hilfsmittel verwendet zu haben.

---

Ort, Datum

---

Unterschrift